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i 
Abstract 
 
Although psychiatric disorders are among the leading causes of disability in modern societies, no 
molecular biomarkers exist for their accurate diagnosis, classification and treatment efficacy 
assessment. Proteomics technologies provide useful tools for identifying protein markers related 
to disease pathophysiology. To unravel the neurobiological underpinnings and identify candidate 
biomarkers for anxiety disorders, we interrogated the mouse model of high (HAB), normal (NAB) 
and low (LAB) anxiety-related behavior by a combined quantitative proteomics and metabolomics 
approach. The cingulate cortex synaptosome proteomes of HAB and LAB mice were compared 
by in vivo 15N metabolic labeling and quantitative proteomics. In addition, the cingulate cortex 
metabolomes of HAB/NAB/LAB mice were quantified, and altered protein and metabolite 
networks were identified by in silico pathway analysis. Differential expression of sideroflexin-5 
(Sfxn5), carbonic anhydrase 2 (Car2), myosin, heavy polypeptide 10 (Myh10) and succinate 
dehydrogenase, subunit b (Sdhb) in HAB and LAB mice was validated by Western blot in an 
independent HAB/NAB/LAB population, providing a set of candidate biomarkers for anxiety-
related behavior. Proteomics, metabolomics and in silico analyses revealed pronounced 
mitochondrial pathway alterations, suggesting previously not highlighted roles of the organelle in 
modulating anxiety-related behavior by affecting energy metabolism, oxidative stress and 
neurotransmission processes. 
To allow an accurate characterization of the HAB/NAB/LAB mouse model, proteomics tools were 
established and optimized. Mouse synaptosome proteome profiling was carried out to create a 
reference map for quantitative proteomics experiments. Furthermore, the quantitative proteomics 
platform based on metabolic labeling of the HAB/NAB/LAB mouse model with the 15N heavy 
isotope was established, and the 15N isotope effect on the proteome during metabolic labeling 
was investigated. 
To elucidate the role of the G72 protein in schizophrenia, the G72/G30 transgenic mouse model 
of schizophrenia-like symptoms was studied with traditional, gel-based proteomics approaches. 
The cerebellar proteomes of G72/G30 transgenic mice were compared with wild type (WT) 
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controls, revealing differential expression of proteins involved in mitochondrial function and 
oxidative stress. 
Taken together, quantitative proteomics approaches were applied to identify disease-specific 
differences in animal models of psychiatric disorders. Our data provide the basis for the 
establishment of a biomarker panel for anxiety disorders and schizophrenia and offer insights 
toward a systemic understanding of mental disease and discovery of novel therapeutic targets. 
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1D    One-dimensional 
2D    Two-dimensional 
2D-PAGE   Two-dimensional polyacrylamide gel electrophoresis 
ABC    ATP-binding cassette 
BAC    Bacterial artificial chromosome 
CI    Confidence interval 
CID    Collision-induced dissociation 
EP    Enolase phosphatase 
EPM    Elevated plus-maze 
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ETC    Electron transport chain 
FDA    Food and Drug Administration 
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IPG    Immobilized pH gradient 
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KEGG    Kyoto encyclopedia of genes and genomes 
LAB    Low anxiety-related behavior 
LC-ESI-MS/MS  Liquid chromatography-electrospray-tandem mass spectrometry 
LTQ    Linear-trap quadrupole 
MALDI    Matrix-assisted laser desorption ionization 
MANOVA   Multivariate analysis of variance 
mRNA    Messenger ribonucleic acid 
MS    Mass spectrometry 
MS/MS   Tandem mass spectrometry 
m/z    Mass-to-charge ratio 
NAB    Normal anxiety-related behavior 
NADPH   Nicotinamide adenine dinucleotide phosphate 
NMDA    N-methyl-D-aspartate 
PAGE    Polyacrylamide gel electrophoresis 
PND    Post-natal day 
RF    Random forest 
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ROS    Reactive oxygen species 
RP-HPLC   Reversed-phase high performance liquid chromatography 
S   Serine 
SAM    S-adenosyl-L-methionine 
SDS    Sodium dodecyl sulfate  
SEM    Standard error of the mean 
SILAC    Stable isotope labeling by amino acids in cell culture  
SNP    Single-nucleotide polymorphism 
SNARE   Soluble N-ethylmaleimide sensitive fusion protein attachment protein  
   receptors 
T   Threonine 
TBS   Tris buffered saline 
TBS-T    Tris buffered saline buffer containing 0.05% Tween 20 
TFFBS    Test- and functional-free biomarker searching 
TOF    Time of flight 
TST    Tail suspension test 
USV    Ultrasonic vocalization test 
UV    Ultra-violet 
WT    Wild type 
XIC    Extracted ion chromatogram 
Y   Tyrosine 
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Atcay   Caytaxin 
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CaMKII  Calcium/calmodulin-dependent protein kinase type II 
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Crym   Mu-crystallin  
DAO   D-amino acid oxidase 
Dld   D-lactate dehydrogenase 
Dlg 1-4   Discs large homologs 1-4 
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Gap43   Neuromudulin 
Gdi1  Rho GDP dissociation inhibitor (GDIR) 
Glo1   Glyoxalase 1 
Glud1   Mitochondrial glutamate dehydrogenase 1 
Glul  Glutamine synthetase (Q91VC6) 
Gphn   Gephyrin 
Gria2   Glutamate receptor 2 (GluR2) 
Gria3   Glutamate receptor 3 
Grm3   Metabotropic glutamate receptor 3 
Gstm1  Glutathione S-transferase M1 
Gstp1  Glutathione S-transferase P1 
Homer 1-3  Homer protein homologs 1-3 
Idh1   Isocitrate dehydrogenase 
Kcnc3  Isoform Kv3.3B of potassium voltage-gated channel subfamily C member 3 
Kpyk2   Pyruvate kinase II 
LacZ   Beta galactosidase 
LG72   Longest G72 splice variant 
MAPK   Mitogen-activated protein kinase 
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Mbp   Myelin basic protein 
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Mdh  Malate dehydrogenase (Q9K2L4, Q9ETZ1, Q9KH77, Q9KH79 variants)   
Myh10   Myosin, heavy polypeptide 10, non-muscle 
Nefm   Neurofilament medium polypeptide 
Odp2  Dihydrolipoyllysine-residue acetyltransferase component of pyruvate 
dehydrogenase complex 
Pcsk1n  Proprotein convertase 1 inhibitor ProSAAS 
PflB   Formate acetyltransferase 1 
Pgam1  Phosphoglycerate mutase 1 
PpcI   Phosphoenolpyruvate carboxylase mutant (Q47521) 
PpsA   Phosphoenolpyruvate synthase 
Prdx2    Peroxiredoxin-2  
Prkc   Protein kinase C family  
Prkcb1   Protein kinase C beta type 
Prkcc   Protein kinase C gamma type 
Prkce   Protein kinase C epsilon type 
PSD95   Discs large homolog 4 or post-synaptic density protein 95 (Dlg4) 
Pta   Phosphate acetyltransferase 
Rgs6   Regulator of G-protein signaling 6 
Sdh   Succinate dehydrogenase 
Sdha  Succinate dehydrogenase [ubiquinone] flavoprotein subunit, mitochondrial 
precursor 
Sdhb  Succinate dehydrogenase [ubiquinone] iron-sulfur subunit, mitochondrial 
precursor 
Sdhc  Succinate dehydrogenase cytochrome b560 subunit, mitochondrial precursor 
Sfxn1   Sideroflexin-1 
Sfxn3   Sideroflexin-3 
Sfxn5   Sideroflexin-5 
Shank1  SH3 and multiple ankyrin repeat domains 1 
Slc17a7  Brain-specific sodium-dependent inorganic phosphate co-transporter (VGlut1) 
Slc1a1  Solute carrier family 1 (Neuronal/epithelial high affinity glutamate transporter, 
system Xag), member 1 
Slc1a2   Isoform Glt-1A of excitatory amino acid transporter 2 
Slc1a3   Excitatory amino acid transporter 1 
Slc25a3  Phosphate carrier protein, mitochondrial precursor 
Slc25a4  ADP/ATP translocase 1 
Slc25a5  ADP/ATP translocase 2 
Slc25a11  Mitochondrial 2-oxoglutarate/malate carrier protein  
Slc25a12  Calcium-binding mitochondrial carrier protein Aralar1 
Slc25a18  Mitochondrial glutamate carrier 2 (33kDa protein) 
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Slc25a22  Mitochondrial glutamate carrier 1 
Slc6a1   Sodium- and chloride-dependent GABA transporter 1 
Slc6a11  Sodium- and chloride-dependent GABA transporter 4 
Slc7a8   Large neutral amino acids transporter small subunit 2 
Snap91  Isoform long of clathrin coat assembly protein AP180 
Sod1   Superoxide dismutase 
Stx1a   Syntaxin-1A 
Syt 1-3   Synaptotagmin 1-3 
TIM  Translocase of the inner mitochondrial membrane 
TnR   Tenascin-R precursor 
TOM  Translocase of the outer mitochondrial membrane 
Tuba1a  Tubulin alpha 1A chain (Q3TGF0) 
Tubb2c  Tubulin beta 2C chain (Q99JZ6) 
Vamp 1-4  Vesicle-associated membrane proteins 1-4 
Vdac 1-3  Voltage-dependent anion-selective channels 1-3 
VEGF   Vascular endothelial growth factor. 
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1 Introduction 
 
1.1 Psychiatric disorders 
 
Although over the last century tremendous progress has been made in the therapy and mortality 
decrease of devastating conditions such as cancer and cardiopathies, no decrease has been 
observed in mortality rates or overall prevalence of psychiatric disorders (Kessler et al., 2005). It 
is therefore not surprising that according to the World Health Organization, psychiatric disorders 
are one of the leading causes of disease burden and disability worldwide (World Health 
Organization, 2008). 
 
1.1.1 Anxiety and depression 
Anxiety can be conceptualized as the emotional anticipation of an aversive situation, which is 
likely to occur and difficult to predict and control (Landgraf, 2001). In its non-pathological form, 
anxiety can be classified into state anxiety, referring to the acute or immediate level of anxiety 
and trait anxiety, which reflects the long-term tendency of an individual to show an increased 
anxiety response (Leonardo and Hen, 2006). It is believed that pathological anxiety evolves from 
normal anxiety behavior along a continuum from physiology to psychopathology (Landgraf et al., 
2007; Rosen and Schulkin, 1998). In its pathological form, anxiety encompasses a wide spectrum 
of conditions, including panic disorder, agoraphobia, social phobia, obsessive-compulsive 
disorder, generalized anxiety disorder, post-traumatic stress disorder and acute stress disorder 
(American Psychiatric Association, 2000). Anxiety disorders constitute the most common 
psychiatric disorders in the industrialized world with an estimated lifetime prevalence ranging from 
14.5% to 28.8% in Europe and in the USA (Jacobi et al., 2004; Kessler et al., 2005). Twin and 
family studies have revealed a 30-40% heritability of anxiety disorders (Hettema et al., 2001), 
suggesting a considerable genetic contribution. Remarkably, there is an up to 60% co-morbidity 
with depression. Depression, one of the most debilitating psychiatric disorders, is highly heritable 
(Fava and Kendler, 2000) and shares common symptoms with anxiety, making mild versions of 
both disorders difficult to distinguish (Kalueff et al., 2007). Antidepressants are also used for the 
treatment of anxiety disorders, indicating convergent underlying pathways (Gorman, 1996; Levine 
et al., 2001; Nutt, 2005).  
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Within the spectrum of anxiety disorders, the facts that they often co-occur (Hettema et al., 2005), 
and most of them respond to a similar spectrum of pharmacological treatments (Gross and Hen, 
2004; Kent et al., 2002) indicates that they share common neurobiological and physiological 
characteristics, as well. At the neuroanatomical level, the amygdala and the limbic system are the 
key players involved in processing anxiogenic stimuli, which are in turn linked to cortex, 
hypothalamus and hippocampus, comprising the neural circuit involved in anxiety. At the synaptic 
level, imbalance between excitatory and inhibitory neurotransmission in these brain areas has 
been proposed to be responsible for the manifestation of anxiety-like behavior (McNaughton, 
1997; Wu et al., 2008). At the neuroendocrine level, the hypothalamic-pituitary-adrenal axis as 
well as neuropeptides (e.g., vasopressin) have been suggested to play a role in the mediation 
and modulation of anxiety symptomatology. Yet, the exact molecular mechanisms of anxiety 
pathogenesis remain elusive.  
 
1.1.2 Schizophrenia 
Auditory hallucinations, delusions, thought disorder and cognitive deficits are the main symptoms 
of schizophrenia, which affects ∼1% of the general population (Freedman, 2003) with disease 
onset appearing in late adolescence. Evidence from genetics, neuroimaging and pharmacology 
suggests that schizophrenia is a heterogeneous group of disorders (Harrison and Weinberger, 
2005; Kirkpatrick et al., 2001). Currently, schizophrenia is viewed as a subtle disorder of brain 
development and synaptic plasticity with a complex contribution from genetic and environmental 
factors (Arnold et al., 2005; Harrison and Weinberger, 2005; Rapoport et al., 2005). As there is up 
to 80% heritability in schizophrenia (Cardno and Gottesman, 2000), useful information concerning 
the underlying disease mechanisms has been derived from association and linkage genetic 
studies. Contributing genes include among others G72 (D-amino acid oxidase activator or DAOA) 
(Abou Jamra et al., 2006), neuregulin 1 (Li et al., 2006), disrupted-in-schizophrenia-1 
(Schumacher et al., 2009) and dysbindin (Straub et al., 2002). Insights from antipsychotic drug 
action have implicated dopamine neurotransmission (Carlsson, 1978) and hypofunction of the 
glutamate N-methyl-D-aspartate (NMDA) receptor (Coyle, 2006) in the pathophysiology of 
schizophrenia. However, as is the case for anxiety disorders, the exact etiology of schizophrenia 
is not fully understood. 
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1.2 Biomarkers for psychiatric disorders 
 
1.2.1 What is a biomarker? 
According to the National Institutes of Health, a biomarker is a characteristic that is objectively 
measured and evaluated as an indicator of normal biological processes, pathogenic processes, 
or pharmacological responses to a therapeutic intervention (Biomarkers Definitions Working 
Group, 2001). Biomarkers are critical to differentiate between distinct biological states. 
Representative biomarkers routinely used in modern biology and medicine include human 
chorionic gonadotropin to detect pregnancy, serum ferritin to assess anemia and cholesterol to 
predict cardiovascular disease risk.  
 
1.2.2 The quest for biomarkers in psychiatric research 
To date, no molecular biomarker exists for any psychiatric disorder. No prognostic test is 
available that could reliably identify individuals at risk of developing psychopathologies due to 
genetic predisposition or vulnerability to relevant environmental stimuli. Diagnosis and disease 
categorization are symptomatic and mainly rely on a subjective, interview-based communication 
with the patient (Turck et al., 2005). Current medication is not without side-effects and/or requires 
weeks to work, while not all patients respond to existing drug treatment (Bystritsky, 2006). Taken 
together, reliable molecular biomarkers in psychiatry are of paramount importance for 
identification of at risk individuals, premorbid diagnosis, patient stratification, disease monitoring 
and effective, personalized treatment.  
Besides clinical practice, biomarkers can accelerate drug discovery by being used as surrogate 
markers of drug efficacy and hence reduce production costs and pipeline development time 
(Schwarz and Bahn, 2008). In basic research, biomarkers can contribute to the elucidation of 
molecular mechanisms of disease pathogenesis. However, because of the complex nature and 
the increased intra-heterogeneity of psychiatric disorders, a single biomarker will not be able to 
unequivocally distinguish between clinical phenotypes. A panel of biomarkers, which depict more 
accurately a disease state is required to significantly represent complex traits like anxiety 
disorders or schizophrenia (Turck et al., 2005). In this context, animal models and novel -omics 
technologies promise to be useful tools for biomarker discovery. 
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1.3 Mouse models for psychiatric disorders 
 
1.3.1 Advantages of mouse models in psychiatric research 
Mental disorder research on human subjects is problematic not only due to ethical issues but also 
due to increased intra-individual heterogeneity unrelated to disease pathology, restricted access 
to human material (e.g., cerebrospinal fluid) and limited control of retrieval protocols consistency 
(Ditzen et al., 2010). Studies on human post-mortem tissue have been informative, but largely 
unreliable due to post-mortem delay-derived changes, confounding clinical conditions, previous 
drug treatment and unavailability of suitable controls. In this respect, the use of model organisms 
represents the best possible alternative to investigate psychiatric disorders. ice constitute a 
valuable model organism because they can be cost-effectively bred, housed and maintained in 
large numbers under standardized laboratory conditions. They have a short life span and can be 
quickly reproduced, enabling long-term studies of a stimulus effect. Advantageously, inbred 
mouse lines have limited heterogeneity relative to human populations, and material acquisition 
and post-mortem tissue preparation can be performed in a consistent manner. A plethora of tools 
(information resources, molecular technologies, genetic manipulation methods, behavioral tests) 
is now available for mice, facilitating the application of diverse experimental approaches. 
Obviously, psychiatric disorders cannot be fully recapitulated in mice given that certain 
manifestations of disease symptomatology (e.g., low self esteem, suicidal ideation) cannot be 
modeled (Cryan and Holmes, 2005). Nevertheless, there is significant similarity between humans 
and mice since they share 99% of their genes (Mouse Genome Sequencing Consortium, 2002), 
whereas brain structural organization and certain neural circuit interconnections, physiological 
parameters and behavioral responses are widely conserved across mammals (Ohl, 2005). While 
caution should be taken in extrapolating conclusions from animal studies to humans, a great 
amount of our current understanding of psychopathologies is derived from mouse models 
(Landgraf et al., 2007). 
 
1.3.2 The HAB/NAB/LAB mouse model of trait anxiety 
1.3.2.1 Bidirectional selective breeding 
Following the same breeding strategy previously applied to rats (Landgraf and Wigger, 2002; 
Liebsch et al., 1998a; Liebsch et al., 1998b), Prof. Rainer Landgraf and colleagues in the group of 
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Behavioral Neuroendocrinology at the Max Planck Institute of Psychiatry in Munich have 
established the HAB/NAB/LAB mouse model of trait anxiety.  Outbred CD1 mice were used for 
selective and bidirectional breeding based on their performance on the elevated plus-maze (EPM) 
(Fig. 1.1). The method of bidirectional selective breeding enhances the representation of genetic 
material associated with a specific trait, thus shifting the animals’ phenotype from the population 
mean (Falconer and Mackay, 1996). The EPM is a physiologically and pharmacologically 
validated behavioral test that assesses anxiety in rodents in a spontaneous and unconditioned 
manner. The EPM principle is based on generating an approach-avoidance conflict between the 
exploratory drive of mice and their innate fear of illuminated, unprotected and heightened areas 
(Lister, 1987; Pellow et al., 1985). It consists of an elevated plus-shaped apparatus with two 
aversive open arms, two dark arms with protecting walls and a neutral zone (see 3.3.2.2 and Fig. 
1.1B). The amount of time spent on the EPM open arms is considered to indicate genetic 
predisposition for trait anxiety and is predictive for stress coping (Ducottet and Belzung, 2004). 
According to the % test time spent on the open arms, mice were bred with the corresponding 
partners to generate the behavioral extreme phenotypes. Mice spending less than 10% of the test 
time on the open arms gave rise to the high anxiety-related behavior (HAB) line, whereas mice 
spending most of the test time on the open arms (∼50% or more) gave rise to the low anxiety-
related behavior (LAB) line. Normal anxiety-related behavior (NAB) mice display an intermediate 
phenotype (time spent on open arms ∼30%) (Fig. 1.1A).  
 
1.3.2.2 Behavioral and molecular characteristics  
The HAB/NAB/LAB mouse model has been extensively studied, revealing behavioral, cognitive 
and molecular alterations in HAB and LAB mice. Apart from the EPM, HAB and LAB lines show 
differences in a battery of behavioral paradigms assessing anxiety-related behavior including the 
ultrasonic vocalization (USV, see 3.3.2.1) and the dark-light avoidance test, with HAB mice 
exhibiting increased anxiety levels (Krömer et al., 2005). In behavioral tests measuring 
depression-like phenotype such as the forced swim and the tail suspension test (TST, see 
3.3.2.2), LAB animals exhibit decreased immobility, indicating a reduced depression-like behavior 
(Krömer et al., 2005). At the cognitive level, HAB exhibit superior performance compared to LAB 
mice in the social recognition test (Bunck, 2008). At the molecular level, vasopressin SNPs and 
decreased vasopressin mRNA expression have been reported in LAB mice (Bunck et al., 2009; 
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Kessler et al., 2007). Additional gene expression differences between HAB and LAB mice have 
been found in a number of brain regions by microarray analysis (Czibere, 2009).  
 
 
 
 
 
 
 
 
 
A        B 
 
 
 
 
Figure 1.1 Breeding scheme of the HAB/NAB/LAB mouse model of trait anxiety 
A. EPM data (% time spent on the open arms) of the parental generation P and generations G1 
to G27 of HAB and LAB mice, with CD1 (NAB) mice as controls. From the fourth generation on, 
HAB and LAB animals differ significantly in their anxiety-related behavior independent of gender 
(**p<0.01, n=40-80 per line and generation). B. Characteristic behavior of HAB and LAB mice on 
the EPM. LAB mice explore the a priori aversive open arms (blue square), while HAB animals 
spend more time in the protective closed arms (red square) (figure kindly provided by Dr. Ludwig 
Czibere). 
 
1.3.3 The G72/G30 transgenic mouse model of schizophrenia-like symptoms 
There is accumulating evidence from linkage and association studies that the G72/G30 region on 
chromosome 13q32-q33 is a strong susceptibility locus for schizophrenia (reviewed in Abou 
Jamra et al., 2006; Detera-Wadleigh et al., 2006). The G72 and G30 genes are transcribed from 
overlapping opposite DNA strands, with only G72 appearing to be actively translated (Chumakov 
et al., 2002). G72 is a primate-specific gene with a complex alternative splicing pattern 
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(Chumakov et al., 2002), whose exact function is largely unknown. To elucidate the functional 
role of the G72 protein and its involvement in schizophrenia, Prof. Andreas Zimmer and 
colleagues at the Institute of Molecular Psychiatry at the University of Bonn generated a G72/G30 
transgenic mouse model by injecting bacterial artificial chromosome (BAC) plasmids containing 
the G72/G30 genomic region into pronuclei of fertilized oocytes from CD1 mice. The G72/G30 
transgenic mice display behavioral phenotypes relevant to psychiatric disorders, including 
impaired motor coordination, sensorimotor gating and olfactory discrimination as well as 
increased compulsive behavior (Otte et al., 2009). 
 
1.4 Biomarker discovery platforms 
 
1.4.1 Quantitative proteomics 
1.4.1.1 Advantages of studying the proteome 
Although genomics have provided useful insights into genes conferring susceptibility to complex 
diseases, many disease-related genes have low penetrance and do not exhibit an effect on the 
phenotype in a predictable and quantifiable manner (Schwarz and Bahn, 2008). Moreover, in a 
given disease state, multiple lesions occur at the gene level that vary across the individuals. On 
the other hand, altered protein signatures have the potential to reflect disease states. Disease-
related changes are depicted at the proteome level, thus relating proteome alterations to the 
disease phenotype. Consequently, interrogation of the proteome can result into an accurate and 
unbiased investigation of disease pathophysiology and drug action mechanisms (Turck et al., 
2005).  
 
1.4.1.2 Mass spectrometry 
Mass spectrometry (MS) -based techniques are powerful tools in proteomics research enabling 
protein identification and quantification in complex mixtures. MS determines the molecular weight 
of chemical compounds, which is characteristic for every molecule, by separating molecular ions 
based on their mass-to-charge ratio (m/z) in a mass spectrometer. The main components of a 
mass spectrometer are an ionization source, a mass analyzer and an ion detector (Fig. 1.2A).  
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Figure 1.2 Components of a mass spectrometer 
A. Generic components of a mass spectrometer. The output of the measurement is a mass 
spectrum, where intensities of different m/z peaks are plotted (figure adapted from 
www.magnet.fsu.edu). B. Simplified set-up of the Ultraflex MALDI-TOF/TOF instrument. C. 
Simplified set-up of the LTQ-Orbitrap instrument. 
 
Once a sample is introduced into the mass spectrometer, it undergoes ionization in the ionization 
source. The charged ions are then electrostatically propelled into the mass analyzer, where they 
are separated according to their m/z ratio and detected by the ion detector (Siuzdak, 1996). The 
output is a mass spectrum (ion intensity at different m/z values) that provides molecular weight 
information of the measured compounds (Fig. 1.2A). Different ion sources and ionization 
techniques can be combined with mass analyzers giving rise to different mass spectrometers 
(see 1.4.1.3). In tandem mass spectrometry (MS/MS), the separation of ions according to their 
m/z is used as a preparative step to isolate an ion with a desired m/z. The selected ion is then 
fragmented, and the m/z of the fragment ions is defined in a second stage of analysis. As a result, 
selected ions in a complex mixture can be studied, and their amino acid sequence can be 
determined (Kinter and Sherman, 2000). 
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1.4.1.3 Mass spectrometry instrumentation 
Ultraflex MALDI-TOF/TOF 
Matrix-assisted laser desorption ionization (MALDI) was first developed by Karas and colleagues 
(Karas et al., 1985). The sample to be analyzed is dissolved in a solid, non-volatile, ultra-violet 
(UV) absorbing material (matrix) and co-crystallizes with it. The mixture is then irradiated with a 
short-pulsed UV laser resulting in matrix ionization, followed by energy and proton transfer to the 
sample. The ionized sample molecules are then directed to a time of flight (TOF) mass analyzer 
(Siuzdak, 1996). In the TOF mass analyzer, the ion population coming from the ion source is 
accelerated by an electrical potential. After acceleration, the ions pass through a field-free region, 
where each ion is traveling with a speed characteristic of its m/z value. At the end of the field-free 
region, the detector measures the flight time (Matthiesen and Mutenda, 2007). In MALDI-
TOF/TOF MS, two TOF analyzers are used consecutively (Fig. 1.2B). The first TOF mass 
analyzer isolates the precursor ions of choice using a velocity filter, and the second analyzes the 
selected ions (Vestal and Cambell, 2005).  
 
LTQ-Orbitrap 
Electrospray ionization (ESI) was first developed by Yamashita and Fenn (Yamashita and Fenn, 
1984). The sample is dissolved in a polar, volatile solvent; the sample solution passes through a 
needle and is sprayed from a strong electric field region. The highly charged droplets are 
electrostatically attracted to the mass spectrometer inlet, and ions are then generated during 
droplet evaporation (Siuzdak, 1996). After ionization, ions are entering a linear-trap quadrupole 
(LTQ) mass analyzer, which is linked to an Orbitrap mass analyzer via a C-trap. From LTQ, ions 
are axially injected in the C-trap and in addition in the Orbitrap mass analyzer, where they are 
electrostatically trapped while rotating around the central electrode performing axial oscillation 
(Fig. 1.2C). The oscillation frequencies are determined using a Fourier transform and are 
converted to masses (Makarov, 2000). For higher analytical sensitivity, samples are first 
separated with reversed-phase high performance liquid chromatography (RP-HPLC), and the 
eluents are directly infused to the mass spectrometer. This set-up [referred to from now on as 
liquid chromatography-electrospray-tandem mass spectrometry (LC-ESI-MS/MS), see 3.1] 
ensures high mass accuracy and resolution, making it the method of choice for quantitative 
proteomics experiments. 
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1.4.1.4 Mass spectrometry-based proteomics 
In a typical proteomics workflow, a protein population is extracted from the material under 
investigation (tissue, cells, etc.) (Fig. 1.3A), and the subproteome of interest is enriched (Fig. 
1.3B). To reduce complexity, extracted proteins are separated by gel-based approaches (i.e. 1D- 
or 2D-gel electrophoresis) and digested with trypsin to generate peptides (Fig. 1.3C). Peptides 
are then extracted (Fig. 1.3D) and analyzed by MS (Fig. 1.3E). The corresponding fragment 
masses are searched against protein databases and are used for protein identification and/or 
quantification (Fig. 1.3F). 
 
 
 
 
 
Figure 1.3 Proteomics workflow scheme 
A. Protein extraction. B. Subproteome enrichment. C. Gel electrophoresis and in gel tryptic 
digestion. D. Peptide extraction. E. MS. F. Database search and data analysis. 
 
1.4.1.5 Quantitative proteomics methodologies 
Two-dimensional polyacrylamide gel electrophoresis 
Until recently, two-dimensional polyacrylamide gel electrophoresis (2D-PAGE) was the main 
proteomics approach for comparing two different states (i.e. disease, control), being based on the 
bidimensional separation of proteins in a complex mixture. In the first dimension, proteins are 
separated according to their isoelectric point by isoelectric focusing (IEF) using immobilized pH 
gradient (IPG) strips. In the second dimension, proteins are separated according to their 
molecular weight on polyacrylamide gels (O'Farrell, 1975). The 2D-gels are then stained, and 
spot signal intensities are compared across the samples. Spots with different intensities between 
the groups under study are excised from the 2D-gels, and the corresponding proteins are 
identified by MS. Although 2D-PAGE is a well-established quantitative approach, the analysis of 
hydrophobic, membrane, extreme pH and high or low molecular weight proteins remains 
challenging. Furthermore, expression of low abundant proteins can be masked by high abundant 
proteins, while reproducibility issues concerning intra-gel variability and sample pre-fractionation 
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can affect quantification accuracy (Fey and Larsen, 2001; Lubec et al., 2003). Consequently, 
quantitative proteomics can profit from a more accurate and sensitive quantification method that 
can deal successfully with quantitative data of a wide dynamic range in an unbiased manner. 
 
In vivo 15N metabolic labeling 
The field of quantitative proteomics has greatly benefited from the introduction of stable isotopes 
(2H, 13C, 15N, 18O) into peptides or proteins for subsequent comparison with an unlabeled peptide 
or protein population. The use of stable isotopes introduces a predictable mass difference 
between the ‘heavy’ and the corresponding ‘light’ peptide that allows the mass analyzer to 
discriminate between the two peptide forms. Relative quantification of the light/heavy peptide pair 
is then achieved by comparing their signal intensities (Fig. 1.4).  
 
 
 
 
 
 
   A      B       C 
Figure 1.4 Isotopologue patterns of the 14N (light) and the 15N (heavy) form of the same 
peptide 
A. Lower expression, B. non-differential expression, C. higher expression of the 15N-labeled 
peptide compared to its 14N (unlabeled) counterpart. Relative quantification of the 14N/15N peptide 
signals is achieved by comparing the sum of the signal intensities of the isotopologue peaks.     
 
15N metabolic labeling together with stable isotope labeling by amino acids in cell culture (SILAC) 
(Krüger et al., 2008; Ong et al., 2002) are currently the gold standards for MS-based quantitative 
proteomics. The strength of these stable isotope labeling techniques compared to all other 
quantitative proteomics methodologies mainly relies on the ability to mix the labeled and 
unlabeled samples prior to sample preparation and treat them simultaneously, so that any 
experimental error during handling will affect both samples in the same way (Bantscheff et al., 
2007; Ong and Mann, 2005). 15N metabolic labeling of whole organisms has been described in 
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yeast (Oda et al., 1999), bacteria (Conrads et al., 2001; Pan et al., 2008), Drosophila 
melanogaster  (Krijgsveld et al., 2003), Caenorhabditis  elegans (Dong et al., 2007; Krijgsveld et 
al., 2003) and plants (Bindschedler et al., 2008; Huttlin et al., 2007; Kierszniowska et al., 2009a; 
Kierszniowska et al., 2009b; Lanquar et al., 2007; Palmblad et al., 2007; Schaff et al., 2008). 
Recently, rodents fed with 15N-labeled algae (Huttlin et al., 2009; McClatchy et al., 2007a; Wu et 
al., 2004) were metabolically labeled with 15N for quantitative proteomics experiments.  
 
15N isotope effect on the proteome 
The use of stable isotopes in proteomics is based on the isotope dilution theory (De Leenheer 
and Thienpont, 1992) according to which, a stable isotope labeled peptide is chemically identical 
to its unlabeled counterpart and therefore the behavior of the two peptides is identical during 
chromatographic and MS workflows. However, in most quantitative proteomics studies where 15N 
metabolic labeling was used, control strategies for the 15N isotope effect were employed either by 
reciprocal labeling of the two states to be compared (Huttlin et al., 2009; Kierszniowska et al., 
2009b; Krijgsveld et al., 2003; Lanquar et al., 2007; Oda et al., 1999) or by the use of a 15N-
labeled internal standard (Dong et al., 2007; Liao et al., 2008; McClatchy et al., 2007a; Pan et al., 
2008; Wu et al., 2004). These measures were introduced to avoid potential confounding 15N-
derived artifacts. Yet to date, no study has examined the actual effects of the 15N isotope 
introduction on a given proteome per se. 
 
1.4.2 Quantitative metabolomics  
The repertoire of small molecules present in cells, tissues and body fluids is known as the 
metabolome. Metabolomics (the study of the metabolome) have emerged to be the newest 
member of the -omics family. Metabolomics reflect the status of diverse biochemical pathways in 
a given metabolic state in health or disease. MS-based metabolomics enable the identification 
and quantification of known as well as new metabolites (Dettmer et al., 2007). In particular, gas 
chromatography (GC) coupled with MS has been used for metabolomics quantification in 
psychiatric and neurodegenerative disorders (Paige et al., 2007; Underwood et al., 2006) due to 
its high sensitivity, quantitative precision and chromatographic resolution and wide dynamic range 
(Quinones and Kaddurah-Daouk, 2009). Altered metabolic signatures can provide useful 
information about disease pathophysiology and together with proteomics information can 
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contribute to a systemic approach for the study of disease pathogenesis and biomarker discovery 
(Kaddurah-Daouk et al., 2008). 
 
1.5 Biomarker discovery in the HAB/NAB/LAB mouse model of trait anxiety 
 
2D-PAGE in amygdala, hypothalamus and motor cortex of HAB, NAB and LAB mice revealed 
differences in two proteins, glyoxalase 1 (Glo1) and enolase phosphatase (EP). Glo1 expression 
was significantly higher in LAB compared to HAB mice in all brain areas examined, with NAB 
animals exhibiting intermediate Glo1 levels (Fig. 1.5). The same pattern was shown by Western 
blot analysis in red blood mouse cells (Ditzen et al., 2006; Krömer et al., 2005). Glo1 is a 
cytosolic enzyme that detoxifies dicarbonyl metabolites, such as methylglyoxal (Thornalley, 1993). 
In mice, Glo1 gene copy number has been associated with anxiety-related behavior (Williams et 
al., 2009), whereas Glo1 and glutathione reductase 1 have been reported to play a causal role in 
anxiety (Hovatta et al., 2005).  In humans, a Glo1 single-nucleotide polymorphism (SNP) has 
been associated with panic disorder without agoraphobia (Politi et al., 2006). Furthermore, Glo1 
mRNA levels in white blood cells have been suggested to be a state-dependent marker of mood 
disorders (Fujimoto et al., 2008). Notably, the predictive validity of Glo1 as a biomarker for the 
HAB/NAB/LAB mouse model has been demonstrated by identifying HAB or LAB in a blind 
manner based on Glo1 expression levels (Krömer et al., 2005). 
EP showed a different motility pattern between HAB, NAB and LAB mice in the second dimension 
of 2D-PAGE in all areas examined (Fig. 1.5) (Ditzen et al., 2006). EP is a member of methionine 
salvage pathway, where methionine is metabolized to S-adenosyl-L-methionine (SAM), a natural 
antidepressant and mood stabilizer also involved in polyamine biosynthesis (Papakostas, 2009). 
Differential expression of polyamines has been repeatedly reported in mental disorders (Fiori and 
Turecki, 2008). Further analyses revealed the presence of line-specific EP SNPs, altered EP 
enzymatic activity in HAB and LAB mice as well as increased polyamine expression in HAB mice 
(Ditzen et al., 2010). Importantly, Glo1 and EP are detectable by Western blot in human red and 
white blood cells, respectively, illustrating their applicability as markers for non-invasive patient 
screening (Ditzen et al., 2006). However, taking into account the multifactorial and polygenic 
nature of anxiety psychopathology, a considerable number of proteins that remain to be identified 
are likely to contribute to anxiety manifestation. 
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Figure 1.5 Two-dimensional polyacrylamide gel electrophoresis-based biomarker 
discovery in HAB/NAB/LAB mice 
Representative 2D-PAGE of amygdala protein extracts from male HAB/NAB/LAB mice (n=12 per 
line). Differences in Glo1 and EP are pointed with arrows (Ditzen et al., 2006). 
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2 Aim of the thesis 
 
The aim of the present study was to identify brain biomarkers and affected pathways in mouse 
models of psychiatric disorders by establishing and employing quantitative proteomics platforms. 
Specifically, the following subjects were addressed:  
 
1. To establish and optimize proteomics tools for accurate characterization of the 
HAB/NAB/LAB mouse model of trait anxiety, a protein profiling of mouse synaptosomes 
was performed to generate a synaptic protein reference map for quantitative studies 
(Chapter 4). Furthermore, a quantitative proteomics platform was established based on 
15N metabolic labeling of the HAB/NAB/LAB mouse model (Chapter 5), and the effect of 
the 15N isotope introduction on the proteome during 15N metabolic labeling was 
investigated (Chapter 7). 
 
2. To identify candidate biomarkers and altered pathways in the HAB/NAB/LAB mouse 
model of trait anxiety, the cingulate cortex synaptosome proteomes of HAB and LAB 
mice were compared by the 15N metabolic labeling quantitative proteomics platform. 
Differences between the HAB, NAB and LAB mouse lines were also investigated by 
quantitative metabolomics, in silico pathway analyses and immuno-based methods 
(Chapter 6). 
 
3. To elucidate the functional role of G72 in schizophrenia, the cerebellar proteomes of 
G72/G30 transgenic mice of schizophrenia-like symptoms and wild type (WT) 
counterparts were compared by 2D-gel-based proteomics (Chapter 8). 
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3 Materials and methods 
 
3.1 Animals, equipment and standard procedures 
 
All animal studies performed were approved by local authorities and conducted according to 
current regulations for animal experimentation in Germany and the European Union (European 
Communities Council Directive 86/609/EEC). Unless otherwise stated, animals were kept in the 
animal facility of the Max Planck Institute of Psychiatry under standard housing conditions (room 
temperature 23±20C, air humidity 60%, food and tap water ad libitum) in groups of 2-4 animals 
per cage. Tissue acquisition and behavioral testing were performed between 8a.m and 1p.m. 
Dissection of the desired brain areas was performed according to the mouse brain atlas (Paxinos 
and Franklin, 2001). Only male animals were studied. Quantitative MS measurements were 
performed with a nanoflow HPLC-2D system (Eksigent, Dublin, CA, USA) coupled online to a 
LTQ-Orbitrap mass spectrometer (Thermo Fisher Scientific, Bremen, Germany) via a 
nanoelectrospray ion source (Thermo Fisher Scientific) (referred to as LC-ESI-MS/MS). For 
sample infusion into the mass spectrometer, in-house packed, fused silica, 3µm RP-C18 (Maisch, 
Monheim, Germany), 0.075mm x 15cm columns connected to distal coated silica tips (New 
Objective, Ringoes, NJ, USA) were used. 15N incorporation calculation and 2D-PAGE spot 
identification MS measurements were performed with an Ultraflex MALDI-TOF/TOF mass 
spectrometer (Bruker Daltonik, Bremen, Germany) equipped with a nitrogen laser operating at 
50Hz (referred to as MALDI-TOF/TOF MS). For pipeting volumes up to 1ml, Gilson pipets 
(Pipetman, Gilson, Middleton, WI) were used. Pipet tips and tubes were purchased from 
Eppendorf (Eppendorf, Hamburg, Germany). For centrifugation steps, a 5804R centrifuge 
(Eppendorf) was used. Ultracentrifugation steps were performed in a L8-70M Ultracentrifuge 
(Beckman Coulter, Krefeld, Germany). Samples were lyophilized in a Savant Speed Vac plus 
SC210A concentrator (Thermo Fisher Scientific). Unless otherwise stated, 12.5% polyacrylamide, 
sodium dodecyl sulfate (SDS) -containing mini gels with ten 1.5mm wells were used for 1D-gel 
electrophoresis. Electrophoretic equipment was purchased from BioRad (BioRad, Hercules, CA, 
USA). Protein content was estimated by the Bradford Assay (BioRad). Absorption at 595nm was 
measured by a DU-640 spectrophotometer (Beckman Coulter). Gels and Western blot 
autoradiographs were scanned by a GS-800 Calibrated Densitometer (BioRad). All commercially 
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available antibodies used for Western blot analysis are listed in Appendix 1. GraphPad Prism was 
used for statistical analysis (v5.03, GraphPad Software, San Diego, CA, USA). Unless otherwise 
specified, statistical significance was accepted for p values <0.05, determined as follows: 
*p<0.05, **p<0.01, ***p<0.001. Data are presented in mean+SEM (standard error of the mean). 
 
3.2 Profiling of mouse synaptosome proteome and phosphoproteome 
 
3.2.1 Synaptosome enrichment from CD1 mouse whole brain 
Synaptosomes are artificially isolated synapses produced by mild disruption of brain tissue (see 
4.1). Synaptosomes were purified according to Gray and Whittaker (Gray and Whittaker, 1962) 
with slight modifications (Filiou et al., 2010a). The whole brain of a CD1 adult mouse was 
homogenized in ten volumes (w/v) of 0.32M sucrose (Sigma Aldrich, St. Louis, MO, USA) and 
4mM HEPES (Sigma Aldrich) buffer (pH 7.4). Cocktail inhibitor tablets (Roche Diagnostics, 
Indianapolis, IN, USA) were used to inhibit phosphatase activity. The homogenate was 
centrifuged twice at 1000g for 10min to pellet the nuclei (nuclear fraction N), the two supernatants 
were combined (supernatant S1) and centrifuged at 17000g for 55min. Supernatant was removed 
(supernatant S2), and the pellet was resuspended in 0.32M sucrose, followed by sucrose 
gradient ultracentrifugation at 64000g for 2h (0.32M/0.8M/1.2M sucrose gradient). The interface 
of 0.8M/1.2M sucrose gradient (containing crude synaptosomes) was collected and centrifuged at 
164000g for 60min. The supernatant was removed (supernatant S3), and the resulting pellet 
(synaptosomal fraction, Syn) was dissolved in distilled water. All steps were performed at 40C.  
 
3.2.2 Western blot analysis of selected synaptosomal proteins  
To investigate the expression of selected identified proteins in different fractions of the 
synaptosomal protocol as well as in cytosolic fraction C, a Western blot analysis was performed. 
The cytosolic fraction C of a whole mouse brain was isolated according to Cox and Emili (Cox 
and Emili, 2006). In addition, five g of nuclear fraction N, cytosolic fraction C, supernatants S1, 
S2, S3 and synaptosomal fraction Syn (see 3.2.1) were resolved by 1D-gel electrophoresis, and 
proteins were electrotransferred to Immobilon PVDF membranes (Millipore, Bellerica, MA, USA) 
at 100V for 1h. Membranes were blocked overnight with 5% (w/v) Carnation instant non-fat dry 
milk in Tris buffered saline (TBS) buffer containing 0.05% Tween 20 (TBS-T) (GE Healthcare, 
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Piscataway, NJ, USA) and incubated with anti-Slc17a7 (NeuroMab, Davis, CA, USA, mouse 
monoclonal, 1:1100), anti-Gria2 (NeuroMab, mouse monoclonal, 1:1100), anti-PSD95 (Genetex, 
Irvine, CA, USA, goat polyclonal, 1:3000), anti-Gap43 (Abcam, Cambridge, UK, rabbit polyclonal, 
1:6000), anti-Prkc (Santa Cruz Biotechnology, Santa Cruz, CA, USA, rabbit polyclonal, 1:1000), 
anti-Crym (Santa Cruz Biotechnology, goat polyclonal, 1:1000) and anti-Mbp (Abcam, rabbit 
monoclonal, 1:2000) primary antibodies for 1.5-2h at room temperature. Membranes were 
incubated for 1h at room temperature with the corresponding anti-rabbit (GE Healthcare), anti-
mouse (GE Healthcare) and anti-goat (Santa Cruz Biotechnology) secondary antibodies. Immune 
complexes were detected by the ECLplus reagent kit (GE Healthcare), membranes transferred to 
a Hypercassette (GE Healthcare) and exposed to Hyperfilm (GE Healthcare) for the required 
amount of time. Equal loading amounts were ensured by staining transfer membranes with 
Coomassie brilliant blue R-250 (BioRad) and comparing signal intensities.  
 
3.2.3 Isoelectric focusing-proteomics sample preparation 
Isoelectric focusing (IEF) is an electrophoretic method, where proteins or peptides are separated 
according to their isoelectric point on an IPG strip. Because of the negative charge of the 
phosphogroup, phosphopeptides have lower isoelectric points compared to non-phosphorylated 
peptides and therefore they migrate to the acidic part of the IPG strip. Due to phosphopeptide 
enrichment at the acidic part of the strip, IEF can be employed as a separation method to 
simultaneously interrogate the proteome and phosphoproteome of mouse synaptosomes. In the 
present study, 1.2mg of whole mouse brain synaptosomal proteins in 100l distilled water were 
dissolved in 200mM ammonium bicarbonate (Merck, Darmstadt, Germany), pH 8.5 (10g/l) and 
8M urea (Genaxxon, Ulm, Germany). After reduction with 10mM dithiothreitol (BioRad) and 
alkylation with 50mM iodoacetamide (BioRad), the urea concentration was reduced by 
ultrafiltration to 2M and a final sample volume of 100l. One hundred l of distilled water were 
added, and the sample was digested first with 24g endoproteinase Lys-C (Wako, Neuss, 
Germany) overnight at room temperature, followed by 24g trypsin (Promega, Madison, WI, USA) 
overnight at 370C. To the digests, distilled water and urea were added to a final volume of 300l 
and a final urea concentration of 2.5M. The digest solution was applied to a pH 3.5-4.5, 18cm, 
non-linear IPG strip (GE Healthcare). After 10h of active rehydration at 50V, IEF was carried out 
in an IEF Cell (BioRad) until 60kVh were reached. The IPG strip was then cut into 47 4mm pieces. 
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For each gel piece, peptide extraction was performed three times with 5% formic acid. Oil 
extraction of the combined peptide fraction was performed three times with 150l hexane (VWR, 
Darmstadt, Germany). The organic phase was discarded and the aqueous fraction lyophilized. 
The resulting pellet was again oil extracted with 10l hexane (VWR) and air-dried overnight. 
Pellets were dissolved in 25l 5% formic acid and lyophilized. Samples were redissolved in 6l 
1% formic acid, and 3l were used for MS analysis. Desalting with OMIX tips (Varian, Palo Alto, 
CA, USA) was performed according to manufacturer´s instructions. 
 
3.2.4 LC-ESI-MS/MS  
For LC-ESI-MS/MS, 3µl from each IPG fraction were loaded onto a fused silica column, washed 
with 0.1% formic acid for 20min and eluted with a gradient of 95% acetonitrile/0.1% formic acid 
from 2% to 45% over 90min at a flow rate of 200nl/min. The mass spectrometer was operated in 
the positive ion mode applying a data-dependent automatic scan switch between MS and MS/MS 
acquisition. Full scans were recorded in the Orbitrap mass analyzer at a mass range of m/z 380-
1600 and a resolution of R=60000 (m/z 400) in profile mode. The MS/MS analysis of the five 
most intense peptide ions for each scan was recorded in the LTQ mass analyzer in centroid 
mode (top5 method). Fragmentation in the LTQ was induced by collision-induced dissociation 
(CID) with a target value of 10000 ions. Ion selection threshold was 500 ions, and the selected 
sequenced ions were dynamically excluded for 120s. Other MS conditions were as follows: Spray 
voltage 1.9-2.1kV, no sheath and auxiliary gas flow, ion transfer tube temperature 190-2000C and 
normalized collision energy 35%. An activation q=0.25 and activation time of 30ms were applied 
for MS/MS acquisitions. 
 
3.2.5 Proteomics data analysis 
MS raw files were searched against a concatenated, forward/reverse decoy, international protein 
index (IPI) mouse database (v3.29) utilizing BioWorks (v3.3.1, Thermo Fischer Scientific) and 
SEQUEST (v28, Thermo Fischer Scientific) softwares. Precursor and fragment ion tolerance was 
set to 5ppm and 1Da, respectively. Trypsin was chosen as enzyme, and up to two missed 
cleavage sites were allowed.  Cysteine carboxyamidomethylation was used as static modification. 
Methionine oxidation and serine, threonine and tyrosine phosphorylation were used as variable 
modifications. Filtering parameters for peptide identifications were minimum Delta Cn: 0.08 and 
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Xcorr: 1.90 (z=1+), 2.70 (z=2+), 3.50 (z=3+), 3.00 (z4+). Due to the isoelectric point-based 
separation at the peptide level, peptides belonging to the same protein can migrate in different 
parts of the strip according to their amino acid composition. Therefore, peptide identifications from 
all IPG fractions were merged with an in-house developed Perl script. Keratin and hemoglobin 
proteins were excluded. Proteins identified by only one peptide sequence in a single fraction were 
removed. Proteins identified by one peptide sequence present in more than one fraction were 
considered for further analysis. Phosphorylated proteins identified by one peptide sequence both 
in its modified and unmodified forms or by more than two phosphopeptides were included. All 
phosphopeptide spectra were manually confirmed. Due to the low phosphorylation stoichiometry, 
phosphopeptides with a low SEQUEST score were also manually validated. Functional 
annotation was performed according to Gene Ontology (GO) using the FatiGO online tool (Al-
Shahrour et al., 2005; http://babelomics3.bioinfo.cipf.es). GO annotations were then grouped into 
ten broader categories. 
 
3.3 15N metabolic labeling of the HAB/NAB/LAB mouse model of trait anxiety 
 
3.3.1 15N metabolic labeling breeding and feeding scheme  
To enable an accurate quantitative proteomics comparison, mice were labeled with the 15N 
isotope through a 15N bacterial protein-based diet (U-15N-SILAM-Mouse, Silantes, Munich, 
Germany). To avoid any diet-specific effects on the proteome, the unlabeled mice that were used 
for the 14N/15N comparison received a 14N (unlabeled) bacterial protein-based diet (U-14N-SILAM-
Mouse, Silantes) with the same composition as the 15N diet (Table 3.1) following the same 
feeding protocol as the 15N bacteria-fed mice. To achieve high 15N incorporation rates, the 15N 
feeding started in utero according to the breeding and feeding protocol shown in Fig. 3.1. In detail, 
females were mated one-to-one to a male. After pregnancy detection, males were separated from 
the dams, and pregnant dams were fed for a four day period ad libitum with both standard food 
(Altromin, Lage, Germany) and the respective 15N or 14N bacteria-based food so as to habituate 
to the new diet. Dams were then fed exclusively with the bacteria-based diet.  For the offspring, 
gender detection was performed on post-natal day (PND) 2. On PND 5, USV was tested, and 
litters got culled to a usual litter size number. On PND 28, animals were weaned and group-
housed (2-4 animals per cage). Groups were composed of mice deriving evenly from all litters so 
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as to minimize cage effects. Each cage was supplied with the 14N or 15N bacterial diet according 
to the diet that the dam received. All animals were tested on PND 49 on the EPM and on PND 51 
in the TST. On PND 5, 14, 28 and 56, animal sampling was performed for 15N metabolic labeling 
efficiency calculation. On PND 56, material from all animals (10 15N HAB, 24 15N NAB, 10 14N 
HAB, 13 14N NAB and 12 14N LAB mice, all males) was acquired. 
 
Bacterial diet composition 
20% Ralstonia eutropha 
[Lyophilized, 15N-labeled (isotope enrichment >98%)  
or 14N bacterial hydrolysate] 
35% Sucrose 
13% Maltodextrin 
10% Corn Starch 
0.3% L-Cystine 
8% Soybean Oil 
7.2% Cellulose 
0.3% Calcium Phosphate, dibasic 
0.025% Ferric Citrate 
1.4% Vitamin Mix, AIN-93-VX (94047) 
0.25% Choline Bitartrate 
0.0024% Tert-butylhydroquinone, antioxidant 
4.5% Mineral Mix, AIN-93M-MX (94049) 
 
Table 3.1 Composition of the bacteria-based diet 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.1 Bacterial diet breeding and feeding protocol 
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3.3.2. Behavioral testing 
3.3.2.1 Ultrasonic vocalization test  
It has been proposed that the number of USV calls induced by separation and isolation of the 
offspring from the dam can be considered as a measure of separation anxiety and is indicative of 
adult emotionality (Brunelli, 2005). Therefore, USV can be used to monitor anxiety-related 
behavior at an early developmental stage (Krömer et al., 2005). On PND 5, each pup was 
separated from its mother and was placed onto a Petri dish (diameter: 15cm, wall height: 1.5cm, 
temperature: 230C kept constant by a water bath below the dish) having no olfactory or auditory 
contact to its litter (Fig. 3.2). USV was recorded for 5min using a Mini-3 Bat detector (Ultrasonic 
Advice, London, UK), fixed about 10cm above the pup and a WM-D6C tape recorder (Sony 
Professional, Cologne, Germany). The number of vocalization calls at 70kHz was quantified by 
Eventlog (v1.0, EMCO Software, Reykjavik, Iceland). Before the introduction of each pup, the 
dish was cleaned with a 70% alcohol solution.  
 
          
 
 
 
 
    A       B 
Figure 3.2 Ultrasonic vocalization test 
A. Experimental set-up. B. Schematic overview of ultrasound recording by the ultrasonic detector 
(figure kindly provided by Dr. Mirjam Bunck). 
 
3.3.2.2 Elevated plus-maze test 
The EPM testing apparatus consists of a plus-shaped platform, 37cm elevated above the floor, 
with two open (30 x 5cm) and two closed (30 x 5 x 15cm) arms with a connecting central zone (5 
x 5cm). The open arms were lit by white light of 300lux, the neutral zone by 60lux and the closed 
arms by 5lux. The EPM apparatus was surrounded by a black curtain to limit visual or auditory 
cues for the tested subject. Mice were transferred from their cage to the EPM apparatus and 
placed on the central part, facing one of the closed arms (Fig. 3.3). The % time spent on the open 
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      A                                   B 
arms (ratio of time spent on the open arms to total time spent on closed and open arms) and the 
total number of entries into all arms were recorded during a 5min exposure by Plus-maze (v2.0, 
Ernst Fricke, Munich, Germany). For all animals tested, EPM was performed on PND 49. Before 
the introduction of each mouse, the maze was cleaned with water containing detergent and 70% 
alcohol. 
Figure 3.3 Elevated plus-maze test 
A. Experimental set-up. B. Schematic overview of the different areas of the maze (figure kindly 
provided by Dr. Mirjam Bunck). 
 
3.3.2.3 Tail suspension test  
The TST is based on the fact that mice subjected to the short-term, inescapable stress of being 
suspended by their tail, immediately engage in active, escape-oriented behavior, followed 
progressively by increasing periods of immobility. Immobility is indicative of a passive, 
depression-like behavior (Cryan et al., 2005).  
 
 
 
 
 
 
 
Figure 3.4 Tail suspension test 
A. Experimental set-up. B. Schematic overview of the behavioral parameters assessed (figure 
kindly provided by Dr. Mirjam Bunck). 
           A                       B 
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The TST experimental set-up consists of a horizontal plastic rod (length 75cm) at a height of 
75cm with four vertical rods (15cm). Mice were suspended by their tails at a height of 35cm 
above the ground by an adhesive autoclave tape for 6min (Fig. 3.4). Four animals were tested 
simultaneously, and each trial was videotaped. Animal behavior (total immobility time) was 
analyzed using Eventlog (v1.0, EMCO Software). For behavioral test data analysis, data 
dependent on two or more variables were compared using univariate analysis of a general linear 
model, subsequently split and further analyzed by Student’s t test (two tailed, unpaired). 
Bonferroni correction was applied to adjust for multiple comparisons (Frank et al., 2009).  
 
3.3.3 Tissue acquisition 
For tissue acquisition on PND 5, 14, 28 and 56, animals were anesthetized and perfused with 
0.9% saline. Whole brain was extracted and cingulate cortex, cerebellum and hippocampus were 
dissected. Pituitary, thymus, heart, lung, liver, spleen, pancreas, adrenals, kidney and muscle 
were also harvested. Prior to perfusion, blood was collected and centrifuged at 13000g for 10min 
at 40C to separate plasma from red blood cells. All samples were snap frozen in liquid nitrogen 
and stored at -800C. 
 
3.3.4 15N metabolic labeling efficiency estimation 
3.3.4.1 Proteomics sample preparation 
15N metabolic labeling efficiency was monitored throughout the breeding protocol in brain and 
plasma at different time points (PND 5, 14, 28 and 56). Up to four 14N/15N mouse pairs were 
assessed per time point (cerebellum and plasma). Equal tissue weights of 14N/15N mouse 
cerebella pairs and equal volumes of 14N/15N plasma pairs were mixed.  Brain samples were then 
homogenized in 250mM sucrose (Sigma Aldrich) buffer containing 50mM Tris-HCl (BioRad), 
5mM MgCl2 (Sigma Aldrich), 1mM dithiothreitol (BioRad), spermine (25g/ml, Sigma Aldrich), 
spermidine (25g/ml, Sigma Aldrich) and cocktail inhibitor tablets (Roche Diagnostics) and 
centrifuged at 25000g for 1h at 40C. The supernatant was concentrated at 13000g, for 30min at 
200C using 3kDa cut off spin filters (Millipore). Plasma samples were diluted 1:10 (v/v) with 0.9% 
saline. Extracted protein mixtures from brain and plasma were resolved by 1D-gel electrophoresis 
and the gel stained with Coomassie brilliant blue R-250 (BioRad).  Several gel bands were 
chosen, cut into small pieces, washed twice with 25mM ammonium bicarbonate (Merck)/50% 
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acetonitrile and digested with trypsin (5ng/l, Promega) overnight at 370C. Peptides were 
extracted with 50% acetonitrile/2% formic acid, lyophilized, redissolved in 10l 0.5% 
trifluoroacetic acid (Sigma Aldrich) and desalted by OMIX tips (Varian). 
 
3.3.4.2 MALDI-TOF/TOF MS-relative quantification 
Samples were diluted 1:1 (v/v) with a saturated matrix solution of 4-hydroxy-alpha-cyano-
cinnamic acid (Bruker Daltonik), spotted onto an AnchorChip 600m target (Bruker Daltonik), air-
dried at room temperature and then analyzed by MALDI-TOF/TOF MS. Ions were accelerated at 
+25kV with 0 nsec of pulsed ion extraction delay. Each spectrum was acquired in reflector 
positive mode summing 100 laser shots and externally calibrated by a peptide mixture standard 
(Bruker Daltonik). MS data were processed using the Flex analysis software (v3.0, Bruker 
Daltonik), and MS/MS data were searched against a Swissprot (v51.6) mouse database by the 
MASCOT software (v2.2, Matrix Science, London, UK). Dynamic oxidation of methionine and 
static carboxyamidomethylation of cysteine were set as amino acid modifications. Precursor and 
fragment ion tolerance was set to 150ppm and 0.7Da, respectively, allowing one missed cleavage 
for the tryptic digestion. MALDI MS raw spectra and MASCOT result files were exported to .dat 
and .xml formats, respectively and submitted to the in-house developed QuantiSpec software 
(Haegler et al., 2009) for calculation of 15N incorporation rates. 
 
3.4 Biomarker and pathway discovery in the HAB/NAB/LAB mouse model of trait 
anxiety  
 
3.4.1 Animals 
14N bacteria-fed HAB and LAB mice were indirectly compared by using 15N NAB mice as internal 
standards (see Fig. 6.1). For the 14N HAB/14N LAB indirect line comparison, three 14N HAB/15N 
NAB and three 15N NAB/14N LAB bacteria-fed, PND 56 mouse pairs were analyzed by LC-ESI-
MS/MS. Selection was based on the EPM performance (% time spent on the open arms), 
ensuring that the chosen mice accurately represent the HAB, NAB and LAB behavioral 
phenotype. The individual data of the animals studied with quantitative MS are given in Appendix 
2. Western blot validation of selected differentially expressed proteins in 14N HAB and 14N LAB 
mice was conducted in an independent population of standard diet-fed (Altromin), HAB/NAB/LAB 
   Materials and methods 
________________________________________________________________________ 
26 
animals of similar age as the bacteria-fed animals (n=8 per line). For quantitative MS and 
Western blot analyses, synaptosomes from cingulate cortices were studied. For quantitative 
metabolomics analysis, cingulate cortices from standard-fed HAB/NAB/LAB animals of similar 
age as the bacteria-fed animals were compared (n=6 per line). 
 
3.4.2 Synaptosome enrichment from HAB/NAB/LAB cingulate cortices 
Synaptosome enrichment and protein content estimation from HAB, NAB and LAB cortices were 
performed as described in 3.2.1 with slight modifications. For the bacteria-fed animals analyzed 
with MS, the 14N and 15N samples were processed separately until generation of the S1 
supernatant. The S1 fractions from 14N and 15N cortices were then mixed 1:1 (w/w) based on 
protein content, and the combined fraction was used for synaptosome enrichment, as in 3.2.1. 
For the standard-fed animals used for Western blot analysis, synaptosome enrichment was 
performed as in 3.2.1. 
 
3.4.3 Proteomics sample preparation from HAB/NAB/LAB synaptosomes 
For quantitative MS, three 14N HAB/15N NAB and three 15N NAB/14N LAB animal pairs were 
compared. For each 14N/15N animal pair, 100g of the combined synaptosomal fraction from the 
corresponding 14N/15N cingulate cortices were resolved by 1D-gel electrophoresis, and the gel 
was stained with Coomassie brilliant blue R-250 (BioRad). Every gel lane was sliced into 25 
fractions that were cut into small pieces and washed twice with 25mM ammonium bicarbonate 
(Merck)/50% acetonitrile, followed by reduction with 10mM dithiothreitol (BioRad) for 30min at 
560C and carboxyamidomethylation with 50mM iodoacetamide (BioRad) for 30min at room 
temperature. Proteins were digested with trypsin (5ng/µl, Promega) overnight at 370C, and 
peptides were extracted twice with 50% acetonitrile/2% formic acid. For every fraction, peptides 
were lyophilized and dissolved in 10l 1% formic acid. 
 
3.4.4 Mass spectrometry-relative quantification-data analysis 
Five l per fraction were analyzed by LC-ESI-MS/MS as described in 3.2.4. MS raw files were 
searched twice against a 14N and a 15N decoy IPI mouse database (v3.46), utilizing BioWorks 
(v3.3.1, Thermo Fisher Scientific) and SEQUEST (v28, Thermo Fischer Scientific) softwares. For 
both searches, precursor and fragment ion mass tolerance was set to 20ppm and 1Da, 
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respectively. Trypsin was chosen as enzyme and up to two missed cleavage sites and only fully 
tryptic peptides were allowed. Cysteine carboxyamidomethylation was used as static modification. 
Methionine oxidation was used as variable modification. Peptide identifications from both 
searches were exported as DTA files, combined and subsequently filtered and assembled into 
proteins by the DTASelect tool (v1.9, Tabb et al., 2002). To achieve a low false positive 
identification rate, the following filtering parameters were used: Minimum Delta Cn: 0.08; Xcorr: 
1.90 (z=1+), 2.70 (z=2+), 3.50 (z3+); purging duplicate spectra on basis of the Xcorr (-t=2); 
minimum charge state: 1; maximum charge state: 6 and a minimum of one identified peptide per 
protein. Extracted ion chromatogram (XIC) generation as well as peptide and protein abundance 
ratio estimation was performed by the ProRata software (v1.0) using default parameters (Pan et 
al., 2006a). 14N/15N peptide pairs were used for relative quantification. The sum of the areas 
under each peak of the isotopologue pattern of the corresponding 14N and 15N peptide spectra 
were compared. Briefly, the identified peptides for every 14N/15N replicate were filtered and 
quantified with a minimum profile signal-to-noise ratio cutoff of 2. Proteins with at least two 
quantified peptides were evaluated for quantification. For the 14N HAB/14N LAB indirect 
comparison, the two 14N HAB/15N NAB and 15N NAB/14N LAB direct comparisons were combined, 
and proteins were further filtered with a maximum confidence interval (CI) width cutoff of 3. 
Quantification results were manually evaluated, and inaccurate quantifications due to incorrect 
isotopologue pattern assignment as well as quantified protein contaminants (e.g., keratin, 
hemoglobin) were excluded. To correct for potential mixing errors during sample preparation, 
quantification results were normalized by substracting the median from all log2 ratios of the 
quantified proteins. Only proteins quantified in at least two out of three biological replicates per 
14N/15N comparison were included for further analysis. Quantified proteins were considered to be 
differentially expressed when their
 
14N HAB/14N LAB protein abundance ratio was >1.3 fold, and 
the corresponding 95% CI did not contain 0.  
 
3.4.5 HAB/NAB/LAB cingulate cortex metabolome comparison  
For quantitative metabolomics analysis, lysates from cingulate cortices (n=6 per line) were 
compared. Samples were measured at the Metabolomics Core, UC Davis Genome Center, CA, 
USA by gas chromatography-time of flight-mass spectrometry (GC-TOF-MS), using a 6890 N gas 
chromatograph (Agilent Technologies, Palo Alto, CA, USA) interfaced to a TOF Pegasus III mass 
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spectrometer (Leco, St. Joseph, MI, USA). GC-TOF-MS was performed according to standard 
operation procedures, as previously described (Zou and Tolstikov, 2009). To identify a set of the 
most informative metabolites (i.e. those metabolites that could contribute reasonably to the 
discrimination between the HAB/NAB/LAB lines), two exploratory statistical analyses, namely 
random forest analysis (RF; Díaz-Uriarte and Alvarez de Andrés, 2006) and the in-house 
developed test- and functional-free biomarker searching method (TFFBS; Yassouridis et al., in 
preparation), were applied. Using the maximum set of metabolites selected by both methods as 
dependent variables and the animal line (HAB/NAB/LAB) as independent variable, a multivariate 
analysis of variance (MANOVA, Wilks multivariate tests of significance) was performed to verify 
whether there is a significant line effect on these metabolites and on which of them the effect is 
more pronounced. Bonferroni post-hoc tests at a 0.05 significance level were then applied to 
localize the line pairs, where each metabolite contributes significantly to the observed line 
differences. Finally, a discriminant analysis was conducted with the maximum set of metabolites 
selected by the exploratory methods to assess the discrimination power of the identified 
metabolite candidates. 
 
3.4.6 Western blot validation of selected differentially expressed proteins 
To confirm quantitative MS results of the 14N HAB/14N LAB indirect comparison, Western blot 
analysis was performed as described in 3.2.2 for the following primary antibodies: Anti-Sfxn5 
(Abnova, Taipei, Taiwan, rabbit polyclonal, 1:100), anti-Car2 (Santa Cruz Biotechnology, goat 
polyclonal, 1:500), anti-Myh10 (Santa Cruz Biotechnology, goat polyclonal, 1:200) and anti-Sdhb 
(Abcam, mouse monoclonal, 1:1100). After development, autoradiographs were scanned, and 
quantification of the signal intensities was performed using QuantityOne (v4.4.0, BioRad). Signal 
intensity was measured as optical density x surface (OD*mm2). Student’s t test (two tailed, 
unpaired) was employed to assess signal intensity differences between the groups under 
comparison.  
 
3.4.7 In silico pathway analysis 
For literature data mining and pathway visualization, Pathway Studio (v7.1, Ariadne Genomics, 
Rockville, MD, USA) was used. To identify altered pathways in HAB and LAB mice based on 
proteomics and metabolomics data, the HAB/LAB log2 ratios of all quantified proteins and 
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metabolites were plotted in a combined histogram. Quantified proteins and metabolites were then 
assigned according to their HAB/LAB log2 ratios to five continuous bins: (-∞, -0.8), [-0.8, -0.4),     
[-0.4, 0.4], (0.4, 0.8], (0.8, +∞). The contents of each bin were compared to Kyoto encyclopedia of 
genes and genomes (KEGG; Kanehisa and Goto, 2000) to identify overrepresented pathways per 
bin. The hypergeometric test was calculated for each pathway per bin using the statistical 
language R (www.R-project.org). The p value threshold for significantly enriched pathways was 
set to 0.01. Pathways with significant enrichment in at least one bin were then hierarchically 
clustered. 
 
3.5 15N isotope effect investigation in HAB mice and Escherichia coli 
 
3.5.1 Animals 
For the 14N HAB/15N HAB comparison, three bacteria-fed, PND 56 14N HAB/15N HAB mouse pairs 
were compared by LC-ESI-MS/MS. Selection criterion was their TST performance (immobility 
time), with the average immobility time of the 14N HAB being higher than the average immobility 
time of the 15N HAB mice, depicting the antidepressant-like effect of 15N on the behavioral 
phenotype of HAB mice (see 5.2.1.2). The individual data of the HAB mice studied with 
quantitative MS are shown in Appendix 2. Western blot validation of differentially expressed 
proteins was performed in an independent population of bacteria-fed, PND 56 14N HAB (n=4) and 
15N HAB (n=7) mice. Cingulate cortex synaptosomes were analyzed with quantitative MS. For 
Western blot analysis, the cingulate cortex cytoplasmic fraction (S1 supernatant from the 
synaptosome protocol, see 3.2.1) was used. For the 14N HAB/15N HAB MS comparison, 
synaptosome enrichment, proteomics sample preparation and quantitative MS were performed as 
described in 3.2.1, 3.4.3 and 3.4.4, respectively. Only proteins whose 15N HAB/14N HAB 
abundance ratio was >1.3 fold, and CI did not contain 0 both at the level of individual replicates 
and at the level of average CI of all replicates were considered to be differentially expressed. 
 
3.5.2 Escherichia coli culture 
E. coli BL21star strain (Invitrogen, San Diego, CA, USA) was taken from glycerol stocks, scraped 
with a sterile loop, streaked out on a LB-agar plate with 100g/ml ampicillin (Sigma Aldrich) as 
selective marker and incubated overnight at 370C. Single colonies were taken and inoculated in 
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2ml of either unlabeled 14N (Spectra 9-U) or 15N-enriched (Spectra 9-N, >98%) media (Cambridge 
Isotope Laboratories, Andover, MA, USA) with 100g/ml ampicillin. The pre-cultures were 
incubated for 6h at 370C with shaking at 220rpm, inoculated into 100ml of the 14N or 15N media 
containing 100g/ml ampicillin and incubated overnight at 370C with shaking at 220rpm. The 
cultures were then centrifuged at 5000rpm for 15min at 40C, supernatants were discarded, and 
14N and 15N E. coli pellets were frozen. For quantitative MS and Western blot analyses, the 14N 
and 15N pellets were dissolved in lysis buffer (1ml/100ml culture) consisting of 100mM Tris-HCl 
(BioRad) pH 8.0, 150mM NaCl (Merck), 1mM EDTA (Sigma Aldrich) and sonicated to break the E. 
coli cells. The lysates were centrifuged at 13000rpm for 12min at 40C, and supernatants 
containing the cytoplasmic fraction were collected.  
 
3.5.3 Escherichia coli proteomics sample preparation-mass spectrometry 
The 14N and 15N E. coli cytoplasmic fractions were combined 1:1 (w/w) based on protein content, 
100g of the 14N/15N mixture were resolved by 1D-gel electrophoresis, and the gel was stained 
with Coomassie brilliant blue R-250 (BioRad). In gel digestion and peptide extraction were 
performed as described in 3.4.3. For every fraction, extracted peptides were lyophilized and 
dissolved in 10l 1% formic acid. Five l were then loaded onto an in-house packed column and 
analyzed by LC-ESI-MS/MS as described in 3.2.4. Two technical replicates were measured per 
fraction. 
 
3.5.4 Escherichia coli proteomics data analysis 
For protein identification, a concatenated, forward/reverse decoy MSDB 
(ftp://ftp.ncbi.nih.gov/repository/MSDB) E. coli database was used. Database search and relative 
quantification were performed as previously described (see 3.4.4). Per replicate, proteins with at 
least two quantified peptides were evaluated for quantification. Peptides with the same sequence 
but different charge states were quantified as different entities. Peptides with the same sequence 
and charge state were grouped, provided that their MS/MS scans were acquired within a 2min 
interval (Pan et al., 2006b). Quantification results were manually evaluated, and inaccurate 
quantifications due to incorrect isotopologue pattern assignment were excluded. In the quantified 
dataset, for protein IDs corresponding to the same protein name, the amino acid sequences were 
manually checked. In all cases, every protein ID corresponded to a different protein variant and 
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therefore was treated as a separate protein entity. For every protein variant, variant-specific 
peptides were identified by MS. Quantification results were normalized by subtracting the median 
from all log2 ratios of the quantified proteins. Proteins were considered to be differentially 
expressed when their
 
14N/15N abundance ratio was >1.3 fold, and their 95% CI did not contain 0 in 
both replicates. Proteins quantified only in one of the two replicates were not considered for 
further analysis. Quantification reproducibility between the two replicates was assessed by 
Pearson correlation analysis that measures linear dependence between two variables.  
 
3.5.5 Western blot validation of selected differentially expressed proteins 
Western blot analysis and signal intensity quantification were performed as in 3.2.2 and 3.4.6, 
respectively. For the 14N HAB/15N HAB comparison, the anti-TnR (Santa Cruz Biotechnology, 
goat polyclonal, 1:400) and anti-Nefm primary antibodies (Abcam, rabbit polyclonal, 1:1000) were 
used. For the 14N/15N E. coli comparison, five g of 14N and 15N E. coli cytoplasmic fractions were 
resolved by 1D-gel electrophoresis. An anti-beta galactosidase (LacZ) primary antibody (Novus 
Biologicals, Littleton, CO, USA, chicken polyclonal, 1:10000) and a secondary anti-rabbit antibody 
(GE Healthcare) were used. Five technical replicates were evaluated per E. coli group. 
 
3.5.6 Pyruvate assay of 14N/15N Escherichia coli cytoplasm 
Pyruvate levels in the 14N and 15N E. coli cytoplasm were assessed using a pyruvate                           
assay kit (Biovision, Mountain View, CA, USA). 14N and 15N  E. coli culture pellets were dissolved 
in 1ml pyruvate assay buffer each, centrifuged, supernatant collected, and the colored product of 
pyruvate oxidation by pyruvate oxidase was measured in triplicate using a GENios Pro microplate 
reader (Tecan, Männedorf, Switzerland) according to manufacturer’s instructions. 14N and 15N 
group differences were statistically evaluated by Student’s t test (two tailed, unpaired).  
 
3.5.7 In silico pathway analysis 
For the 14N HAB/15N HAB comparison, the FatiGO online tool (http://babelomics3.bioinfo.cipf.es) 
was used to compare over- or underrepresented functional groups in the differentially expressed 
and all quantified proteins. Pathway Studio (Ariadne Genomics) was utilized for literature data 
mining and pathway visualization. For the 14N/15N E. coli comparison, the functional clustering 
annotation tool DAVID (Dennis et al., 2003; http://david.abcc.ncifcrf.gov/home.jsp) was used. 
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3.6 Biomarker discovery in the G72/G30 transgenic mouse model of 
schizophrenia-like symptoms 
 
3.6.1 Animals 
Two transgenic mouse lines, G72Tg1 and G72Tg2, were generated carrying four and six copies 
of the human BAC clone RP11-111A8 containing the whole G72/G30 genomic region, 
respectively (see 1.3.3; Otte et al., 2009). Dissected cerebella from transgenic (G72Tg1 and 
G72Tg2, heterozygotes) and WT CD1 adult mice, bred in the animal facility of the University of 
Bonn were received for analysis. 
 
3.6.2 Sample preparation from G72/G30 transgenic and wild type cerebella  
Mouse brain cerebella were homogenized to powder in liquid nitrogen with mortar and pestle, and 
homogenates were solubilized using the PlusOne sample grinding kit (GE Healthcare) in IEF 
rehydration buffer [7M urea (Genaxxon), 2M thiourea (Sigma Aldrich), 100 mM dithiothreitol 
(BioRad), 4% CHAPS (BioRad), 0.2% biolytes (BioRad), 0.001% bromophenol blue (BioRad), 
phosphatase inhibitors (Sigma Aldrich), protease inhibitors (Roche Diagnostics) and pepstatin 
(Roche Diagnostics)].  
 
3.6.3 Two-dimensional Western blot  
Cerebellar homogenates from G72Tg1 transgenic and WT mice were compared. Per sample, 
150g of cerebellar protein homogenates were applied on pH 3-10, 11cm, non-linear IPG strips 
(BioRad), followed by active rehydration for 12h at 50V and IEF until 35kVh were reached. IPG 
strips were then layered on top of 10-20% linear gradient Criterion Tris-HCl gels (BioRad). After 
electrophoresis, proteins were transferred for 1h at 100V to Immobilon PVDF membranes 
(Millipore), followed by overnight blocking with 5% (w/v) Carnation instant non-fat dry milk in TBS-
T buffer at 40C. Membranes were simultaneously incubated for 2h at room temperature with the 
1410 (1:200) and 1411 (1:350) anti-G72, rabbit polyclonal antibodies (non-commercially available, 
provided by Dr. Isabel Benzel), followed by incubation with an anti-rabbit secondary antibody (GE 
Healthcare) for 45min at room temperature. After each incubation step, membranes were rinsed 
with TBS-T. Membranes were treated with ECLplus (GE Healthcare) for 5min, transferred to a 
Hypercassette (GE Healthcare) and exposed to Hyperfilm (GE Healthcare). Both 1410 and 1411 
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anti-G72 antibodies are directed against a peptide within G72 variant AY138546 
(VTRKEGWKRRHEDGY). Generation, purification and validation of these antibodies are 
described elsewhere (Benzel et al., 2008). 
 
3.6.4 Two-dimensional polyacrylamide gel electrophoresis 
Three G72Tg1 and three G72Tg2 mice were compared to three WT per line. Per sample, 150g 
cerebellar protein homogenates were applied on pH 3-10, 17cm, non-linear IPG strips (BioRad). 
IPG strips were actively rehydrated for 12h at 50V until 60kVh were reached. After equilibration 
for 15min in 2% dithiothreitol (BioRad) and 13min in 2.5% iodoacetamide (BioRad), IPG strips 
were layered on top of a 12.5% SDS polyacrylamide gel and run overnight at 150V. Gels were 
fixed in 10% acetic acid/50% methanol and treated with ProQ diamond fluorescent 
phosphoprotein stain (Invitrogen), followed by colloidal Coomassie brilliant blue G (Sigma Aldrich). 
ProQ and Coomassie stained gel images were acquired with a fluorescent Molecular Imager FX 
(BioRad) and a GS-800 Calibrated Densitometer (BioRad), respectively. Image analysis, spot 
intensity quantification and normalization were performed with the PDQuest Advanced 2D 
analysis software (v8.0, BioRad). 
 
3.6.5 Identification of differentially expressed proteins 
Gel spots representing protein expression differences between the G72/G30 transgenic and WT 
mice were excised, destained with 20mM ammonium bicarbonate (Merck)/acetonitrile 1:1 (v/v), 
air-dried overnight and digested with trypsin (5ng/l, Promega) in 1mM ammonium bicarbonate  
(Merck, 15min at 400C, 5h at 370C). Peptides were extracted twice in 2% trifluoroacetic acid and 
acetonitrile/2% trifluoroacetic acid 1:1 (v/v), lyophilized and dissolved in 5l 0.3% trifluoroacetic 
acid. MALDI-TOF/TOF MS was performed as described in 3.3.4.2. Only hits with confidential 
index >95% were considered significant. For the identified differentially expressed proteins, 
Pathway Studio (Ariadne Genomics) was utilized for literature data mining and pathway 
visualization.  
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4 Profiling of mouse synaptosome proteome and 
phosphoproteome 
 
4.1 Introduction 
 
Synapses are the main structures for inter-neuron communication. Neurotransmitter- and signal 
transduction-related events represent brain responses to behavioral experience (Bai and 
Witzmann, 2007). Since synapses constitute the fundamental information processing unit in the 
brain, synaptic dysfunction is believed to be an underlying mechanism for psychiatric and 
neurodegenerative disorders (Mohn et al., 1999; Snyder et al., 2005; Südhof, 2008). At the post-
translational modification level, reversible synaptic phosphorylation is required for basal 
neurotransmission (Smart, 1997) and is involved in learning and memory (Sunyer et al., 2008). 
Protein kinases and phosphatases have been implicated in the regulation of neurotransmitter 
release (Takahashi et al., 2003), receptor trafficking (Braithwaite et al., 2006), long term 
potentiation (Malenka and Nicoll, 1999) and memory consolidation (Bozon et al., 2003). Therefore, 
a thorough characterization of the synaptic proteome and phosphoproteome is crucial for 
understanding the organization of the synaptic machinery and its role in health and disease. 
Synaptosomes are artificially produced, isolated synapses. After mild disruption of brain tissue, 
nerve terminals detach from their axons and post-synaptic and glial cells to which they are 
connected. Subsequently, the pre-synaptic membranes reseal and enclose the nerve terminal 
contents to form synaptosomes. Synaptosomes are made up of the entire pre-synaptic terminal 
(mitochondria, cytoplasm, cytoskeleton, external membranes and synaptic vesicles) and often a 
part of the attached post-synaptic side (post-synaptic membrane and post-synaptic density) 
(Schrimpf et al., 2005). Under metabolizing conditions, synaptosomes respire, take up oxygen 
and glucose, maintain a normal membrane potential and release neurotransmitters in a calcium-
dependent manner (Whittaker, 1993), thus retaining the molecular neurotransmission machinery 
and mimicking synaptic function in vivo.  
The synaptic machinery is of paramount importance in anxiety pathophysiology. Anxiety disorders 
are associated with alterations in neurotransmission, including serotonin, dopamine and gamma-
aminobutyric acid (GABA) neurotransmitter systems (Nemeroff, 2003; Stein et al., 2002). 
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Furthermore, current anxiolytic treatment regulates neurotransmission (Gorman, 2002), 
neurotransmitter modulators constitute potential therapeutic targets (Nemeroff, 2003), and 
neurotransmitter receptors modulate anxiety levels (Barkus et al., 2010). Conceptually, the 
equilibrium between excitatory and inhibitory neurotransmission is critical for physiological anxiety, 
and disturbances of this synaptic balance can lead to pathological anxiety (Wu et al., 2008). Due 
to the pivotal role of synaptic neurobiology in anxiety manifestation, synaptosomes were chosen 
to be studied for identifying disease-specific markers and elucidating the molecular mechanisms 
underlying anxiety-related behavior in the HAB/NAB/LAB mouse model (Chapter 6). 
Before comparing the synaptosome proteomes of HAB/NAB/LAB mice in a quantitative manner, a 
profiling of the synaptosome proteome and phosphoproteome of a CD1 mouse was performed to 
get insights into the protein composition of synaptosomes, and create a reference protein map for 
the subsequent quantitative proteomics experiments. It has been previously shown in our group 
that IEF can be used for phosphopeptide enrichment (Maccarrone et al., 2006). To achieve a 
simultaneous, comprehensive analysis of the mouse synaptosome proteome and 
phosphoproteome, IEF was employed as a fractionation step, followed by LC-ESI-MS/MS.  
 
4.2 Results 
 
4.2.1 Western blot analysis of selected synaptosomal proteins 
To evaluate the specificity of the synaptosome enrichment procedure and investigate the 
expression of selected identified proteins in synaptosomes, a Western blot analysis was 
performed using fractions from different steps of the synaptosome enrichment protocol. A 
cytosolic fraction of a whole mouse brain was additionally included. Antibodies for synaptic 
proteins (anti-Gria2, anti-PSD95 and anti-Slc17a7) were used to test for synaptosome enrichment 
specificity. Glutamate receptor 2 (Gria2 or GluR2) binds L-glutamate in excitatory synapses 
activating ion transport channels. Discs large homolog 4 (PSD95) is a post-synaptic density 
protein marker, whereas brain specific sodium-dependent inorganic phosphate co-transporter 
(Slc17a7 or VGlut1) takes up glutamate into synaptic vesicles at pre-synaptic nerve terminals. All 
three antibodies showed satisfactory enrichment in the synaptosomal fraction and were not 
present in nuclei or in the supernatants S2 and S3 that do not include the synaptosomal fraction 
(see 3.2.1). Cytosolic proteins such as mu-crystallin (Crym) and protein kinase C family members 
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(Prkcb1, Prkcc, Prkce) were present but not specific for the synaptosomal fraction, as expected. 
Neuromudulin (Gap43), a neuronal marker, was also present in the synaptosomal fraction. Myelin 
basic protein (Mbp), which is involved in axon myelination and is commonly present as impurity in 
synaptosome preparations, was not detected in the synaptosomal fraction (Fig. 4.1). 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.1 Western blot analysis of selected proteins in different steps of the synaptosome 
enrichment protocol 
For the synaptosome-specific proteins Gria2, PSD95 and Slc17a7, no signals in N, S2 and S3 
fraction as well as enriched signals in Syn fraction were detected. The neuronal-specific protein 
Gap43 and the cytosolic proteins Crym and Prkc exhibited a wide expression pattern including 
the Syn fraction. No detectable signal for Mbp was observed in Syn fraction. Nuclear fraction N 
was used as a negative control for non-nuclear proteins. 
N: Nuclear fraction; C: Cytosolic fraction; S1, S2, S3: Successive supernatants in the 
synaptosome enrichment protocol (see 3.2.1); Syn: Synaptosomal fraction; Slc17a7: Brain-
specific sodium-dependent inorganic phosphate co-transporter; Gria2: Glutamate receptor 2; 
PSD95 (Dlg4): Post-synaptic density protein 95; Gap43: Neuromudulin; Prkc: Protein kinase C 
family; Crym:  Mu-crystallin; Mbp: Myelin basic protein. 
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4.2.2 Synaptosome proteome 
Analysis of whole mouse brain synaptosomes resulted in the identification of 4794 non-redundant 
protein hits, 2980 of which were identified with more than two peptides. False positive 
identification rate at the protein level was 0.35% after filtering and excluding one peptide hits 
using a decoy database. The identified proteins cover a wide range of molecular weights and 
isoelectric points (Fig. 4.2). The complete list of all identified proteins is available online (Filiou et 
al., 2010a; Table S1). 
 
 
 
 
 
 
 
 
       
     A 
 
 
 
 
 
 
 
     
        
     B 
 
Figure 4.2 Physicochemical properties of synaptosomal proteins 
A. Molecular weight distribution. B. Isoelectric point distribution. 
 
   Synaptosome profiling 
________________________________________________________________________ 
38 
Among the identified proteins were key components of synaptic function, including proteins 
involved in vesicle transport [synaptotagmin 1-3 (Syt1-3), vesicle-associated membrane proteins 
1-4 (Vamp1-4)], clathrin-mediated endocytosis [clathrin light chain B (Cltb), clathrin heavy chain 
(Cltc), isoform long of clathrin coat assembly protein AP180 (Snap91)] and post-synaptic density 
components [discs large homologs 1-4 (Dlg1-4), homer protein homologs 1-3 (Homer1-3), 
gephyrin (Gphn), calcium/calmodulin-dependent protein kinase type II (CaMKII)]. In addition, 
cytoskeletal proteins and metabolic enzymes, including the complete list of enzymes that are part 
of the citric acid cycle as well as enzymes involved in glycolysis and fatty acid metabolism were 
detected. Potential therapeutic targets for brain disorders, such as sodium- and chloride-
dependent GABA transporter 1 (Slc6a1) (LaRoche and Helmers, 2004), superoxide dismutase 
(Sod1) (Zhang et al., 2009a) and myristoylated alanine-rich C-kinase substrate (Marcks) (Watson 
et al., 1998) were also identified. GO analysis indicated that the majority of the annotated proteins 
are implicated in energy metabolism (41%), followed by structural organization (17%) and 
developmental processes (12%) (Fig. 4.3A). Enzyme/enzyme regulator activity characterizes 
28% of the proteins, whereas 22% are involved in protein-protein interactions (Fig. 4.3B). 
Interestingly, many identified proteins participate in phosphorylation-related processes; 200 
proteins exhibit kinase activity (GO: 0016301), 152 proteins phosphotransferase activity (GO: 
0016773), 193 pyrophophosphatase activity (GO: 0016462), while 18 proteins bind to kinases 
(GO: 0019900), and 493 proteins are involved in signal transduction (GO: 0007165). 
 
 
 
 
 
 
 
 
 
 
 
     A 
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      B 
Figure 4.3 Gene Ontology analysis of the synaptosome proteome 
A. Biological process annotation.  B. Molecular function annotation. 
 
4.2.3 Synaptosome phosphoproteome 
The interrogation of mouse synaptosomes for phosphoproteins resulted in the identification of 
264 phosphorylation sites, 205 of which were unambiguously assigned. Of the total phosphosites 
identified, 69% represent serine (S), 28% threonine (T) and 3% tyrosine (Y) modifications in 
accordance to the relative distribution of modified residues in other large scale mouse synaptic 
phosphoproteome studies (Collins et al., 2005; Trinidad et al., 2006). The identified phosphosites 
correspond to 133 unique phosphopeptides belonging to 118 phosphorylated proteins (Appendix 
3). Intriguingly, eight identified proteins (Atcay, Cadps, Cartpt, Cend1, Kcnc3, Pcsk1n, Rgs6, 
Slc7a8) are reported for the first time to be phosphorylated (Table 4.1). In detail, calcium-
dependent secretion activator 1 (Cadps or Caps1) is an essential component of the synaptic 
vesicle machinery (Jockusch et al., 2007). Cell cycle exit and neuronal differentiation protein 1 
(Cend1) participates in cell cycle exit and differentiation coordination of neuronal precursors 
(Politis et al., 2007). Isoform Kv3.3B of potassium voltage-gated channel subfamily C member 3 
(Kcnc3) is a potassium channel protein expressed in cerebellum (Goldman-Wohl et al., 1994). 
Regulator of G-protein signaling 6 (Rgs6) controls secondary messenger cascades and interacts 
with transcription regulatory proteins (Liu and Fisher, 2004). Caytaxin (Atcay) inhibits kidney-type 
glutaminase, an enzyme that converts glutamine to glutamate and may thus regulate glutamate 
synthesis in synapses during neurotransmission (Buschdorf et al., 2006). Furthermore, large 
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neutral amino acids transporter small subunit 2 (Slc7a8) is an amino acid transporter, whereas 
cocaine- and amphetamine-regulated transcript protein precursor (Cartpt) and proprotein 
convertase 1 inhibitor ProSAAS (Pcsk1n) are important neuropeptides for brain function. MS/MS 
spectra of novel phosphosites for the Rgs6 and Cend1 proteins are shown in Fig. 4.4.  GO 
analysis of the phosphorylated dataset showed that major functional categories are energy 
metabolism (25%), structural organization (21%) and developmental processes (15%) (Fig. 4.5A). 
Moreover, 37% of the phosphorylated proteins are involved in protein-protein interactions, 
followed by enzyme/enzyme regulator activity (18%) (Fig. 4.5B).  
 
Table 4.1 Novel phosphorylated synaptosomal proteins and their assigned sites of 
phosphorylation 
Eight novel phosphorylated proteins were identified. Underlined residues indicate unambiguously 
assigned phosphosites. 
 
 
 
 
 
 
 
 
 
 
 
      A 
Protein  Phosphorylated peptide  Phosphorylated residues 
Atcay LGGAVEDSSSPPSTLNLSGAHR S8 S10 
Cadps PSSPSPSVVSEK S5 S7 S10 
Cartpt ALDIYSAVDDASHEK S6 S12 
Cend1 PAPTVPAAPSSPDATSEPK S10 S11 T15 S16 
Kcnc3 SLSSIVGLSGVSLR S1 S3 
Pcsk1n ILTGSSEPEAAPAPR T3 
Rgs6 SVYGVTDETQSQSPVHIPSQPIR T6 T9 S11 
Slc7a8 NHPGSDTSPEAEASSGGGGVALK S5 T7 S14 S15 
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      B 
Figure 4.4 Representative MS/MS spectra of novel phosphosites 
A. Phosphorylation at S11 for the Rgs6 peptide SVYGVTDETQSQSPVHIPSQPIR was 
unambiguously assigned. B. For the Cend1 peptide PAPTVPAAPSSPDATSEPK, 
phosphorylation at S10 and S11 could not be unambiguously assigned. In the MS/MS spectra, 
the mono, double and triple charged b and y ions identified are shown. Peaks marked by (#) in 
the ion superscript denote phosphorylated fragment ions. Underlined in the peptide sequence are 
the (potential) phosphorylation sites. Red and blue peaks correspond to b and y ions, respectively. 
 
 
 
 
 
 
 
 
 
 
        A 
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          B 
Figure 4.5 Gene Ontology analysis of the synaptosome phosphoproteome 
A. Biological process annotation. B. Molecular function annotation. 
 
4.3 Discussion 
 
Although a number of studies have been performed to characterize the synaptic mouse proteome, 
comprehensive proteomics investigations of mouse synaptosomes have been rare. In the only 
study where the whole mouse brain synaptosome proteome was examined, Schrimpf and 
colleagues analyzed synaptosomes by isotope-coded affinity tags, strong cation exchange 
chromatography and LC-ESI-MS/MS and identified 1113 proteins (Schrimpf et al., 2005). Here, 
an in-depth analysis of the mouse synaptosome proteome and phosphoproteome is presented. 
We identified 2980 unique proteins with two or more peptides, including 118 phosphoproteins, 
which is the most detailed mouse synaptosome protein dataset described to date (Filiou et al., 
2010a). IEF is an effective fractionation method at the peptide level compared to classical 1D-gel 
electrophoresis at the protein level (Filiou, unpublished observations), resulting in a 
comprehensive analysis of brain tissue subproteomes. IEF fractionation is a highly sensitive 
method for the detection of low stoichiometry proteins and significantly increases the dynamic 
range of the analysis. A substantial number of low abundant proteins identified by only two or few 
peptides are reported. For the synaptic proteome, the successful identification of such proteins is 
of major importance since the key components of the synaptic machinery that are responsible for 
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neurotransmission and synaptic plasticity (e.g., neurotransmitters and their receptors) are present 
in very low amounts.   
GO analysis of the protein dataset showed that apart from neurotransmission and synaptic 
plasticity, synaptosomal proteins participate in a variety of biological processes, including 
metabolism and development (Fig. 4.3A). Interestingly, 109 proteins participate in response to 
stress (GO: 0006950) and 125 in apoptosis (GO: 0006915), indicating that the synapse itself has 
developed mechanisms to retain its homeostasis. Our data support the observation that the 
molecular complexity of the synaptic proteome is greater than expected (Pocklington et al., 2006). 
Isolation of synaptosomal proteins is innately demanding, since synaptosomes constitute no pre-
existing subcellular organelle. Employing a well-established protocol, also used by others 
(Witzmann et al., 2005), only few protein identifications indicated contamination from astrocytes, 
myelin and serum (astrocytic phosphoprotein, myelin-forming proteins, albumin), whereas 
Western blot analysis showed satisfactory enrichment and specificity for synaptic proteins. No 
myelin basic protein, a myelin contamination marker, was detected (Fig. 4.1), thus ensuring the 
validity of the current protocol to study synaptosomes in an accurate manner and to be further 
used for quantitative studies of the synaptosome proteome (Chapter 6). 
IPG-based fractionation was applied to analyze complex protein mixtures from mouse brain and 
investigate the synaptosome phosphoproteome without employing additional steps for 
phosphoprotein enrichment. To date, only one other study has employed IEF to analyze 
phosphopeptides in brain tissue (Beranova-Giorgianni et al., 2006). In that report, a human 
pituitary protein extract was analyzed by IEF, and peptide mixtures were enriched for 
phosphopeptides with immobilized metal affinity chromatography resulting in the identification of 
73 phosphorylated peptides corresponding to 26 proteins. In the present study, 133 
phosphopeptides corresponding to 118 phosphoproteins were identified using a comparable 
amount of tissue. Large scale synaptosome phosphoproteome studies (Collins et al., 2005; 
Munton et al., 2007) often employ additional steps such as immobilized metal affinity or strong 
cation exchange chromatography to specifically enrich for phosphopeptides. In the current study, 
no additional phosphoenrichment step was performed, and both the synaptic proteome and 
phosphoproteome were investigated. This accounts for the relatively lower number of identified 
phosphopeptides compared to studies focusing exclusively on the phosphoproteome. Due to the 
low stoichiometry and the reversible nature of phosphorylation, the presence of phosphoproteins 
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may be masked by the expression of high abundant synaptic proteins making their identification 
in a complex mixture challenging.  
Taken together, a considerable percentage of the synaptosome proteome is involved in the 
regulation of phosphorylation and dephosphorylation events, suggesting that this post-
translational modification is of major importance in synaptic terminals. We performed a detailed 
literature search of the phosphorylated dataset and found 33 proteins that are reported to be 
implicated in psychiatric/neurodegenerative disorders. Among these, 13 proteins have been 
shown to be associated with more than one disorder, suggesting a possible role in multiple 
disease pathways (Filiou et al., 2010a).  Remarkably, phosphorylation events in eight neuronal-
specific proteins are for the first time reported. Four of the novel phosphorylated proteins (Atcay, 
Carptp, Slc8a2, Pcsk1n) have been implicated in neuropsychiatric disorders. The novel 
phosphorylation sites found in the present study may point out relevant mechanisms involved in 
disease pathobiology and deserve further investigation.  
In conclusion, the most comprehensive mouse synaptosome proteome analysis described to date 
was conducted. IEF coupled with LC-ESI-MS/MS is an effective proteomics platform that can be 
employed for the simultaneous analysis of the proteome and phosphoproteome of complex 
mixtures, such as brain synaptosome protein extracts.  Synaptosomes are characterized by 
considerable functional diversity and the explicit investigation of the synaptosomal protein 
constituents and especially low abundant synaptic proteins will aid the further understanding of 
brain neurochemistry and synapse function, provide a reference map for synaptic large scale 
quantification studies in mouse models, reveal key components of neurotransmission and point to 
potential candidates for therapeutic intervention. 
 
 
 
   
15N metabolic labeling 
________________________________________________________________________ 
45 
5 15N metabolic labeling of the HAB/NAB/LAB trait anxiety 
mouse model 
 
5.1 Introduction 
 
In vivo 15N metabolic labeling has been applied so far to a wide range of organisms to address a 
variety of biological questions. In Rhodopseudomonas palustris, 15N metabolic labeling has been  
used to characterize p-coumarate anaerobic catabolism under different carbon sources (Pan et 
al., 2008). In C. elegans, 15N metabolic labeling has been employed to compare WT and 
germless strains (Krijgsveld et al., 2003) as well as to elucidate insulin signaling targets in insulin-
receptor deficient mutants (Dong et al., 2007). In Arabidopsis thaliana, the effects of oxidative 
stress (Bindschedler et al., 2008), cadmium exposure (Lanquar et al., 2007) and sucrose 
resupply after carbon starvation (Kierszniowska et al., 2009b) have been investigated by 15N 
metabolic labeling. In vivo 15N metabolic labeling is a powerful technique that also holds great 
promise for the study of higher organisms, including mammals (McClatchy et al., 2007a; Wu et al., 
2004). Recently, the 15N metabolic labeling approach was applied to an animal model of colon 
cancer in order to identify tumor-specific markers (Huttlin et al., 2009). To date, 15N metabolic 
labeling has not been yet applied to study animal models of psychopathologies. Here, the 
HAB/NAB/LAB mouse model was metabolically labeled with 15N via a bacterial, protein-based, 
15N-labeled diet. The high 15N incorporation achieved in vivo provides 15N-labeled tissue to be 
used in quantitative proteomics experiments, ensuring an accurate relative quantification of 
14N/15N material. 
 
5.2 Results 
 
5.2.1 Behavioral characteristics of bacteria-fed HAB/NAB/LAB mice 
No physiological, morphological or developmental defects were observed in the bacteria-fed 
animals. No differences in overall food consumption before weaning were observed for any 
mouse line, 14N or 15N bacterial diet (Frank et al., 2009). At the behavioral phenotype level, 
anxiety-related and depression-like behaviors were examined. 
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5.2.1.1 Anxiety-related behavior 
Anxiety-related behavior was assessed on PND 5 by USV (see 3.3.2.1) and on PND 49 by EPM 
(see 3.3.2.2). USV calls (Fig. 5.1A) and % time spent on the open EPM arms (Fig. 5.1B) were the 
main behavioral parameters examined. HAB, NAB and LAB animals showed the significant 
phenotypic divergence observed in the mice of the standard breeding both in USV and EPM tests 
(Frank et al., 2009, data not shown), indicating that the bacterial diet per se exerted no effect on 
anxiety-related behavior in all lines. In both tests, no significant difference was observed between 
14N and 15N bacteria-fed animals of the same line, showing that the introduction of the 15N isotope 
did not influence anxiety-related behavior. 
 
 
 
 
 
 
 
 
 
A            B 
Figure 5.1 Anxiety-related behavior in the ultrasonic vocalization and the elevated plus-
maze test 
A. An increased number of USV calls during the test time were observed in bacteria-fed HAB 
compared to LAB mice, with NAB mice exhibiting an intermediate behavior, similar to the animals 
of the standard breeding. No significant difference in the number of USV calls was found between 
14N and 15N bacteria-fed HAB or NAB animals. All available bacteria-fed animals on PND 5 were 
tested (27 14N HAB, 29 15N HAB, 46 14N NAB, 83 15N NAB, 29 14N LAB). B. HAB, NAB and LAB 
animals exhibited the significant anxiety-related, line-specific phenotypic divergence, similar to 
the animals of the standard breeding. HAB spent less time on the EPM open arms compared to 
LAB mice, and NAB mice exhibited an intermediate behavior. No significant difference in % time 
spent on the open arms was observed between 14N and 15N bacteria-fed HAB or NAB animals. 
The 15N diet had no effect on locomotion as measured by the total number of entries into all arms 
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(Frank et al., 2009; data not shown). On the EPM, 10 14N HAB, 10 15N HAB, 13 14N NAB, 24 15N 
NAB and 12 14N LAB mice were tested. 
 
5.2.1.2 Depression-like behavior 
Depression-like behavior was assessed on PND 51 by TST (see 3.3.2.3.). Total immobility time 
was the main behavioral parameter examined. The bacterial diet per se had no influence on the 
depression-like behavior compared to the animals of the standard breeding (Frank et al., 2009; 
data not shown). Intriguingly, a significant decrease in total immobility time in bacteria-fed 15N 
HAB compared to 14N HAB mice was observed, indicating a bacterial diet-independent, 
antidepressant-like effect of the 15N isotope in HAB mice (Fig. 5.2). 
 
 
 
 
 
 
 
 
 
Figure 5.2 Depression-like behavior in the tail suspension test 
Total immobility time indicative of depression-like behavior was significantly reduced in bacteria-
fed 15N HAB compared to 14N HAB mice (**p<0.01). Bacteria-fed 15N HAB still showed 
significantly increased total immobility time compared to 14N LAB mice (**p<0.01). No significant 
difference in immobility time was observed between bacteria-fed 14N NAB and 15N NAB mice. The 
same animals that were tested on the EPM were also tested here. 
 
5.2.2 15N metabolic labeling efficiency estimation 
15N incorporation efficiency was monitored at different developmental time points (PND 5, 14, 28 
and 56) in cerebellum and plasma of 15N bacteria-fed mice. Already on PND 5, 15N incorporation 
was >50.0% both in cerebellum and plasma. At early developmental time points, 15N 
incorporation in cerebellum was lower than in plasma due to the slow protein turnover in the brain. 
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However, on PND 56, the 15N incorporation in brain increased, reaching up to 92.0% both in 
cerebellum and plasma (Fig. 5.3). Representative examples of 14N/15N peptide pairs throughout 
development are shown in Fig. 5.4. 
 
 
 
 
 
 
 
A                      B 
                  
 
                
 
   
  C 
Figure 5.3 15N metabolic labeling efficiency at different developmental time points 
A. Cerebellum. B. Plasma. C. Table of average 15N incorporation rates at different PNDs. 
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Figure 5.4 Representative 14N/15N peptide spectra from different developmental time points 
and their corresponding 15N incorporation rates 
A. Brain beta-actin peptide IWHHTFYNELR. B. Plasma serum albumin peptide 
LGEYGFQNAILVR. As 15N incorporation increases, the isotopologue pattern of the 15N-labeled 
peptide (on the right) is shifted towards higher m/z ratios due to the presence of more ‘heavy’ 
nitrogens in the peptide backbone. 
 
5.3 Discussion 
 
A breeding and feeding protocol was established for in vivo metabolic labeling of mice with 15N 
through a bacterial protein-based diet. The bacterial protein-based diet did not interfere with 
normal development, and no side-effects were observed apart from a slight body weight reduction 
of the bacteria- compared to standard-fed animals (Frank et al., 2009). To date, metabolic 
labeling of rodents has been performed using a 15N-labeled, blue-green algae diet (Spirulina) (Wu 
et al., 2004; McClatchy et al., 2007a; Huttlin et al., 2009). All published efforts to label rodents 
with 15N and relevant proteomics applications are summarized in Table 5.1. According to our 
experience, offspring fed exclusively with the Spirulina-based diet exhibited severe 
developmental problems (Frank et al., 2009). Therefore, the bacteria-based diet was chosen due 
to the lack of side-effects in normal development and its lower cost compared to the Spirulina-
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based diet. Notably, a four day habituation period was introduced, during which mice had access 
ad libitum both to standard and bacterial food so as to ensure optimal transition to the new diet 
(Fig. 3.1). The bacterial diet did not influence anxiety-related behavior both at early and late 
developmental stages (as measured by USV and EPM, respectively), thus enabling proteomics 
analyses for identifying anxiety-related changes in an unbiased manner. Although the bacterial 
diet per se had no effect on the depression-like phenotype compared to the standard diet, an 
antidepressant-like effect of the 15N isotope was observed in HAB mice (see 5.2.1.2). This is the 
first time that the introduction of the 15N isotope has been reported to affect the behavioral 
characteristics of labeled organisms. Further investigation of this effect at the molecular level can 
shed light on pathways involved in the depression-like behavior in HAB (discussed in Chapter 7). 
For quantitative MS experiments, a satisfactory 15N incorporation is required to guarantee an 
accurate 14N/15N quantification. In the only study where mice have been metabolically labeled 
with 15N, 15N feeding started at the age of 3 weeks for 44 days, achieving an 82.8% 15N 
incorporation in brain. Here, a labeling protocol was established starting with 15N feeding in utero 
until early adulthood (8 weeks of age), achieving a 92.0% 15N incorporation in brain and 91.3% in 
plasma.  By starting the 15N feeding in utero, high 15N incorporation was achieved already at early 
developmental time points (Fig. 5.3). In the future, this will enable MS-based quantitative studies 
to investigate the ontogenetic development of anxiety-related behavior.  
Stable isotope labeling approaches have revolutionized the proteomics field and are to date the 
most sensitive quantitative proteomics approaches due to the ability of mixing the samples under 
comparison prior handling. Consequently, any error during experimental handling is introduced 
uniformly in both samples, and relative quantification accuracy is not affected (see 1.4.1.5). 
Although the generation of a 15N-labeled mouse is of considerable cost, all resulting 15N-labeled 
tissues can be used in a plethora of experimental workflows as internal standards, facilitating 
highly sensitive proteomics comparisons and providing an overall cost-effective, highly precise 
tool for quantitative proteomics. Incomplete labeling was until recently the main bottleneck for 15N 
metabolic labeling applications, as the complex nature of partially 15N-labeled spectra hindered 
accurate 14N/15N quantification. To address this issue, optimized in silico identification and 
quantification strategies for partially labeled peptides (Gouw et al., 2008; Zhang et al., 2009b) and 
several software solutions were developed to allow accurate 14N/15N quantification for partially 
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labeled material, both for MALDI (Haegler et al., 2009) and ESI instruments (Pan et al., 2006a; 
Park et al., 2008; Park and Yates, 2010). 
Taken together, a novel 15N metabolic labeling workflow that does not interfere with normal 
mouse development and results in high 15N incorporation rates even in organs with slow protein 
turnover (i.e. brain) has been established. This is the first time that 15N metabolic labeling has 
been applied to a mouse model of psychopathology. 15N-labeled NAB mice can be used in 
quantitative proteomics experiments to investigate anxiety-related protein changes (Chapter 6). 
Furthermore, the investigation of the 15N antidepressant-like effect in HAB mice can shed light on 
pathways involved in depression manifestation (Chapter 7). 
 
Organism Diet Labeling protocol 
15N brain 
incorporation 
(%) 
Application 
From PND 21 for 44 days 
(Wu et al., 2004) 74.3 
Protein synthesis inhibition  
in liver 
(Wu et al., 2004) 
In utero until PND 45 
(McClatchy et al., 2007a) 87.0 - 
Rat 
 
15N labeled 
Spirulinaa 
 From weaning on  
(for dams) 
until PND 45 for pups 
(McClatchy et al., 2007a) 
95.0 
Developmental comparison 
of synaptosomal 
cerebellum proteome 
(McClatchy et al., 2007b) 
and nuclear cortex 
phosphoproteins 
(Liao et al., 2008) 
15N labeled 
Spirulinaa 
From weaning on  
until PND 68 
(Wu et al., 2004 adapted) 
82.8 Colon cancer (Huttlin et al., 2009) Mouse 
 
15N labeled 
Ralstonia 
eutrophab  
In utero until PND 56, 
4 day habituation period 
(Frank et al., 2009) 
92.0 Anxiety disorders (Frank et al., 2009) 
 
a
 Spectra Stable Isotopes (now part  of  Cambridge Isotope Laboratories) 
b Silantes 
 
Table 5.1 Published approaches for metabolically labeling rodents with 15N 
15N-labeled rats have been used for developmental brain proteome and phosphoproteome 
comparisons. 15N metabolic labeling in mice has been applied to a model of colon cancer and the 
HAB/NAB/LAB model of trait anxiety. 
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6 Biomarker and pathway discovery in the HAB/NAB/LAB mouse 
model of trait anxiety  
 
6.1 Introduction 
 
Although anxiety disorders are the most common psychiatric disorders, no molecular markers 
exist for their prognosis, classification or treatment outcome. In our efforts to unravel the 
neurobiological underpinnings and identify candidate biomarkers for anxiety disorders, we 
interrogated the HAB/NAB/LAB mouse model of trait anxiety utilizing a quantitative multi-omics 
approach. As brain region of interest, the cingulate cortex was chosen. The cingulate cortex is in 
close connection to the amygdala, and its activation has been proposed to modulate amygdala’s 
response to fear (Coplan and Lydiard, 1998; Milad and Rauch, 2007; Muigg et al., 2008). 
Neuroimaging studies in humans and lesion analyses in animal models have implicated cingulate 
cortex areas in the modulation of emotional behavior (Drevets and Savitz, 2008; Etkin and Wager, 
2007; Hasler et al., 2007). Notably, alterations in cingulate cortex have been reported in panic 
disorder (Asami et al., 2008) as well as in other psychiatric conditions, including depression 
(Ballmaier et al., 2004) and schizophrenia (Carter et al., 1997). Furthermore, the cingulate cortex 
tissue amount obtained per animal allows proteomics interrogation of synaptosomes.  
Due to the key role of the synaptic machinery in anxiety pathophysiology (summarized in 4.1), we 
focused our proteomics investigation on synaptosomes. The quantitative proteomics platform 
based on 15N metabolic labeling (described in Chapter 5) and quantitative MS were applied to 
compare the cingulate cortex synaptosome proteomes of HAB and LAB mice. To circumvent 15N 
isotope-derived alterations, an indirect comparison workflow was employed using 15N-labeled 
NAB animals as internal standards (Fig. 6.1). 
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Figure 6.1 Proteomics strategy for HAB/LAB relative quantification 
Cingulate cortices from 15N bacteria-fed NAB as well as from 14N bacteria-fed HAB and LAB mice 
were excised and cytoplasmic fractions were mixed 1:1 (w/w) based on protein content for every 
14N/15N comparison. 15N bacteria-fed NAB mice were compared pairwise with 14N HAB and 14N 
LAB mice in two parallel steps. Data from the 14N HAB/15N NAB and 15N NAB/14N LAB 
comparisons were combined to indirectly compare the 14N HAB and 14N LAB synaptosome 
proteomes. 
 
In addition, the cingulate cortex metabolomes of HAB/NAB/LAB mice were quantified utilizing an 
established quantitative metabolomics platform in collaboration with the Metabolomics Core of 
UC Davis, CA, USA (Fig. 6.2). Moreover, differential expression of selected proteins was 
validated by Western blot in an independent, standard-fed HAB/NAB/LAB population and in silico 
pathway analyses based on proteomics and metabolomics data were performed to unravel 
altered networks in HAB and LAB animals. 
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Figure 6.2 Metabolomics strategy for HAB/NAB/LAB relative quantification 
Metabolite levels were quantified in cingulate cortex lysates of HAB/NAB/LAB mice employing a 
GC-TOF-MS-based quantitative platform.  
GC-TOF-MS: Gas chromatography-time of flight-mass spectrometry. 
 
6.2 Results 
 
6.2.1. HAB/LAB cingulate cortex synaptosome proteome comparison 
For quantitative MS analysis, three bacteria-fed 14N HAB and three 14N LAB mice were compared. 
In total, 2678 non-redundant proteins were quantified in all 14N/15N measured replicates. Of these, 
1214 were quantified in at least two out of three biological replicates per 14N/15N direct 
comparison (14HAB/15NAB and 15NAB/14LAB) and were considered for further analysis. Among 
them, 273 were found differentially expressed in HAB and LAB synaptosomes >1.3 fold (listed in 
Appendix 4), with 92 proteins showing expression differences 2 fold. Intriguingly, Glo1 was the 
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protein with the highest expression difference in HAB and LAB animals, exhibiting a 6.25 fold 
increased expression in LAB mice, thus confirming previous findings (Ditzen et al., 2006; Krömer 
et al., 2005). 
 
6.2.2 HAB/NAB/LAB cingulate cortex metabolome comparison 
For quantitative metabolomics analysis, 281 chromatographic peaks were quantified in all 
replicates (n=6 per line), 129 of which were assigned to known metabolites. Two explorative 
statistical analyses (RF and TFFBS) were employed, revealing a maximum set of 11 metabolite 
entities that seemed to be the most informative and most capable to accurately discriminate 
between the HAB/NAB/LAB lines (Table 6.1). Multivariate analysis showed a significant effect of 
the set of the 11 metabolite entities [Wilks multivariate tests of significance; effect of group: 
F(22,10)=10.71, f<0.0001], which was also significant for xylose, dehydroascorbate 1, 
dehydroascorbate 3 and four other metabolites, whose identity is unknown (203235, 239332, 
216860, 284389) (prime candidate metabolite biomarkers, univariate F-tests, *p<0.05). 
Subsequent Bonferroni post-hoc tests were used to localize in which of the line pairs HAB/LAB, 
HAB/NAB or NAB/LAB the selected metabolite entities show significant differences (arrows in 
Table 6.1).  
 
HAB/LAB HAB/NAB NAB/LAB 
Metabolitesa 
RF TFFBS RF TFFBS RF TFFBS 
Dehydroascorbate 1b* ↓ ↓ ↓ ↓   
Dehydroascorbate 3b* ↓ ↓ ↓ ↓   
Xylose* ↓ ↓   ↓ ↓ 
203235*    ↓   
216860*    ↓  ↑ 
239332*   ↓ ↓ ↑ ↑ 
284389*      ↓ 
Adenosine-5-monophosphate+      ↑ 
Flavin-adenine dinucleotide+    ↓   
Succinate+     ↑ ↑ 
234580+  ↓  ↓   
 
a numerical IDs correspond to quantified metabolites of unknown identity  
b quantified chromatographic peaks that correspond to the same metabolite 
* prime candidate metabolite biomarkers (univariate F-tests *p< 0.05 at a corrected level of significance) 
+ informative metabolites (metabolites identified as significant at the uncorrected level of significance only) 
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Table 6.1: Metabolites with the best discrimination power between HAB/NAB/LAB lines 
List of metabolites that can discriminate between the HAB/NAB/LAB mouse lines (based on RF, 
TFFBS and MANOVA analyses). ↓: Ratio between the compared groups <1; ↑: Ratio between 
the compared groups  >1. 
 
To assess the discrimination power of the set of the 11 metabolite entities, a discriminant analysis 
was performed resulting in an excellent overall classification rate of 100%. In a second 
discriminant analysis, the seven prime candidate metabolite biomarkers were used as 
discriminators, and excellent discrimination power (100%) was also achieved. To assess whether 
there is a subset of the prime candidate metabolite biomarkers that can discriminate between the 
three lines, all possible combinations of the prime candidate metabolite biomarkers as 
discriminators were considered. We found that dehydroascorbate 3, xylose and metabolite 
239332 constitute the minimum set of metabolites that can discriminate between the 
HAB/NAB/LAB lines (discrimination power 100%). Both dehydroascorbate and xylose were found 
at elevated levels in LAB compared to HAB mice. 
 
6.2.3 Western blot validation of selected differentially expressed proteins  
To validate quantitative MS data, differential expression of selected proteins (Table 6.2) was 
confirmed by Western blot in cingulate cortex synaptosomes of an independent, standard-fed 
HAB/NAB/LAB population. Selection criteria for the proteins to be validated were the quality of 
MS raw data, the number of quantified peptides and antibody availability. Representative MS raw 
spectra and Western blot analysis are shown in the following sections. 
Protein  
symbol 
IPI  
Accession 
Protein  
name 
HAB/LAB  
abundance  
ratio 
Quantified  
non-redundant  
peptides 
Sfxn5 IPI00221602 Sideroflexin-5 2.14 9 
Car2 IPI00121534 Carbonic anhydrase 2 1.87 13 
Myh10 IPI00338604 
Myosin,  
heavy polypeptide 10,  
non-muscle 
0.76 36 
Sdhb IPI00338536 
Succinate dehydrogenase 
[ubiquinone] iron-sulfur 
subunit  
2.00 11 
 
Table 6.2 Differentially expressed proteins in HAB and LAB synaptosomes confirmed by 
Western blot 
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6.2.3.1 Sideroflexin-5 (Sfxn5) 
Sfxn5 belongs to the sideroflexin protein family of mitochondrial transmembrane transporters. 
Apart from Sfxn5 (Fig. 6.3), two other sideroflexin family members were expressed at higher 
levels in HAB mice (Sfxn1 and Sfxn3, both 1.74 fold).  
 
A 
B 
 
Figure 6.3 Increased Sfxn5 expression in HAB mice 
A. Increased expression of the Sfxn5 peptide HGTLRPGVTNEQLWSAQK in bacteria-fed 14N 
HAB compared to 15N NAB mice (left) and in 15N NAB compared to 14N LAB mice (right). B. 
Significantly increased Sfxn5 expression in standard-fed HAB (n=6) and NAB (n=8) compared to 
LAB (n=8) mice (**p=0.0043 and *p=0.0209, respectively). 
 
6.2.3.2 Carbonic anhydrase 2 (Car2) 
Car2, expressed at higher levels in HAB mice (Fig. 6.4), is a cytosolic protein that belongs to the 
family of carbonic anhydrases, which catalyze the reversible conversion of carbon dioxide to 
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bicarbonate ions, facilitating the transport and elimination of carbon dioxide from tissues (Breton, 
2001). 
 
 
 
 
 
 
 
 
 
 
A 
 
 
 
 
 
B 
 
Figure 6.4  Increased Car2 expression in HAB mice 
A. Increased expression of the Car2 peptide SIVNNGHSFNVEFDDSQDNAVKL in bacteria-fed 
14N HAB compared to 15N NAB mice (left) and 15N NAB compared to 14N LAB mice (right). B. 
Significantly increased Car2 expression in standard-fed HAB (n=6) and NAB (n=7) compared to 
LAB (n=8) mice (*p=0.0165 and *p=0.0491, respectively). 
 
6.2.3.3 Myosin, heavy polypeptide 10 (Myh10) 
Myh10, expressed at higher levels in LAB mice (Fig. 6.5), belongs to the myosin family of motor 
proteins. Unlike conventional myosin family members, Myh10 localizes in filopodia tips (Berg and 
Cheney, 2002).  
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A 
B 
 
Figure 6.5 Increased Myh10 expression in LAB mice 
A. Increased expression of the Myh10 peptide SLEAEILQLQEELASSER in bacteria-fed 15N NAB 
compared to 14N HAB (left) and 14N LAB compared to 15N NAB mice (right). B. Significantly 
increased Myh10 expression in standard-fed LAB (n=7) compared to HAB (n=5) mice 
(*p=0.0289), with NAB mice (n=7) exhibiting intermediate intensities. 
 
6.2.3.4 Succinate dehydrogenase, subunit b (Sdhb) 
Succinate dehydrogenase (Sdh) links the electron transport chain (ETC) and the citric acid cycle 
by catalyzing the reduction of ubiquinone to ubiquinol with the oxidation of succinate to fumarate. 
It consists of four subunits named a-d. Apart from Sdhb (Fig. 6.6), Sdha and Sdhc were also 
expressed at higher levels in HAB mice. 
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A 
 
 
 
 
 
B 
 
Figure 6.6 Increased Sdhb expression in HAB mice 
A. Increased expression of the Sdhb peptide DLVPDLSNFYAQYK in bacteria-fed 14N HAB 
compared to 15N NAB mice (left) and 15N NAB compared to 14N LAB mice (right). B. Significantly 
increased expression of Sdhb in standard-fed HAB (n=8) compared to NAB (n=8) mice 
(*p=0.0398). Increased expression of HAB compared to LAB mice did not reach significance.  
 
6.2.4 In silico analysis of altered pathways in HAB and LAB mice 
 
Pathway Studio analysis was performed to search the literature and visualize inter-connections 
between proteins and metabolites with altered levels in HAB and LAB mice and cellular 
processes (Fig. 6.7) as well as major psychiatric disorders (Fig. 6.8). 
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Figure 6.7 Differentially expressed proteins and metabolites pertinent to oxidative stress-
related processes 
A number of proteins and metabolites with altered levels in HAB and LAB animals have been 
implicated in oxidative stress-related processes in the literature. Highlighted proteins denote 
confirmed differential expression by Western blot (protein names corresponding to the 
abbreviations used here are given in Appendix 4).  
ROS: Reactive oxygen species. 
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Figure 6.8 Differentially expressed proteins related to major psychiatric disorders 
A number of differentially expressed proteins in HAB and LAB mice have been related to 
psychiatric disorders, although only few to anxiety. Highlighted proteins denote confirmed 
differential expression by Western blot (protein names corresponding to the abbreviations used 
here are given in Appendix 4). 
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In a second in silico pathway analysis approach, all quantified proteins and metabolites in 
HAB/LAB mice were plotted in a combined histogram according to their HAB/LAB log2 ratios and 
were then assigned to five continuous bins (based on their HAB/LAB log2 ratios), as shown in Fig. 
6.9. Components of each bin were compared to the KEGG database in order to identify 
significantly overrepresented pathways (Fig. 6.10). 
 
Figure 6.9 HAB/LAB log2 ratio distribution of all quantified proteins and metabolites 
Quantified proteins and metabolites were assigned to five color-coded bins according to their 
HAB/LAB log2 ratios as follows: Dark blue, decreased HAB/LAB log2 ratio (-∞, -0.8); light blue, 
moderately decreased HAB/LAB log2 ratio [-0.8, -0.4); grey, non-differential HAB/LAB log2 ratio    
[-0.4, 0.4]; white, moderately increased HAB/LAB log2 ratio (0.4, 0.8]; yellow, increased HAB/LAB 
log2 ratio (0.8, +∞). As expected, the majority of the quantified proteins and metabolites were not 
differentially expressed. 
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Figure 6.10 Significantly overrepresented pathways in the quantified proteins and 
metabolites dataset  
Bins are color-coded according to Fig. 6.9 (center top). On the left, the hierarchical clustering of 
the significantly overrepresented pathways based on their p values is shown. Statistical 
significance for overrepresented pathways was accepted for p<0.01. 
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 ABC: ATP-binding cassette; GnRH: Gonadotropin-releasing hormone; MAPK: Mitogen-activated 
protein kinase; SNARE: Soluble N-ethylmaleimide sensitive fusion protein attachment protein 
receptors; VEGF: Vascular endothelial growth factor; Wnt: Wingless-type MMTV integration site  
family member. 
 
Of interest are predominantly pathways that appear significantly overrepresented only in the 
increased or decreased HAB/LAB log2 ratio bins (indicating increased expression in HAB or LAB 
mice, respectively). Oxidative phosphorylation was the most significant overrepresented pathway 
(p=2.04E-84), exclusively appearing in the increased HAB/LAB log2 ratio bin (yellow). Overall, 
metabolic pathways were also significantly overrepresented in the increased HAB/LAB log2 ratio 
bin (yellow) although specific energy-related pathways such as glycolysis and pentose phosphate 
pathway were found significantly overrepresented in the moderately decreased HAB/LAB log2 
ratio bin (light blue). Moreover, calcium signaling pathway and cell adhesion molecules were 
significantly overrepresented in the moderately decreased HAB/LAB log2 ratio bin (light blue). 
Significantly overrepresented in the decreased HAB/LAB log2 ratio bin (dark blue) were pathways 
involved in antioxidant defense (e.g., glutathione metabolism, vitamin B6 metabolism). 
 
6.2.5 Altered networks in HAB and LAB mice 
Having interrogated the HAB/NAB/LAB mouse model of trait anxiety at the proteome, 
metabolome and pathway levels, several altered systems in HAB and LAB mice emerged such as 
glycolysis, neurotransmission and mitochondrial function and are discussed below. 
 
6.2.5.1 Glycolysis 
Eight out of the ten enzymes catalyzing glycolysis pathway reactions, including the proteins that 
catalyze the three committed steps of the pathway (hexokinase, phosphofructokinase and 
pyruvate kinase), were differentially expressed in HAB and LAB synaptosomes. Importantly, 
seven of those enzymes showed increased expression in LAB mice (Fig. 6.11). 
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Figure 6.11 Glycolysis divergencies between HAB and LAB cingulate cortex 
synaptosomes 
 
6.5.2.2 Neurotransmission 
Glutamate and GABA are the main excitatory and inhibitory neurotransmitters, respectively. 
Increased expression of glutamate (Grm3, Gria2, Gria3) and GABA (Gabbr1) receptors as well as 
glutamate (Slc1a1, Slc1a2) and GABA (Slc6a1) transporters was found in HAB compared to LAB 
synaptosomes, suggesting an overall increased neurotransmission activity in HAB mice. In 
addition, proteins involved in glutamate metabolism, such as the mitochondrial glutamate 
dehydrogenase 1 (Glud1) and glutamate decarboxylase 2 (Gad2), were found differentially 
expressed in HAB and LAB synaptosomes. The calcium signaling pathway involved in 
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neurotransmission regulation was also overrepresented in the bin with a moderate increase in 
HAB mice (Fig. 6.10). 
 
6.2.5.3 Mitochondrial function 
Citric acid cycle and oxidative phosphorylation 
Besides glycolysis, energy production takes place in mitochondria via the citric acid cycle and 
oxidative phosphorylation. Increased expression in LAB synaptosomes was observed for the citric 
acid cycle enzyme isocitrate dehydrogenase (Idh1), which catalyzes the conversion of isocitrate 
to alpha-ketoglutarate, whereas increased expression of the Sdh subunits a, b and c was 
observed in HAB synaptosomes. As previously mentioned, Sdh couples the citric acid cycle and 
oxidative phosphorylation. Strikingly, subunits of all complexes participating in the ETC, including 
NADH dehydrogenase  (complex I), Sdh (complex II), cytochrome bc1 (complex III), cytochrome 
c oxidase (complex IV) as well as ATP synthase showed higher expression in HAB compared to 
LAB synaptosomes, in most cases 2 fold (Fig. 6.12). 
 
 
 
 
 
 
 
 
Figure 6.12 The electron transport chain in the inner mitochondrial membrane 
The energy obtained through electron transfer down the ETC (complexes I to IV) creates an 
electrochemical proton gradient across the mitochondrial membrane, which allows ATP synthase 
to generate ATP. Red denotes increased expression in HAB mice. 
 
Oxidative stress 
Apart from producing ATP for energy metabolism, the ETC is one of the most prominent 
mechanisms of reactive oxygen species (ROS) generation that lead to oxidative stress. We found 
evidence for an increased antioxidant activity in LAB mice. At the proteome level, increased 
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expression of proteins with antioxidant properties, such as superoxide dismutase (Sod1) and 
peroxiredoxin-2 (Prdx2) was found in LAB mice. At the metabolome level, elevated levels of 
dehydroascorbate and xylose, two of the prime candidate metabolite biomarkers (see 6.2.2), 
were observed in LAB mice. Dehydroascorbate is the oxidized form of vitamin C (ascorbic acid), 
a known antioxidant (Sies et al., 1992). Unlike vitamin C, dehydroascorbate can cross the blood-
brain barrier with the aid of glucose transporters, thus being the transportable form of vitamin C in 
the brain (Agus et al., 1997). Furthermore, the monosaccharide xylose can be converted to D-
xylulose-5-phosphate and enter the pentose phosphate pathway, an alternative pathway to 
glycolysis that generates NADPH, another key player in antioxidant defense. At the pathway level, 
overrepresentation of mechanisms involved in antioxidant defense, such as vitamin B6 and 
glutathione metabolism as well as the pentose phosphate pathway were found in the bins with 
increased expression in LAB mice (Fig. 6.10).  
 
Mitochondrial import and transport 
Increased expression of proteins participating in transport into and within mitochondria were 
observed in HAB synaptosomes. Among them were members of the translocases of the inner-
outer mitochondrial membrane (TIM-TOM) complex (Tim16, Tim22, Tim23, Tom22), which 
constitute the molecular machinery for mitochondrial protein import (Neupert, 1997), metaxin 1 
and  2, which participate in the pre-protein mitochondrial import complex (Armstrong et al., 1997; 
Armstrong et al., 1999) as well as the voltage-dependent anion-selective channel (Vdac) proteins 
1, 2 and 3, which form pores in the outer mitochondrial membrane for diffusion of molecules in 
the mitochondrion (De Pinto and Palmieri, 1992). Notably, seven members of the mitochondrial 
membrane carrier family, which facilitate transport of molecules across mitochondrial membranes 
(Palmieri, 2004) were expressed at higher levels in HAB synaptosomes. These included 
ADP/ATP translocases (Slc25a4, Slc25a5) that assist the exchange of ADP and ATP between 
cytosol and mitochondria, glutamate carriers 1 and 2 (Slc25a22, Slc25a18), phosphate and 
oxoglutarate/malate carriers (Slc25a3, Slc25a11) as well as the calcium-binding protein Alalar 1 
(Slc25a12). In addition, numerous proteins located in mitochondria showed increased expression 
in HAB synaptosomes. Apart from sideroflexins, prohibitins - proteins with multiple functions in 
mitochondrial senescence and dynamics (Artal-Sanz and Tavernarakis, 2009) - showed 2 fold 
increased expression in HAB synaptosomes. 
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6.3  Discussion 
 
A multi-omics approach combined with in silico pathway analysis was applied to the 
HAB/NAB/LAB mouse model of trait anxiety to unravel the neurobiological underpinnings and 
identify candidate biomarkers for anxiety disorders. The cingulate cortex synaptosome proteomes 
of HAB and LAB mice were compared by in vivo 15N metabolic labeling and quantitative 
proteomics. In addition, the cingulate cortex metabolome profiles of HAB/NAB/LAB mice were 
quantified. Selected differentially expressed candidates were validated by Western blot and 
affected pathways were identified by in silico analyses. Our data provide a panel of phenotype-
specific markers, suggesting a key role for mitochondria in modulating anxiety-related behavior 
that has not been reported previously. 
Differential expression of four proteins in HAB and LAB synaptosomes, namely Sfxn5, Car2, 
Myh10 and Sdhb, was confirmed in an independent HAB/NAB/LAB population. Sfxn5, a member 
of the sideroflexin family, showed increased expression in HAB mice.  So far, limited information 
is available for sideroflexin functions (Fleming et al., 2001; Yoshikumi et al., 2005), and no 
association with psychiatric disorders has been reported. Sfxn1 mutations have been linked to 
abnormal iron deposition in mitochondria resulting in sideroblastic anemia in mice (Fleming et al., 
2001). Interestingly, pre- and post-natal iron deficiency in rats led to increased anxiety-related 
behaviors (Beard et al., 2002; Eseh and Zimmerberg, 2005), suggesting a potential role of iron 
transport pathways in anxiety pathogenesis. Car2 was found expressed at higher levels in HAB 
compared to LAB mice. Increased Car2 expression has been also reported in a Down syndrome 
mouse model as well as in young Down syndrome patients (Palminiello et al., 2008). Carbonic 
anhydrases are ubiquitously expressed proteins, and carbonic anhydrase inhibitors have been 
used for the treatment of bipolar disorder (Brandt et al., 1998; Hayes, 1994) and atypical 
psychosis (Inoue et al., 1984). Myh10, with an increased expression in LAB mice, has been 
shown to promote filopodia extension by relocalizing integrins (Zhang et al., 2004) and to 
participate in axon path-finding by regulating netrin receptors (Zhu et al., 2007). Increased Myh10 
expression in LAB mice may thus indicate implication of neuronal cell adhesion mechanisms in 
anxiety modulation. Notably, knock-out mice for cell adhesion-related molecules exhibited 
increased anxiety-related behavior (Blundell et al., 2009; Schmalzigaug et al., 2009). Taken 
together, these data point toward novel mechanisms for understanding anxiety pathobiology and 
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implicate proteins not previously reported in anxiety pathogenesis (i.e. Sfxn5, Myh10) that provide 
the basis for the establishment of a panel of candidate biomarkers for trait anxiety. 
Due to the high costs involved in generating 15N-labeled mice, the number of replicates used in 
the present study was limited. The animals used for the analyses were carefully chosen so as to 
accurately represent the phenotype of the individual mouse lines. The HAB and LAB mouse lines 
are inbred for many generations and therefore animal-to-animal variability is significantly lower 
compared to outbred animals. Furthermore, all validation assays were performed in a standard-
fed, independent population so that any potential diet effect could be excluded, and results could 
be confirmed in a larger dataset. Due to the low amount of cingulate cortex synaptosomes 
obtained from a single mouse, using one 15N NAB animal per 14N HAB/14N LAB pair was not 
feasible and thereby different 15N NAB mice were used as internal labeled standards for HAB and 
LAB animals. Great care was taken in choosing NAB animals with the smallest possible variability 
with regard to phenotypic parameters as well as animal and cingulate cortex tissue weights. 
Apart from single molecules, the biomarker discovery pipeline should extend to affected pathways, 
given that network dysfunctions rather than single molecular lesions are involved in the 
pathobiology of complex diseases such as anxiety disorders. Here, our proteomics, metabolomics 
and in silico analyses revealed pronounced alterations in mitochondrial functions, indicating a key 
role of mitochondria in anxiety-related behavior. In particular, decreased expression levels of 
glycolysis enzymes with simultaneous increased expression levels of ETC components were 
observed in HAB synaptosomes. Increased oxidative phosphorylation activity enhances ROS 
production and oxidative stress, which result in oxidative damage, lipid peroxidation and cell 
death. There is a mounting body of evidence that links oxidative stress to anxiety disorders. In 
human studies, increased ROS markers in patients with panic (Kuloglu et al., 2002b) and 
obsessive-compulsive (Behl et al., 2010; Kuloglu et al., 2002a) disorders have been reported. In 
mice, well-established anxiety-related behavior biomarkers, such as Glo1 and glutathione 
reductase 1 exert a neuroprotective role against oxidative damage (Ditzen et al., 2006; Gingrich, 
2005; Hovatta et al., 2005; Krömer et al., 2005), and alterations in oxidative stress-related 
proteins have been described in a mouse model of anxiety (Szego et al., 2010). Moreover, 
anxiety-related behavior has been correlated with oxidative status in mouse brain (Rammal et al., 
2008a) and blood (Bouayed et al., 2007; Rammal et al., 2008b). Remarkably, mitochondria-
directed antioxidant treatment led to decreased anxiety-related behavior in rats (Stefanova et al., 
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2010). In the present study, an increased expression of all ETC members that produce ROS and 
reduced levels of proteins and metabolites involved in antioxidant defense were found in HAB 
mice, implicating dysfunctional antioxidant protection in these animals. 
Most cellular systems exhibit flexibility in shifting their metabolism between glycolysis and 
oxidative phosphorylation according to energetic demands or nutrient availability. Most 
importantly, the therapeutic potential of modulating this reallocation has been demonstrated in 
several diseases (Chen et al., 2007; Huber et al., 2004; Riepe et al., 1997). Shifting energy 
metabolism from oxidative phosphorylation to glycolysis can attenuate oxidative damage and 
suppress apoptosis (Hunter et al., 2007; Jeong et al., 2004; Vaughn and Deshmukh, 2008). 
Nutrient-sensitized screening has also revealed the ability of several Food and Drug 
Administration (FDA)-approved drugs to redirect oxidative phosphorylation to glycolysis (Gohil et 
al., 2010). This may provide a means for modulating high anxiety-related behavior that warrants 
further investigation. 
An increased expression of proteins participating in mitochondrial import and transport was 
observed in HAB mice. Proteins such as the Vdac family or hexokinase have been proposed to 
participate or modulate the permeability transition pore complex, which regulates the exchange of 
small metabolites between the cytosol and the mitochondrial matrix. In response to ROS or 
calcium overload, the permeability transition pore complex allows a deregulated entry of small 
molecules into the mitochondrion, altering mitochondrial permeability and eventually leading to 
cell death (Kroemer et al., 2007). Interestingly, mice lacking members/modulators of the 
permeability transition pore complex exhibited alterations in anxiety-related behavior (Luvisetto et 
al., 2008).  
Altered levels of proteins involved in neurotransmission were also observed in HAB mice. There 
is a close interplay between synapses and mitochondria. Mitochondria are located in synaptic 
terminals and tethered to sites where synaptic vesicle release occurs (Kageyama and Wongriley, 
1982). In functional synapses, mitochondria supply ATP and regulate calcium levels, modulating 
neuronal polarity (Mattson and Partin, 1999), neurotransmission (Billups and Forsythe, 2002), 
receptor signaling (Kann et al., 2003) and synaptic plasticity (Vanden Berghe et al., 2002). An 
increased synaptic activity has been shown to induce mitochondrial-encoded gene expression 
(Williams et al., 1998). In particular, inhibition of mitochondrial Sdh that we have found to be 
differentially expressed in HAB and LAB synaptosomes resulted in altered NMDA-mediated 
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neurotransmission (Calabresi et al., 2001). Since neurotransmission disequilibrium is a hallmark 
of anxiety disorders (McNaughton, 1997), an altered activity of proteins involved in energy 
production and transport in mitochondria may in turn lead to neurotransmission perturbations and 
influence anxiety-related behavior.  
Taken together, we submit a mitochondrion-centered hypothesis for the anxiety-related molecular 
alterations (Fig. 6.13) based on proteomics and metabolomics data and in silico pathway 
information (Filiou et al., 2009; Filiou et al., submitted). Although mitochondrial involvement has 
been suggested for other psychiatric disorders such as bipolar disorder (Kato, 2006; Stork and 
Renshaw, 2005) and schizophrenia (Ben-Shachar and Lainfenfeld, 2004), little is known about 
the role of mitochondria in anxiety disorders. In our dataset, mitochondria appear to be the 
common denominator of the energy metabolism, oxidative stress and neurotransmission 
divergencies observed between HAB and LAB mice. The shift from glycolysis to oxidative 
phosphorylation results in enhanced ROS production and consequently, increased oxidative 
stress and oxidative damage with an impact on anxiety-related behavior. On a second level, 
mitochondrial alterations affect the excitatory-inhibitory neurotransmission equilibrium modulating 
the processing of anxiogenic stimuli. Our hypothesis is further supported by increased anxiety-
related behavior observed in mice deficient for mitochondrial proteins (Einat et al., 2005) as well 
as by the modulation of mitochondrial function by glucocorticoid stress hormones (Du et al., 2009). 
The structural and functional characteristics of mitochondria enable their selective targeting by 
drugs for therapeutic purposes. The therapeutic potential of selective mitochondrial targeting has 
already been demonstrated in cancer (Fulda et al., 2010) and neurodegenerative disorders 
(Armstrong, 2007) and may also provide a novel promising approach for the treatment of anxiety 
disorders. 
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Figure 6.13 Mitochondria-modulated alterations in anxiety-related behavior 
Divergencies in mitochondrial energy metabolism, import and transport processes are observed 
between HAB and LAB mice. HAB mice exhibit an increase in mitochondrial relative to non-
mitochondrial energy metabolism and reduced levels of proteins and metabolites involved in 
antioxidant defense compared to LAB mice. An increase in ETC complexes leads to increased 
ROS production and oxidative stress. Mitochondrial alterations also have an impact on 
neurotransmission in the context of ATP supply and calcium regulation modulating anxiety-related 
behavior. 
CA cycle: Citric acid cycle; ETC: Electron transport chain; ROS: Reactive oxygen species; Sdhb: 
Succinate dehydrogenase, subunit b; Sfxn5: Sideroflexin-5. 
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7 15N isotope effect investigation in HAB mice and Escherichia 
coli 
 
7.1 Introduction 
 
The effect of the 15N introduction on the behavioral phenotype of HAB mice (see 5.2.1.2) raised 
the question whether the 15N introduction also exerts an effect on the HAB mouse proteome. To 
address this, we compared the cingulate cortex synaptosome proteomes of bacteria-fed 14N HAB 
and 15N HAB mice by employing the 14N/15N quantification platform (Fig. 7.1). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7.1 Proteomics strategy for 14N HAB/15N HAB relative quantification 
Cingulate cortices from bacteria-fed 14N HAB and 15N HAB were excised and cytoplasmic 
fractions were mixed 1:1 (w/w) based on protein content for 14N/15N relative quantification. 
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In a second set of experiments, we examined whether the 15N introduction exerts an effect on the 
proteome of a different biological system. To investigate 15N isotope-derived changes, the 
cytoplasmic proteomes of E. coli grown in 14N (unlabeled) or 15N-enriched media were compared. 
Criteria for selecting E. coli were the ability to label bacteria in a fast and highly efficient manner 
via growing them in 15N-enriched media and their reduced complexity compared to mammals that 
eliminates the presence of 15N isotope-independent, confounding factors affecting protein 
expression levels (e.g., social stress, maternal care). To ensure an accurate proteomics 
comparison, the 14N and 15N media used had identical compositions (apart form the 15N isotope), 
and the 14N and 15N E. coli cultures were grown simultaneously under the same conditions. 
Relative quantification was performed employing the 14N/15N quantification platform (Fig. 7.2). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7.2 Proteomics strategy for 14N /15N Escherichia coli relative quantification 
Cytoplasms from E. coli grown in 14N or 15N media were mixed 1:1 (w/w) based on protein content 
for subsequent 14N/15N relative quantification. 
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7.2 Results 
 
7.2.1  Investigation of the 15N isotope effect in HAB mice 
7.2.1.1 14N HAB/15N HAB cingulate cortex synaptosome proteome comparison 
Three bacteria-fed 14N HAB/15N HAB pairs were compared. In total, 1897 non-redundant proteins 
were quantified in at least two out of three 14N HAB/15N HAB pairs. Applying stringent criteria, we 
found 49 differentially expressed proteins >1.3 fold in at least two out of three 14N HAB/15N HAB 
pairs. A detailed list of differentially expressed proteins and their abundance ratios is given in 
Appendix 5. 
 
7.2.1.2 Western blot validation of selected differentially expressed proteins  
Differential expression of selected proteins was confirmed by Western blot in cingulate cortices of 
an independent, bacteria-fed 14N HAB and 15N HAB population (Table 7.1). Representative MS 
raw spectra and Western blot analysis are presented in the following sections. 
 
Protein  
symbol 
IPI  
Accession 
Protein  
name 
15N HAB/14N HAB 
abundance ratio 
Quantified  
non-redundant  
peptides 
TnR IPI00227126 Tenascin-R precursor 0.31 11 
Nefm IPI00323800 Neurofilament 
medium polypeptide 0.47 4 
 
Table 7.1 Differentially expressed proteins in 14N HAB and 15N HAB synaptosomes 
confirmed by Western blot 
 
Tenascin-R (TnR) 
TnR was the most highly differentially expressed protein in 14N HAB and 15N HAB mice (Fig. 7.3). 
TnR belongs to a family of extracellular matrix glycoproteins and is expressed in the central 
nervous system (Pesheva et al., 1989). 
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Figure 7.3 Decreased TnR expression in 15N HAB mice 
A. Decreased expression of the TnR peptide VVYSTLAGEQYHEVLPK in bacteria-fed 15N HAB 
compared to 14N HAB mice. B. Significantly decreased TnR expression in bacteria-fed 15N HAB 
(n=4) compared to 14N HAB (n=4) mice (*p=0.0460). 
 
Neurofilament medium polypeptide (Nefm) 
Neurofilaments are structural parts of the neuronal cytoskeleton, classified in light, medium and 
heavy based on their molecular weight. Decreased Nefm expression was observed in 15N HAB 
compared to 14N HAB mice (Fig. 7.4). 
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Figure 7.4 Decreased Nefm expression in 15N HAB mice 
A. Decreased expression of the Nefm peptide SNHEEEVADLLAQASHITVER in bacteria-fed 15N 
HAB compared to 14N HAB mice. B. Significantly decreased Nefm expression in bacteria-fed  15N 
HAB (n=7) compared to 14N HAB (n=4) mice (**p=0.0018). Significance was retained after 
exclusion of the very low Nefm-expressing 15N HAB outlier (fifth from the right, **p=0.0031). 
 
7.2.1.3 In silico analysis of altered pathways in 14N HAB and 15N HAB mice 
Pathway Studio analysis revealed relevance of numerous differentially expressed proteins to 
depression (Fig. 7.5). Furthermore, the functional composition of the differentially expressed and 
all quantified proteins in 14N HAB/15N HAB animals was compared using FatiGO and significant 
differences in energy metabolism-related processes were found (Table 7.2). 
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Figure 7.5 Differentially expressed proteins in 14N HAB and 15N HAB cingulate cortex 
synaptosomes and their relevance to depression 
Twenty one of the differentially expressed proteins in 14N HAB and 15N HAB mice have been 
directly or indirectly related to depression in the literature (protein names corresponding to the 
abbreviations used here are given in Appendix 5). 
 
Overrepresented GO terms in the differentially 
expressed dataset GO ID Adjusted p value 
carbohydrate metabolic process GO: 0005975 0.00463 
cofactor metabolic process GO: 0051186 0.00463 
coenzyme metabolic process GO: 0006732 0.00473 
cofactor catabolic process GO: 0051187 0.00473 
energy derivation by oxidation of organic compounds GO: 0015980 0.01490 
acetyl-coenzyme A metabolic process GO: 0006084 0.00059 
coenzyme catabolic process GO: 0009109 0.00270 
cellular respiration GO: 0045333 0.00321 
cellular carbohydrate metabolic process GO: 0044262 0.01220 
acetyl-coenzyme A catabolic process GO: 0046356 0.00962 
aerobic respiration GO: 0009060 0.00830 
citric acid cycle GO: 0006099 0.00710 
 
Table 7.2 Overrepresented functional groups in the differentially expressed protein dataset 
compared to all quantified proteins in 14N HAB/15N HAB mice  
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7.2.1.4 Altered networks in 14N HAB and 15N HAB mice 
Quantitative MS and in silico pathway analysis revealed protein expression differences 
predominantly related to energy metabolism. Strikingly, decreased expression of five enzymes 
catalyzing subsequent steps of the citric acid cycle was found in 15N HAB compared to 14N HAB 
mice (Fig. 7.6). Expression differences in synaptic proteins (Shank1, PSD95, Stx1a) and proteins 
involved in neurotransmitter transport (Slc6a11 and Slc1a3) were also observed in 14N HAB and 
15N HAB mice. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7.6 Citric acid cycle divergencies between 14N HAB and 15N HAB cingulate cortex 
synaptosomes 
Decreased expression of five enzymes catalyzing subsequent steps of the citric acid cycle in 15N 
HAB compared to 14N HAB mice. 
 
7.2.2  Investigation of the 15N isotope effect in Escherichia coli 
7.2.2.1 14N/15N Escherichia coli cytoplasmic proteome comparison  
For relative quantification, two technical replicates of 14N/15N E. coli cytoplasmic fractions were 
measured. In total, 390 non-redundant proteins were identified by MS in both replicates. The false 
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positive identification rate was estimated to be 2% after filtering using a decoy database. Of the 
identified proteins, 166 were quantified in both replicates and were considered for further analysis. 
To assess quantification reproducibility between the two replicates, the protein 15N/14N log2 ratios 
in both replicates were compared, indicating satisfactory quantification accuracy (r=0.93) (Fig. 
7.7A). The average 15N/14N log2 ratio distribution of the quantified proteins indicated that the 
majority of the proteins were not differentially expressed (Fig. 7.7B). However, 18 proteins were 
found to be consistently differentially expressed >1.3 fold in 15N compared to 14N E. coli 
cytoplasm in both replicates (Table 7.3). 
 
 
 
                
 
 
 
 
 
 
 
A         B 
 
Figure 7.7 Quantification reproducibility of mass spectrometry measurements and 15N/14N 
log2 ratio distribution of quantified proteins 
A. Reproducibility of quantitative MS measurements as estimated by Pearson correlation analysis. 
The 15N/14N log2 ratios of quantified proteins in both technical replicates were compared. Proteins 
with consistent 15N/14N log2 ratios in both replicates are expected to distribute along the line y=x. 
The Pearson correlation coefficient showed satisfactory quantification reproducibility between the 
two measurements (r=0.93). B. Distribution of average 15N/14N log2 ratios of the quantified 
proteins in both replicates. 
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a
 different protein variants, treated as two different entities 
 
Table 7.3 Differentially expressed proteins in 14N and 15N Escherichia coli cytoplasm  
15N/14N abundance ratios were calculated from the average 15N/14N log2 ratios of the two 
replicates. Pep No refers to unique quantified peptides. Proteins whose differential expression 
was validated by Western blot are indicated with a bold italic font. 
 
7.2.2.2 Western blot validation of beta galactosidase 
Beta galactosidase is an inducible hydrolytic enzyme that catalyzes the conversion of beta 
galactosides to monosaccharides. Increased expression of beta galactosidase was found in 15N 
compared to 14N E. coli cytoplasmic fraction (Q8VNN2_ECOLI or LacZ, 1.8 fold increase in 15N, 
15 unique quantified peptides in both replicates). Selected beta galactosidase 14N/15N peptide 
pairs are shown in Fig. 7.8A. Increased expression of beta galactosidase in the 15N compared to 
the 14N E. coli cytoplasm was confirmed by Western blot (Fig. 7.8B). To assess biological 
variability, beta galactosidase expression was also investigated in different 14N and 15N E. coli 
cytoplasmic fraction preparations, revealing consistent increased expression in the 15N cytoplasm 
(data not shown). 
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Figure 7.8 Increased beta galactosidase expression in 15N Escherichia coli cytoplasm 
A. Increased expression of the beta galactosidase peptides LPSEFDSAFLR (left) and 
LQGGFVWVWDQSLIK (right) in the 15N compared to 14N E. coli cytoplasm.  B. Significantly 
increased expression of beta galactosidase in 15N compared to 14N E. coli cytoplasm 
(***p<0.0001). Five technical replicates were measured per group. 
 
7.2.2.3 Pyruvate metabolism divergencies between 14N and 15N Escherichia coli  
Increased expression of three enzymes implicated in pyruvate metabolism (PPSA_ECOLI, 
PFLB_ECOLI, Q47521_ECOLI) was found in the 15N E. coli cytoplasmic fraction in both 
replicates (Table 7.3). Phosphoenolpyruvate synthase (PPSA_ECOLI or PpsA, 1.37 fold increase 
in 15N, 20 unique peptides quantified in both replicates) catalyzes the reversible phosphorylation 
of pyruvate to phosphoenolpyruvate. Formate acetyltransferase 1 (PFLB_ECOLI or PflB, 1.93 
fold increase in 15N, 31 unique peptides quantified in both replicates) catalyzes the reversible 
conversion of pyruvate and coenzyme A into formate and acetyl-coenzyme A and is involved in 
anaerobic glucose metabolism. In addition, 1.87 fold increased expression of a 
phosphoenolpyruvate carboxylase mutant (Q47521_ECOLI or PpcI mutant, six unique peptides 
quantified in both replicates) was observed in 15N cytoplasm. Phosphoenolpyruvate carboxylase 
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catalyzes the addition of carbon dioxide to phosphoenolpyruvate to form inorganic phosphate and 
oxaloacetate, an intermediate of the citric acid cycle. Unlike the WT variant, the 
phosphoenolpyruvate carboxylase mutant identified here, cannot be activated from the glycolysis 
intermediate fructose 1,6-biphosphate (Sutton et al., 1986). Selected quantified 14N/15N peptide 
signals of PPSA_ECOLI (PpsA) and PFLB_ECOLI (PflB) are shown in Fig. 7.9A. To further 
investigate the effect of the 15N isotope on pyruvate metabolism, pyruvate levels in 14N and 15N E. 
coli cytoplasmic fractions were assessed with a colorimetric-based assay and were found 
significantly higher in the 15N compared to the 14N cytoplasm (Fig. 7.9B). Pyruvate metabolism 
alterations in 15N E. coli cytoplasm are summarized in Fig. 7.10. 
 
 
 
 
 
 
 
A           
 
 
 
 
 
 
              B 
Figure 7.9 Relative quantification of pyruvate metabolism in 15N and 14N Escherichia coli 
cytoplasm 
A. Increased expression of the phosphoenolpyruvate synthase (PpsA) peptide 
ALLEFDDQEPQEPQLQNEIR (left) and the formate acetyltransferase 1 (PflB) peptide 
VDDLAVDLVER (right) in 15N compared to 14N E. coli cytoplasm. B. Elevated levels of pyruvate 
(***p<0.0001) in 15N compared to 14N E. coli cytoplasm. Three technical replicates were 
measured per group. 
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Figure 7.10 Pyruvate metabolism alterations in 15N Escherichia coli cytoplasm 
Schematic representation of the pyruvate metabolism pathway (modified from the KEGG 
database). Reactions involved in the generation of phosphoenolpyruvate and oxaloacetate, 
intermediates of glycolysis and citric acid cycle, respectively were affected by the 15N introduction.  
Dld: D-lactate dehydrogenase; Kpyk2: Pyruvate kinase II; Mdh: Malate dehydrogenase (Q9KH79, 
Q9K2L4, Q9KH77, Q9ETZ1 variants); Odp2: Dihydrolipoyllysine-residue acetyltransferase 
component of pyruvate dehydrogenase complex; PflB: Formate acetyltransferase 1; PpcI:  
Phosphoenolpyruvate carboxylase mutant (Q47521); PpsA: Phosphoenolpyruvate synthase; Pta: 
Phosphate acetyltransferase. 
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7.2.2.4 In silico analysis of altered pathways in 14N and 15N Escherichia coli  
GO analysis revealed that the differentially expressed proteins were predominantly involved in 
biosynthetic and metabolic processes (Filiou et al., in preparation). We compared the differentially 
expressed proteins and all quantified proteins and found that phosphorylation-related processes 
(phosphorylation, GO: 0016310; phosphorus metabolic process, GO: 0006793; phosphate 
metabolic process, GO: 0006796; *p=0.0240 for each) were significantly overrepresented in the 
group of differentially expressed proteins. The proteins with increased expression in 15N 
cytoplasm were then compared to all quantified proteins, and no significantly overrepresented 
groups were found. However, when comparing only the proteins with decreased expression in 15N 
cytoplasm to all quantified proteins, aspartate family amino acid metabolic process (GO: 0009066; 
*p=0.0450) was found significantly overrepresented in the group of proteins with decreased 
expression in 15N cytoplasm. 
 
7.3  Discussion 
 
Although 15N metabolic labeling in cell culture and live organisms is widely employed for 
quantitative proteomics experiments, the 15N isotope effect on protein expression during 
metabolic labeling has not been studied. After observing the effect of the 15N introduction on the 
behavioral phenotype of HAB mice, the 15N isotope effect on the HAB mouse synaptosome 
proteome was investigated. We found 49 differentially expressed synaptosomal proteins in three 
14N HAB/15N HAB cingulate cortex pairs. Pronounced changes in the citric acid cycle (Fig. 7.6) as 
well as in other energy metabolism-related processes (Table 7.2) and alterations in synaptic 
proteins were observed in 15N HAB mice. Decreased expression of TnR and Nefm in 15N HAB 
mice was confirmed by Western blot in an independent 14N HAB/15N HAB population. Much of our 
knowledge concerning the role of TnR in the brain is derived from studies of TnR-deficient mice, 
where alterations in neurotransmission and synaptic plasticity (Bukalo et al., 2007; Gurevicius et 
al., 2004; Saghatelyan et al., 2001) as well as increased anxiety-related behavior and impaired 
motor coordination (Freitag et al., 2003) have been reported. In addition, altered neurofilament 
levels have been found in depressed patients (Gudmundsson et al., 2010) and in a rat depression 
model (Reinés et al., 2004).  
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In HAB mice, 15N metabolic labeling resulted in the modulation of depression-like behavior 
assessed by the total immobility time in the TST. Many of the differentially expressed proteins 
caused by 15N metabolic labeling have been previously reported in the literature to be related to 
the depression phenotype (Fig. 7.5). However, this finding does not imply that the 15N 
incorporation has antidepressant, therapeutic properties and one has to be careful to not over-
interpret the antidepressant-like effects of the 15N isotope in HAB mice. 15N incorporation to an 
organism can affect protein architecture (Hartmann et al., 2003) and as a result, enzymatic 
reactions and pathways can be altered in an unpredictable manner. Yet, the 15N isotope effect 
provides a means for studying affected pathways involved in depression-like behavior. 
On a second level of analysis, the 15N isotope effect was studied in E. coli cultures.  E. coli is an 
organism of lower complexity compared to mice, used both as a model organism for quantitative 
proteomics experiments and as a stable isotope source to metabolically label higher organisms 
(Krijgsveld et al., 2003). Strikingly, more than 10% of the quantified proteins were found to be 
differentially expressed in the 14N and 15N E. coli cytoplasm, demonstrating that the introduction of 
the 15N isotope on a proteome alters protein expression, a fact that needs to be taken into 
consideration when planning and executing quantitative proteomics experiments using 15N 
metabolic labeling. The 18 differentially expressed proteins in 14N and 15N E. coli cytoplasms were 
primarily involved in pyruvate metabolism, energy production and amino acid biosynthesis. 
Pyruvate is the endpoint of glycolysis, a central metabolic cascade conserved in all organisms. 
Via gluconeogenesis, pyruvate can be converted to carbohydrates, whereas through its 
conversion to oxaloacetate pyruvate can enter the citric acid cycle, thus being a key metabolite 
for major metabolic cascades. Increased expression of enzymes involved in pyruvate metabolism 
(PFLB_ECOLI, Q47521_ECOLI, PPSA_ECOLI) as well as elevated pyruvate levels were found in 
15N cytoplasm. In addition, increased expression in 15N cytoplasm of beta galactosidase, an 
enzyme also involved in energy catabolism was demonstrated in 15N cytoplasm both by MS and 
Western blot analyses. Lactose catabolism by beta galactosidase leads to the production of 
galactose and glucose, the starting point of glycolysis. Apart from energy metabolism, alterations 
were observed in five proteins (AK2H_ECOLI, Q9F6G4_ECOLI, Q6LEL0_ECOLI, 
Q8RMX0_ECOLI, Q68QZ6_ECOLI, see Table 7.3) involved in aspartate amino acid family 
biosynthesis. Decreased expression in 15N E. coli cytoplasm was found for MukE 
(Q6ITT5_ECOLI) and CpsC (Q1PG46_ECOLI), proteins that participate in chromosome 
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segregation (Yamanaka et al., 1996)  and transcription regulation (Bae et al., 2000), respectively. 
Enrichment analysis revealed that in the group of differentially expressed proteins 
phosphorylation-related processes were significantly overrepresented compared to all quantified 
proteins. Intriguingly, six of the differentially expressed proteins exhibit kinase activity 
(AK2H_ECOLI, PPSA_ECOLI, Q2EVI1_ECOLI, Q6LEL0_ECOLI, Q8RMX0_ECOLI, 
Q68QZ6_ECOLI, see Table 7.3), whereas PPSA_ECOLI has recently been reported to be 
phosphorylated (Macek et al., 2008). In conclusion, the introduction of the 15N isotope in E. coli 
does not only affect essential metabolic pathways, such as glycolysis but also fundamental 
functions related to chromosome, transcription and post-translational modification regulation. 
In the literature, the 15N isotope effect has been considered to be trivial since a substitution of 15N 
for 14N only results in a relatively small mass difference (Van Langenhove, 1986). To assess the 
effect of the 15N isotope, Bigeleisen (Bigeleisen, 1949) estimated the maximum ratio of the 14N 
and 15N specific rate constants (K14N/K15N) and found that it was within the error limits of normal 
measurements, concluding that the 15N isotope effect on a reaction process is insignificant. On 
the other hand, it is known that a chemical bond involving a heavy isotope is stronger and 
therefore more difficult to break than the same bond involving the corresponding light isotope of 
the same element (Melander and Saunders, 1980). If the cleavage of this bond is the rate-limiting 
step of a reaction, then the reaction will proceed slower for the molecule with the heavy isotope. 
We propose that minor synergistic changes introduced by the substitution of 14N for 15N may 
account for slight structural conformational changes in a protein. When these alterations occur in 
an enzyme’s active site or in the peptide backbone of a rigid cluster, they could cause alterations 
in enzyme catalytic activity or distortions in spatial structure, respectively. As shown in our studies 
of HAB mice and E. coli, such alterations at the molecular level can affect biochemical reactions 
and pathways in an unpredictable manner. Our hypothesis is further supported by a study that 
compared 15N- or 13C-labeled to unlabeled Cu-thiolate cluster in yeast and found spectroscopic 
differences between the clusters, suggesting that stable isotope labeling can indeed affect the 
molecular architecture of a protein (Hartmann et al., 2003). 
We show that the introduction of the 15N isotope affects evolutionary well-conserved pathways 
present in all organisms such as the glycolysis and the citric acid cycle as well as ubiquitous 
regulatory mechanisms such as phosphorylation. We have demonstrated the effect of the 15N 
incorporation at the proteome level both in low complexity organisms and mammals, where 
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additionally the behavioral phenotype was influenced. Future studies include validation of current 
findings in E. coli cultures grown in 14N and 15N media from other commercial sources, 
quantitative MS analyses of more biological replicates and assessment of metabolite levels by 
enzymatic methods. Preliminary data from E. coli grown in 14N and 15N media from another 
commercial source (Silantes) confirmed elevated pyruvate levels in 15N cytoplasm in different 
biological replicates, whereas reduced E. coli growth rates in 15N compared to 14N media were 
consistently observed (Filiou et al., in preparation).  
To the best of our knowledge, this is the first time that alterations in protein expression due to the 
introduction of 15N isotope during metabolic labeling have been reported.  Since 15N metabolic 
labeling is currently one of the most accurate quantitative MS methods with great potential for in 
vivo and in vitro studies (Filiou et al., accepted), the 15N isotope effect on the labeled proteome 
should be taken into consideration when planning quantitative proteomics experiments. The use 
of a labeling control strategy is therefore critical to avoid 15N isotope-derived, misleading 
analytical and biological information. 
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8 Biomarker discovery in the G72/G30 transgenic mouse model 
of schizophrenia-like symptoms 
 
8.1 Introduction 
 
Although a number of animal models of schizophrenia-like symptoms have been established, no 
mouse model addressing the molecular and behavioral effects of the G72 protein was up to now 
available since the G72/G30 locus that encodes for the G72 protein is primate-specific. The 
establishment of a transgenic mouse model for the G72/G30 locus (Otte et al., 2009) has enabled 
for the first time the examination of the G72 protein function at the level of a model organism. Due 
to the low G72 transcript expression in humans, only limited information is available on G72 
tissue-specific expression patterns (Benzel et al., 2008). Increased expression of the G72 and 
G30 transcripts was found in mouse cerebella compared to other brain areas examined (Otte et 
al., 2009). Therefore, the cerebellum was selected to investigate proteome alterations caused by 
the introduction of the G72/G30 transgene in CD1 mice. However, unambiguous detection of the 
G72 protein in cerebellum with conventional Western blot analysis was not feasible due to the 
presence of confounding protein signals. To ensure optimal protein separation and G72 protein 
detection, a 2D-Western blot approach was employed. In addition, to achieve a molecular 
characterization of the G72/G30 transgenic animals, cerebellar proteomes of G72/G30 transgenic 
animals were compared to WT counterparts by 2D-PAGE. For all experiments, male animals 
heterozygous for the G72/G30 transgene were used. 
 
8.2  Results 
 
8.2.1 Detection of the G72 protein in G72/G30 transgenic mice 
To ensure that the G72 protein was present in G72/G30 transgenic mice, a 2D-Western blot 
analysis was performed in cerebellar protein homogenates, revealing the presence of a protein 
with the physicochemical characteristics of the long splice variant LG72 in G72/G30 transgenic 
(G72Tg1) but not in WT mice (Fig. 8.1). This led to the conclusion that the transgenic G72/G30 
animals produce the LG72 protein encoded by the longest G72 open reading frame. 
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Figure 8.1 G72 protein detection in cerebella of G72/G30 transgenic mice by 2D-Western 
blot 
A. The anti-G72 antibodies detected a protein signal corresponding to the LG72 molecular weight 
and isoelectric point in G72/G30 transgenic mice (arrow). B. This signal was not detected in WT 
mice. 
 
8.2.2 Protein expression differences in G72/G30 transgenic and wild type mice 
Cerebellar protein homogenates from both transgenic lines (G72tg1 and G72tg2, see 3.6.1) and 
WT mice were compared. 2D-PAGE analysis revealed a number of cerebellar protein expression 
differences between G72/G30 transgenic and WT animals (Table 8.1). Among the differentially 
expressed proteins, increased expression of glutathione transferase family members was 
observed. In particular, increased expression of glutathione S-transferase M1 (Gstm1) was 
consistently found in both transgenic lines (Fig. 8.2), whereas increased glutathione S-transferase 
P1 (Gstp1) expression was detected in G72Tg1 line. In addition, altered expression of 
cytoskeleton-related components, such as tubulins and the actin-binding protein cofilin-1 was 
observed in G72/G30 transgenic mice. Increased expression of phosphoglycerate mutase 1, rho 
GDP dissociation inhibitor and glutamine synthetase involved in glycolysis, signal transduction 
regulation and neurotransmitter biosynthesis, respectively, was found in the G72Tg2 line. 
Pathway Studio analysis indicated involvement of the differentially expressed proteins in oxidative 
stress and apoptosis, while implication of two proteins in schizophrenia has been previously 
reported in the literature (Fig. 8.3). 
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G72Tg1 
Protein ID G72/G30 trasgenic/WT 
abundance ratio Protein name 
GSTP1_MOUSE 2.29 Glutathione S-transferase P1 
GDIR_MOUSE 2.04 Rho GDP dissociation inhibitor 
GSTM1_MOUSE 1.54 Glutathione S-transferase M1 
Q3TGF0_MOUSE 0.42 Tubulin alpha 1A chain 
G72Tg2 
Protein ID G72/G30 trasgenic/WT 
abundance ratio Protein name 
Q91VC6_MOUSE 2.84 Glutamine synthetase 
Q99JZ6_MOUSE 2.52 Tubulin beta 2C chain 
PGAM1_MOUSE 2.41 Phosphoglycerate mutase 1 
GSTM1_MOUSE 1.59 Glutathione S-transferase M1 
COF1_MOUSE 1.45 Cofilin-1 
 
Table 8.1 Protein expression differences in G72/G30 transgenic and wild type cerebella 
Four and five differentially expressed proteins were found in the G72Tg1/WT and the G72Tg2/WT 
comparison, respectively.  
 
 
 
 
 
 
 
 
 
 
Figure 8.2 Increased Gstm1 expression in G72/G30 transgenic mice 
Representative 2D-gel images indicating an increased signal intensity of the spot corresponding 
to Gsmt1 (arrows) in G72/G30 transgenic (G72Tg1) (left) compared to WT mice (right).  
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Figure 8.3 Pathway analysis of differentially expressed proteins in G72/G30 transgenic and 
wild type mice 
Differentially expressed proteins have been related to oxidative stress and apoptosis (different 
nomenclature between pathway and proteomics analyses is due to different databases employed 
for data processing). 
Cfl1: Cofilin-1; Gdi1: Rho GDP dissociation inhibitor; Glul: Glutamine synthetase; Gstm1: 
Glutathione S-transferase M1; Gstp1: Glutathione S-transferase P1; Pgam1: Phosphoglycerate 
mutase 1; Tuba1a: Tubulin alpha 1; Tubb2c: Tubulin beta 2. 
 
8.3 Discussion  
 
Although the G72/G30 locus is one of the most robust susceptibility regions for schizophrenia, the 
functional role of the G72 protein remains unclear. It has been reported that G72 binds to and 
activates in vitro D-amino acid oxidase (DAO) (Chumakov et al., 2002) which in turn oxidizes D-
serine, an allosteric co-activator of glutamanergic NMDA (Mothet et al., 2000), in accordance with 
the NMDA hypofunction hypothesis of schizophrenia. However, G72 has been recently proposed 
to be a mitochondrial protein that promotes mitochondrial fragmentation, failing to show in vivo 
interaction with DAO (Kvajo et al., 2008). In the context of a potential G72 role in mitochondrial 
function, our 2D-PAGE analysis revealed expression differences in members of  the glutathione 
   Biomarker discovery in G72/G30 mice 
________________________________________________________________________ 
94 
S-transferase family that are involved in detoxifying endogenous and xenobiotic compounds by 
catalyzing their conjugation to glutathione (Board, 2007). Because of the protective role of 
glutathione against ROS damage, a possible increase in oxidative stress due to G72 expression 
is suggested. Our data are further supported by altered activity of ETC complex I, accumulation of 
oxidized lipids in cerebellum and reduced glutathione activity in G72/G30 transgenic animals 
(Otte et al., in preparation). Taken together, an increased oxidative stress-related activity in 
G72/G30 transgenic mice is observed, pointing toward a mitochondrial role of G72, in accordance 
with oxidative stress and mitochondrial dysfunction reported in schizophrenia (Wood et al., 2009). 
The 2D-PAGE analysis performed revealed protein expression differences in G72/G30 transgenic 
and WT mice, thus providing useful insights into the functional role of the G72 protein. To achieve 
a more detailed characterization of the G72/G30 transgenic mouse model, future studies include 
brain tissue comparison of G72/G30 transgenic and WT animals by 15N metabolic labeling and 
quantitative MS using 15N-labeled CD1 mice as internal standards (similar to the quantitative 
proteomics platform used for the HAB/NAB/LAB trait anxiety mouse model). 
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9 Outlook and perspectives 
 
9.1 Biomarker discovery in psychiatric disorders 
 
The combination of powerful proteomics and metabolomics technologies and well-established 
rodent models of psychopathologies bridges behavioral biology, genetics, protein biochemistry 
and bioinformatics into a multidisciplinary approach to disentangle the pathobiology of psychiatric 
disorders. Here, we have thoroughly analyzed the HAB/NAB/LAB mouse model of trait anxiety 
and report altered proteins and pathways in HAB and LAB animals. We have confirmed 
differential expression of four selected proteins (Sfxn5, Car2, Myh10, Sdhb) identified by 
quantitative proteomics in an independent HAB/NAB/LAB population (Filiou et al., 2010b; Filiou et 
al., 2010c; Filiou et al., submitted), providing a panel of phenotype-specific markers. Most 
importantly, we highlight the role of mitochondria in modulating anxiety-related behavior by 
exerting an effect on energy metabolism, oxidative stress, molecular transport and 
neurotransmission pathways. Further investigation of the present findings in a larger population of 
HAB/NAB/LAB mice as well as assessment of the predictive validity of the identified candidate 
biomarkers are the next steps toward the establishment of anxiety-related behavior markers. 
Since the therapeutic potential of modulating mitochondrial energy metabolism (Gohil et al., 2010) 
and selectively targeting mitochondrial proteins (Fulda et al., 2010) has been demonstrated in 
disease, future work includes functional analyses to elucidate mitochondrial alterations in HAB 
and LAB mice (with special focus on oxidative stress and import/transport mechanisms) and 
pinpoint potential mitochondrial targets for therapeutic intervention. Moreover, the biomarker 
discovery pipeline based on 15N metabolic labeling will be applied to other models of 
psychopathologies beginning with G72/G30 transgenic mice, thus expanding the findings 
acquired from the 2D-gel-based approach. Undoubtedly, there is a long way from animal models 
to the implementation of biomarkers for patient diagnosis. However, the data presented here aid 
significantly our understanding concerning protein networks implicated in the molecular 
neurobiology of trait anxiety at the synapse. The four validated candidates (Sfxn5, Car2, Myh10, 
Sdhb) share increased sequence similarity with the corresponding proteins in humans and are 
involved in well-conserved pathways, indicating their potential applicability for screening of human 
specimens. Eventually, a robust set of well-characterized biomarkers in HAB/NAB/LAB animals 
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will be tested in human samples in order to transfer the knowledge gained from animal models to 
humans. These candidate biomarkers in combination with affected pathways apart from 
advancing our understanding concerning the underlying mechanisms of anxiety-related behavior 
may also lead to novel therapeutic targets for anxiety disorders. 
 
9.2 Proteomics technologies 
 
The development of high-throughput methodologies to perform non-hypothesis driven research 
has revolutionized the biomedical field.  Recent advances in establishing sophisticated 
proteomics platforms to quantify protein differences between two states have enabled the 
comparison of disease and control conditions at a holistic level. Consequently, large scale 
proteomics quantification studies can shed light on the molecular pathophysiology of psychiatric 
diseases in a way that has not been possible before. Yet, to benefit from the proteomics toolbox, 
fine-tuning of existing platforms for the material in question is of pivotal importance. In the present 
study, we optimized a previously reported IEF-based method for phosphopeptide analysis 
(Maccarrone et al., 2006) and applied it to brain tissue, resulting in the most detailed proteome 
and phosphoproteome synaptosome profiling described to date (Filiou et al., 2010a). At the 
quantitative level, we established an in vivo 15N metabolic labeling strategy for mice, achieving 
high 15N incorporation even in tissues with slow protein turnover (i.e. brain) without affecting 
normal development (Frank et al., 2009). 15N-labeled WT mouse specimens can serve as internal 
standards for a battery of quantitative proteomics experiments and can be practically used to 
interrogate any disease animal model (Filiou et al., accepted). The use of stable isotope labeling 
is currently the state-of-the-art quantitative MS-based approach. For the first time, we showed 
that the introduction of the 15N isotope can affect not only the labeled proteome but also the 
behavioral phenotype of the labeled organisms (Frank et al., 2009). This is of great importance to 
the field of quantitative proteomics because it demonstrates the indispensable need for employing 
a labeling control strategy when performing metabolic labeling experiments. Taken together, the 
proteomics technologies and relevant methodological considerations presented here shed light 
into proteomics platforms and provide robust and reliable tools that can be utilized in a wide 
range of applications in model organisms and human specimens for in-depth proteome profiling, 
accurate relative quantification and biomarker discovery. 
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11 Appendixes 
 
Appendix 1: Alphabetical list of the commercially available antibodies used 
 
Antigen Name Commercial 
source 
Catalog No Type 
Car2 Santa Cruz Biotechnology sc-17244 goat polyclonal 
Crym Santa Cruz Biotechnology sc-22423 goat polyclonal 
Gap43 Abcam ab12274 rabbit polyclonal 
Gria2 NeuroMab 73-067 mouse monoclonal 
LacZ Novus Biologicals NB600-305 rabbit polyclonal 
Mbp Abcam ab53294 rabbit monoclonal 
Myh10 Santa Cruz Biotechnology sc-47205 goat polyclonal 
Nefm Abcam ab30309 rabbit polyclonal 
PrkC Santa Cruz Biotechnology sc-10800 rabbit polyclonal 
PSD95 Genetex GTX12093 goat polyclonal 
Sdhb Abcam ab14714 mouse monoclonal 
Sfxn5 Abnova PAB4481 rabbit polyclonal 
Slc17a7 NeuroMab 75-066 mouse monoclonal 
TnR (N-20) Santa Cruz Biotechnology sc-9874 goat polyclonal 
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Appendix 2: Bacteria-fed HAB/NAB/LAB animals used for quantitative proteomics analyses 
 
 
14N/15N pair EPMa TSTb 
Cingulate 
cortex 
weight 
(mg) 
Animal 
Weight 
(g) 
EPMa TSTb 
Cingulate 
cortex 
weight 
(mg) 
Animal 
Weight  
(g) 
Line comparison 
(14N HAB/15N NAB) 
14N HAB 15N NAB 
1 2.66 143.8 28.3 24 26.86 59.6 25.8 26 
2 4.10 99.7 23.7 29 25.20 40.7 31.4 25 
3 5.10 75.0 38.3 28 30.90 92.1 43.5 21 
Line comparison 
(14N LAB/15N NAB) 
14N LAB 15N NAB 
1 65.65 0.0 32.7 25 24.36 122.4 34.2 23 
2 79.72 1.2 37.2 24 25.24 43.8 46.2 23 
3 77.18 0.0 49.0 22 20.56 73.1 42.5 24 
15N isotope effect 
comparison 
(14N HAB/15N HAB) 
14N HAB 15N HAB 
1 2.47 52.6 30.9 25 10.13 44.2 24.6 18 
2 6.97 83.8 27.7 29 11.34 29.7 27.0 21 
3 10.40 113.2 30.6 27 6.99 46.6 27.1 24 
 
a
 % of test time spent on the EPM open arms 
b
 total immobility time in sec during TST 
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Appendix 3: Phosphorylated peptides and proteins in whole mouse brain synaptosomes 
Protein namea Phosphopeptides identified 
Phosphosites 
Identifiedb 
Ablim1 RIKEN full-length enriched library, clone: 
F520009N11 product: Actin-binding LIM protein 1, full 
insert sequence 
TLSPTPSAEGYQDVR T1 T5 
Ablim3 Actin-binding LIM protein 3 TSETSISPPGSSIGSPNR S7 S11 
Acly RIKEN full-length enriched library, clone: 
4922505F07 product: ATP citrate lyase, full insert 
sequence 
PAM*PQDSVPSPR S10 
Adcy9 Adenylate cyclase type 9 GQGTASPGSVSDLAQTVK T4 S6 S9 S11 
Add1 Isoform 1 of Alpha-adducin SPPDQSAVPNTPPSTPVK S14 T15 
Add2 Isoform 3 of Beta-adducin TESVTSGPLSPEGSPSK T5 S6 S10 S14 S16 
Akap12 PKC binding protein SSeCKS PLESPTSPVSNETTSSFK T6 S10 T13 
Akap5 similar to A-kinase anchor protein 5 isoform 1 SSAIQM*GTPELEK T8 
Als2 Isoform 2 of Alsin TVVLTPTYSGEADALLPSLR T1 T7 Y8 S9 
Ank2 ankyrin 2, brain isoform 2 GSPIVQEPEEASEPK S2 
Ank2 ankyrin 2, brain isoform 3 ARSYIETETESR S3 Y4 
SQVETEDLILKPGVVHVIDIDR S1 
GSYM*EVEDNRSQVETEDLILK Y3 S11 T15 Aqp4 Isoform 2 of Aquaporin-4 
SQVETEDLILK S1 
Atcay Caytaxin LGGAVEDSSSPPSTLNLSGAHR S8 S10 
Bcas1 Breast carcinoma amplified sequence 1 homolog TPSPPEPEPAGTAQK T1 
Bin1 Isoform 1 of Myc box-dependent-interacting protein 1 SPSPPPDGSPAATPEIR S3 
BM948371 similar to Brain-enriched guanylate kinase-
associated protein isoform 1 RPSVDTPVTDVGFLR S3 
SQASEEESPVSPLGRPR S8 S11 
Bsn Isoform 1 of Protein bassoon 
YLGQGLQYGSFTDLR Y8 S10 T12 
Cadps Isoform 2 of Calcium-dependent secretion 
activator 1 PSSPSPSVVSEK S5 S7 S10 
Cartpt Isoform Long of Cocaine- and amphetamine-
regulated transcript protein precursor ALDIYSAVDDASHEK S6 S12 
Cend1 Cell cycle exit and neuronal differentiation 
protein 1 PAPTVPAAPSSPDATSEPK S10 S11 T15 S16 
Chgb Secretogranin-1 precursor SSYEGHPLSEER S9 
Clasp1 CLASP1 isoform 11 
Clasp2 protein 
SRSDIDVNAAASAKc S1 S3 
ALQSPEHHIDPIYEDR S4 
Ctnnd2 Isoform 1 of Catenin delta-2 
TSTAPSSPGVDSVPLQR S6 
Cttn Src substrate cortactin KQTPPASPSPQPIEDRPPSSPIYEDAAPFK T3 S7 S19 S20 Y23 
D3Bwg0562e Plasticity related gene 1 protein PGSSQLVHIPEETQENISTSPK S18 T19 
Dlg2 Isoform 1 of Discs large homolog 2 AISLEGEPR S3 
Dmxl2 Dmx-like 2 NLASPEGTLATLGLK S4 T8 
Dnajc5 protein SLSTSGESLYHVLGLDK S1 S3 T4 S5 S8 
Dst Isoform 1 of Bullous pemphigoid antigen 1, isoforms 
1/2/3/4 SVSVDMEKLQPLYETLR T15 
Ebag9 Receptor-binding cancer antigen expressed on 
SiSo cells (Fragment) KLSGDQITLPTTVDYSSVPK S3 T8 
EG624619 similar to metaxin 3 FSGAPLKINIIDNTWR T14 
GISQTNLITTVTPEK S3 T5 T9 T10 T12 
VESTSVGSISPGGAK S8 S10 Epb4.1l3 Isoform 1 of Band 4.1-like protein 3 
AEEATPVTALR T5 T8 
Epb4.9 Dematin HLSAEDFSR S3 
Epn2 Isoform 1 of Epsin-2 GSSQPNLSTSYSEQEYGK S3 
Fbxo41 F-box only protein 41 RHSTEGEEGDVSDVGSR S3 
Fcho2 RIKEN full-length enriched library, clone: 
C530046K19 product: Hypothetical protein, full insert 
sequence 
PAHPNNLHHTMASLDELKVSIGNITLSPAVSR S13 S20 T25 S27 
Fxyd1 Phospholemman precursor TGEPDEEEGTFRSSIR T10 S13 
Appendixes 
_____________________________________________________________________ 
114 
Proteina Phosphopeptides identified 
Phosphosites 
Identifiedb 
G3bp2 Isoform A of Ras GTPase-activating protein-
binding protein 2 SATPPPAEPASLPQEPPK S1 
Gabbr2 Ortholog of human G protein-coupled receptor 51 
GPR51 DPIEDINSPEHIQR S8 
Gap43 Neuromodulin EGDGSATTDAAPATSPK T14 S15 
Gm996 Novel protein SPAQAPEPAAEGLGR S1 
Gng3 Guanine nucleotide-binding protein G(I)/G(S)/G(O) 
gamma-3 subunit precursor GETPVNSTM*SIGQAR T3 S7 T8 
Gpm6a Neuronal membrane glycoprotein M6-a EEQELHDIHSTR S10 T11 
Gpr37l1 Endothelin B receptor-like protein 2 precursor PRESPPLLPLGTPC S4 
NSELVSPVKPER S6 
Gprin1 G protein-regulated inducer of neurite outgrowth 1 
SPSAEAAAPPPGPR S1 S3 
Iqsec1 Isoform 2 of IQ motif and Sec7 domain-containing 
protein 1 
Iqsec2 IQ motif and Sec7 domain-containing protein 2 
M*QFSFEGPEKc S4 
Kbtbd11 Kbtbd11 protein ASAAEGSEASPPSLR S10 
Kcnc3 Isoform KV3.3B of Potassium voltage-gated 
channel subfamily C member 3 SLSSIVGLSGVSLR S1 S3 
Kcnd2 Potassium voltage-gated channel subfamily D 
member 2 GSVQELSTIQIR S2 
Kcnma1 Isoform 1 of Calcium-activated potassium 
channel subunit alpha 1 RLEDEQPPTLSPK S11 
Klc1 64 kDa protein KYDDDISPSEDK Y2 S7 S9 
Madd MAP-kinase activating death domain SPTENVNTPVGK T3 
Magi2 Isoform 4 of Membrane-associated guanylate 
kinase, WW and PDZ domain-containing protein 2 IIPQEELNSPTSAPSSEK S12 
Mapt 76 kDa protein SPVVSGDTSPR T8 S9 
Marcks Myristoylated alanine-rich C-kinase substrate GEATAERPGEAAVASSPSK S15 S18 
Mgea6 Cutaneous T-cell lymphoma-associated antigen 5 
homolog AFLSPPTLLEGPLR S4 
Mlf2 Myeloid leukemia factor 2 LAIQGPEDSPSR S9 
Mllt4 similar to Afadin LPYLVELSPGR S8 
SPFEIISPPASPPEM*TGQR S7 S11 T16 
QLSPESLGTLQFGELSLGK S3 S6 T9 Mtap1a Isoform 1 of Microtubule-associated protein 1A 
VPSAPGQESPVPDTK S3 S9 
VLSPLRSPPLLGSESPYEDFLSADSK S3 S7 S13 
SVSPGVTQAVVEEHCASPEEK S17 
DVSDERLSPAK S8 
Mtap1b Microtubule-associated protein 1B 
TPEEGGYSYEISEK T1 
TGVIQTSTEQSFSK T6 S7 
KETSPETSLIQDEVALK S4 T7 
VDHGAEIITQSPSR T9 S11 S13 Mtap2 Microtubule-associated protein 2 
GSAQESLDTISPK S11 
Mtap4 Mtap4 protein AAVGVTGNDITTPPNK T11 T12 
Mtap6 microtubule-associated protein 6 isoform 1 AQSPLLPEPLK S3 
Nbea Isoform 3 of Protein neurobeachin TPLENVPGNLSPIK S11 
ASPAPTPTPAGAASPLAAVAAPATDAPQAK S2 T6 T8 S14 Ncam1 Isoform N-CAM 180 of Neural cell adhesion 
molecule 1, 180 kDa isoform precursor NPPEAATAPASPK S11 
Ncam2 Isoform Long of Neural cell adhesion molecule 2 
precursor ITNHEDGSPVNEPNETTPLTEPEK S8 
Ncbp1 Nuclear cap-binding protein subunit 1 SKATNDEIFSILK S10 
Ndrg2 Isoform 1 of Protein NDRG2 TASLTSAASIDGSR T1 T5 S6 S9 
Nfasc Neurofascin precursor PLQGSQTSLDGTIK S5 
Palm Isoform 1 of Paralemmin SETLVNAQQTPLGTPK T10 T14 
Pcsk1n ProSAAS precursor ILTGSSEPEAAPAPR T3 
Pde8b RIKEN full-length enriched library, clone: 
C630023C23 product: Similar to HIGH-AFFINITY CAMP-
SPECIFIC AND IBMX-INSENSITIVE 3',5'-CYCLIC 
PHOSPHODIESTERASE 8B 
ESIDVKSISSR S9 
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Proteina Phosphopeptides identified 
Phosphosites 
Identifiedb 
Pdpk1 3-phosphoinositide-dependent protein kinase 1 ANSFVGTAQYVSPELLTEK S3 T7 Y10 
Pex2 Isoform 3 of PEX5-related protein NHSLEEEFER S3 
Pik4ca Phosphatidylinositol 4-kinase, catalytic, alpha 
polypeptide TSSVSSISQVSPER S8 S11 
VGSPLTLTDAQTR S3 
Pkp4 Isoform 1 of Plakophilin-4 
SAVSPDLHITPIYEGR S1 
Plekha6 Pleckstrin homology domain-containing family A 
member 6 AYVPLESPPTVPPLPNESR T10 
Ppfia2 Liprin-alpha-2 VASVSLEGLNLAR S3 S5 
Prkaca Isoform 2 of cAMP-dependent protein kinase, 
alpha-catalytic subunit TWTLCGTPEYLAPEIILSK T3 T7 Y10 
Prkcb1 Protein kinase C beta type HPPVLTPPDQEVIR T6 
Prkcc Protein kinase C gamma type M*GPSSSPIPSPSPSPTDSK S10 S12 T16 S18 
Prrt3 Proline-rich transmembrane protein 3 precursor GSVGPAPSLSELDLRPPSPINLSR S18 
Psmd1 26S proteasome non-ATPase regulatory subunit 1 TVGTPIASVPGSTNTGTVPGSEK T1 T4 S7 
Psmd2 26S proteasome non-ATPase regulatory subunit 2 TPVQSQQPSATTPSGADEK S9 T11 T12 S14 
Ptprn Receptor-type tyrosine-protein phosphatase-like N 
precursor AEDSSEGHEEEVLGGR S5 
Ptprn2 Receptor-type tyrosine-protein phosphatase N2 
precursor ADSVAGAIQSDPAEGSQESHGR S10 S16 S19 
Rab11fip5 Rab11 family-interacting protein 5 PLTAAPVEASPDRK S10 
Rgs6 Regulator of G-protein signaling 6 SVYGVTDETQSQSPVHIPSQPIR T6 T9 S11 
Rtn4 Isoform 1 of Reticulon-4 RGSGSVDETLFALPAASEPVIPSSAEK S5 T9 
Rtn4 Isoform 2 of Reticulon-4 LPEDDEPPARPPAPAGASPLAEPAAPPSTPAAPK S18 S28 T29 
Sgip1 Isoform 3 of SH3-containing GRB2-like protein 3-
interacting protein 1 NLSSEEVAR S3 
Sgta Isoform 1 of Small glutamine-rich tetratricopeptide 
repeat-containing protein A APDRTPPSEEDSAEAER T5 S8 
Shank2 Isoform 1 of SH3 and multiple ankyrin repeat 
domains protein 2 APSPVVSPTELSK S7 S12 
Slc6a5 Isoform a of Sodium- and chloride-dependent 
glycine transporter 2 SASTGAQTFQSADAR T4 T8 
Slc7a8 Large neutral amino acids transporter small 
subunit 2 NHPGSDTSPEAEASSGGGGVALK S5 T7 S14 S15 
Slc8a2 Sodium-calcium exchanger GISALLLNQGNGDK S3 
Snap91 Isoform Long of Clathrin coat assembly protein 
AP180 PGNNEGSGAPSPLSK S7 
Sntb2 Beta-2-syntrophin GPAGEASASPPVR S7 
Snx27 sorting nexin family member 27 isoform 1 SESGYGFNVR S3 
Sparcl1 SPARC-like protein 1 precursor PSALNSEEETHEQSTEQDK S6 
Spnb2 Spectrin beta chain, brain 1 TLETPAAQM*EGFLNR T1 T4 
Stx1b2 Syntaxin-1B2 SAKDSDDEEEVVHVDR S1 S5 
Synj1 synaptojanin 1 TPGPPSSQGSPVDTQPAAQK T1 S6 S7 S10 
Tgoln2 Trans-Golgi network integral membrane protein 2 
precursor TESGETLAGDSDFSLKPEK T6 S11 
Tjp2 Tight junction protein ZO-2 VQVAPLQGSPPLSHDDR S9 S13 
Tnik Isoform 1 of Traf2 and NCK-interacting protein kinase 
(Fragment) SEGSPVLPHEPSK S1 S4 
Ttc7b tetratricopeptide repeat domain 7B isoform 1 VEQALSEVASSLQSSAPK S6 S10 S11 S14 S15 
Vdac1 Isoform Pl-VDAC1 of Voltage-dependent anion-
selective channel protein 1 LTFDSSFSPNTGK S5 S6 T11 
Vps35 Vacuolar protein sorting-associated protein 35 RESPESEGPIYEGLIL S3 
- 16 kDa protein IPESELGSPTLTSAQK S8 T10 T12 S13 
- 35 kDa protein HPSSQLAGPGVEGGEGTQK S3 S4 
- 39 kDa protein GILAADESTGSIAK S8 T9 S11 
1200015F23Rik Protein FAM82C SHSLPNSLDYAQASER S1 S3 S7 
1700019D03Rik RIKEN full-length enriched library, clone: 
2410136C24 product: Hypothetical protein, full insert 
sequence 
TPSPGEQQQVQEVK S3 
6330569M22Rik Isoform 1 of Protein FAM40A AASPPASASDLIEQQQK S3 S7 
6430548M08Rik Uncharacterized protein KIAA0513 TVTM*ISPEDEQK S6 
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a
 proteins reported for the first time to be phosphorylated are indicated with a bold italic font 
b
 unambiguously assigned phosphosites are indicated with a bold font 
c
 phosphorylated peptide sequences belonging to two different proteins 
* methionine oxidation 
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Appendix 4: Differentially expressed proteins (>1.3 fold) in HAB/LAB cingulate cortex 
synaptosomes 
Protein ID 
HAB/LAB 
abundance 
ratio 
HAB/LAB 
log2 ratio  log2 CI Protein Name 
IPI00112327 2.83 1.5 [0.7, 2.2] Mtx1 Metaxin-1 
IPI00130322 2.83 1.5 [0.8, 2.2] Ndufa7 NADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 7 
IPI00130640 2.83 1.5 [1.1, 1.9] Hrsp12 Ribonuclease UK114 
IPI00113606 2.64 1.4 [0.6, 2.2] Agk Isoform 1 of Acylglycerol kinase, mitochondrial precursor 
IPI00116748 2.64 1.4 [1.1, 1.8] Ndufa10 NADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 10, mitochondrial precursor 
IPI00226387 2.64 1.4 [0.5, 2.2] Pgam5 Isoform 2 of Phosphoglycerate mutase family member 5 precursor 
IPI00330754 2.64 1.4 [1.0, 1.8] Bdh1 D-beta-hydroxybutyrate dehydrogenase, mitochondrial precursor 
IPI00113869 2.46 1.3 [0.7, 1.9] Bsg Isoform 2 of Basigin precursor 
IPI00117300 2.46 1.3 [0.8, 1.7] Ndufs5; BC002163 NADH dehydrogenase [ubiquinone] iron-sulfur protein 5 
IPI00121288 2.46 1.3 [0.8, 1.7] Ndufb10 NADH dehydrogenase [ubiquinone] 1 beta subcomplex subunit 10 
IPI00131896 2.46 1.3 [0.9, 1.6] Brp44 Brain protein 44 
IPI00132050 2.46 1.3 [0.6, 2.0] Ndufc2; LOC675851 NADH dehydrogenase [ubiquinone] 1 subunit C2 
IPI00132623 2.46 1.3 [0.8, 1.8] Ndufb9 NADH dehydrogenase [ubiquinone] 1 beta subcomplex subunit 9 
IPI00133215 2.46 1.3 [0.8, 1.8] Ndufb7 NADH dehydrogenase [ubiquinone] 1 beta subcomplex subunit 7 
IPI00313475 2.46 1.3 [1.0, 1.6] Atp5c1 ATP synthase subunit gamma, mitochondrial precursor 
IPI00341322 2.46 1.3 [0.7, 2.0] Ndufb6 NADH dehydrogenase [ubiquinone] 1 beta subcomplex subunit 6 
IPI00453777 2.46 1.3 [0.9, 1.7] Atp5d ATP synthase subunit delta, mitochondrial precursor 
IPI00480233 2.46 1.3 [0.7, 2.0] mt-Nd5 NADH dehydrogenase subunit 5 
IPI00850053 2.46 1.3 [0.3, 2.3] LOC100045547 similar to Calcium/calmodulin-dependent protein kinase type II gamma chain 
IPI00110265 2.30 1.2 [0.8, 1.6] Sirt2 Isoform 1 of NAD-dependent deacetylase sirtuin-2 
IPI00118986 2.30 1.2 [0.9, 1.5] LOC100047429; Atp5o ATP synthase subunit O, mitochondrial precursor 
IPI00120212 2.30 1.2 [0.9, 1.5] Ndufa9 NADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 9, 
mitochondrial precursor 
IPI00123712 2.30 1.2 [0.4, 1.9] Timm23 Mitochondrial import inner membrane translocase subunit Tim23 
IPI00127841 2.30 1.2 [0.8, 1.5] Slc25a5 ADP/ATP translocase 2 
IPI00128023 2.30 1.2 [0.8, 1.6] Ndufs2 NADH dehydrogenase [ubiquinone] iron-sulfur protein 2, 
mitochondrial precursor 
IPI00130460 2.30 1.2 [0.6, 1.8] Ndufv1 NADH dehydrogenase [ubiquinone] flavoprotein 1, mitochondrial precursor 
IPI00131176 2.30 1.2 [0.9, 1.5] mt-Co2 Cytochrome c oxidase subunit 2 
IPI00132531 2.30 1.2 [0.7, 1.7] Ndufb5 NADH dehydrogenase [ubiquinone] 1 beta subcomplex subunit 5, 
mitochondrial precursor 
IPI00133167 2.30 1.2 [0.3, 2.1] ENSMUSG00000045886; LOC100047446; Magmas Mitochondrial import inner membrane translocase subunit Tim16 
IPI00228150 2.30 1.2 [0.8, 1.5] Immt Isoform 1 of Mitochondrial inner membrane protein 
IPI00229008 2.30 1.2 [0.7, 1.7] Ndufs4 NADH dehydrogenase [ubiquinone] iron-sulfur protein 4, 
mitochondrial precursor 
IPI00230715 2.30 1.2 [0.9, 1.5] Ndufa13 NADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 13 
IPI00266836 2.30 1.2 [0.4, 2.0] 1810026J23Rik Uncharacterized protein C19orf52 homolog 
IPI00308162 2.30 1.2 [1.0, 1.4] Slc25a12 Calcium-binding mitochondrial carrier protein Aralar1 
IPI00308882 2.30 1.2 [1.0, 1.5] Ndufs1 NADH-ubiquinone oxidoreductase 75 kDa subunit, mitochondrial precursor 
IPI00341282 2.30 1.2 [0.8, 1.5] Atp5f1 ATP synthase subunit b, mitochondrial precursor 
IPI00344004 2.30 1.2 [0.9, 1.6] Ndufa12 NADH dehydrogenase (ubiquinone) 1 alpha subcomplex, 12 
IPI00109275 2.14 1.1 [0.8, 1.4] Slc25a22 Mitochondrial glutamate carrier 1 
IPI00110825 2.14 1.1 [0.6, 1.6] 
Ndufc2 RIKEN full-length enriched library, clone: 2010300P09 product: 
1810004I06RIK PROTEIN (SIMILAR TO NADH DEHYDROGENASE 
(UBIQUINONE) 1, SUBCOMPLEX UNKNOWN, 2) (14.5KD, B14.5B) 
homolog 
IPI00111885 2.14 1.1 [0.8, 1.4] Uqcrc1 Cytochrome b-c1 complex subunit 1, mitochondrial precursor 
IPI00114246 2.14 1.1 [0.5, 1.7] Ndufb11 NADH dehydrogenase [ubiquinone] 1 beta subcomplex subunit 11, mitochondrial precursor 
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Protein ID 
HAB/LAB 
abundance 
ratio 
HAB/LAB 
log2 ratio log2 CI Protein Name 
IPI00115564 2.14 1.1 [0.9, 1.3] Slc25a4 ADP/ATP translocase 1 
IPI00116843 2.14 1.1 [0.7, 1.6] ENSMUSG00000064363; mt-Nd4 NADH-ubiquinone oxidoreductase chain 4 
IPI00119138 2.14 1.1 [0.8, 1.3] Uqcrc2 Cytochrome b-c1 complex subunit 2, mitochondrial precursor 
IPI00120232 2.14 1.1 [0.8, 1.5] Ndufs7 NADH dehydrogenase [ubiquinone] iron-sulfur protein 7, 
mitochondrial precursor 
IPI00121309 2.14 1.1 [0.8, 1.4] Ndufs3 NADH dehydrogenase [ubiquinone] iron-sulfur protein 3, 
mitochondrial precursor 
IPI00126917 2.14 1.1 [0.8, 1.4] 1700071K01Rik RIKEN full-length enriched library, clone: 1700071K01 product: Prohibitin (B-cell receptor associated protein 32) homolog 
IPI00130280 2.14 1.1 [0.9, 1.3] Atp5a1 ATP synthase subunit alpha, mitochondrial precursor 
IPI00131177 2.14 1.1 [0.5, 1.7] Letm1 Leucine zipper-EF-hand-containing transmembrane protein 1, 
mitochondrial precursor 
IPI00132390 2.14 1.1 [0.7, 1.5] Ndufb4; 100041273; 100042503 NADH dehydrogenase [ubiquinone] 1 beta 
subcomplex subunit 4 
IPI00132728 2.14 1.1 [0.8, 1.4] Cyc1 Isoform 1 of Cytochrome c1, heme protein, mitochondrial precursor 
IPI00133240 2.14 1.1 [0.7, 1.5] Uqcrfs1 Cytochrome b-c1 complex subunit Rieske, mitochondrial precursor 
IPI00133403 2.14 1.1 [0.4, 1.8] Ndufb3 NADH dehydrogenase [ubiquinone] 1 beta subcomplex subunit 3 
IPI00133440 2.14 1.1 [0.8, 1.4] Phb Prohibitin 
IPI00136716 2.14 1.1 [0.7, 1.4] Grm3 Metabotropic glutamate receptor 3 precursor 
IPI00170093 2.14 1.1 [0.6, 1.5] Ndufs8 NADH dehydrogenase [ubiquinone] iron-sulfur protein 8, 
mitochondrial precursor 
IPI00221602 2.14 1.1 [0.7, 1.5] Sfxn5 Sideroflexin-5 
IPI00223092 2.14 1.1 [0.7, 1.5] Hadha Trifunctional enzyme subunit alpha, mitochondrial precursor 
IPI00230507 2.14 1.1 [0.9, 1.4] Atp5h ATP synthase subunit d, mitochondrial 
IPI00331182 2.14 1.1 [0.8, 1.4] Gpd2 Glycerol phosphate dehydrogenase 2, mitochondrial 
IPI00387430 2.14 1.1 [0.6, 1.6] Ndufb8 NADH dehydrogenase [ubiquinone] 1 beta subcomplex subunit 8, 
mitochondrial precursor 
IPI00468481 2.14 1.1 [1.0, 1.3] Atp5b ATP synthase subunit beta, mitochondrial precursor 
IPI00626928 2.14 1.1 [0.4, 1.9] Tmem65 Transmembrane protein 65 
IPI00109611 2.00 1 [0.4, 1.7] 2310056P07Rik E2-induced gene 5 protein homolog 
IPI00111770 2.00 1 [0.6, 1.4] Atp5k ATP synthase subunit e, mitochondrial 
IPI00115089 2.00 1 [0.3, 1.6] Entpd2 Isoform Long of Ectonucleoside triphosphate diphosphohydrolase 2 
IPI00115949 2.00 1 [0.5, 1.4] Cox7a2l; EG629383 Cox7a2l protein 
IPI00116154 2.00 1 [0.4, 1.6] Cox5b; OTTMUSG00000000426; LOC100045602; LOC100046079 
cytochrome c oxidase, subunit Vb 
IPI00120984 2.00 1 [0.7, 1.4] Ndufa8 NADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 8 
IPI00121576 2.00 1 [0.6, 1.4] Apoo Apolipoprotein O 
IPI00125929 2.00 1 [0.6, 1.3] Ndufa4 NADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 4 
IPI00128345 2.00 1 [0.6, 1.4] Ndufs6 NADH dehydrogenase [ubiquinone] iron-sulfur protein 6, 
mitochondrial precursor 
IPI00132347 2.00 1 [0.6, 1.3] 
Uqcrb RIKEN full-length enriched library, clone: 1500015I13 product: 
UBIQUINOL-CYTOCHROME C REDUCTASE BINDING PROTEIN 
homolog 
IPI00133399 2.00 1 [0.6, 1.5] Ndufa6 NADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 6 
IPI00227302 2.00 1 [0.7, 1.3] Slc4a10 Solute carrier family 4, sodium bicarbonate co-transporter-like, 
member 10 
IPI00229598 2.00 1 [0.7, 1.2] Cnp Isoform CNPI of 2',3'-cyclic-nucleotide 3'-phosphodiesterase 
IPI00318645 2.00 1 [0.6, 1.4] Ndufa11 NADH dehydrogenase (ubiquinone) 1 alpha subcomplex 11 isoform 3 
IPI00321718 2.00 1 [0.7, 1.3] Phb2 Prohibitin-2 
IPI00331332 2.00 1 [0.7, 1.4] Ndufa5 NADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 5 
IPI00338536 2.00 1 [0.6, 1.5] Sdhb Succinate dehydrogenase [ubiquinone] iron-sulfur subunit, 
mitochondrial precursor 
IPI00420244 2.00 1 [0.4, 1.5] Slc1a1 Solute carrier family 1 (Neuronal/epithelial high affinity glutamate transporter, system Xag), member 1 
IPI00113244 1.87 0.9 [0.3, 1.5] Ttyh1 Isoform 1 of Protein tweety homolog 1 
IPI00117978 1.87 0.9 [0.7, 1.2] Cox4i1 Cytochrome c oxidase subunit 4 isoform 1, mitochondrial precursor 
IPI00120076 1.87 0.9 [0.2, 1.6] Ckmt2 Creatine kinase, sarcomeric mitochondrial precursor 
IPI00120719 1.87 0.9 [0.6, 1.2] Cox5a Cytochrome c oxidase subunit 5A, mitochondrial precursor 
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Protein ID 
HAB/LAB 
abundance 
ratio 
HAB/LAB 
log2 ratio log2 CI Protein Name 
IPI00121419 1.87 0.9 [0.5, 1.4] LOC631451; EG432822 hypothetical protein 
IPI00121443 1.87 0.9 [0.5, 1.3] Cox6a1 Cytochrome c oxidase polypeptide VIa 
IPI00121534 1.87 0.9 [0.6, 1.3] Car2 Carbonic anhydrase 2 
IPI00124771 1.87 0.9 [0.7, 1.1] Slc25a3 Phosphate carrier protein, mitochondrial precursor 
IPI00132039 1.87 0.9 [0.5, 1.3] Mtch2 Mitochondrial carrier homolog 2 
IPI00133608 1.87 0.9 [0.2, 1.7] Ociad1 Isoform 1 of OCIA domain-containing protein 1 
IPI00169925 1.87 0.9 [0.4, 1.4] Ndufv2 Isoform 1 of NADH dehydrogenase [ubiquinone] flavoprotein 2, 
mitochondrial precursor 
IPI00225254 1.87 0.9 [0.3, 1.6] Mtx2 Metaxin-2 
IPI00225306 1.87 0.9 [0.3, 1.5] Slc4a7 Isoform 1 of Sodium bicarbonate co-transporter 3 
IPI00225390 1.87 0.9 [0.4, 1.3] Cox6b1 Cytochrome c oxidase subunit VIb isoform 1 
IPI00226140 1.87 0.9 [0.4, 1.4] Maob Amine oxidase [flavin-containing] B 
IPI00230289 1.87 0.9 [0.8, 1.0] Slc1a2 Isoform Glt-1A of Excitatory amino acid transporter 2 
IPI00230754 1.87 0.9 [0.7, 1.2] Slc25a11 Mitochondrial 2-oxoglutarate/malate carrier protein 
IPI00312174 1.87 0.9 [0.1, 1.7] Ptges2 Prostaglandin E synthase 2 
IPI00313390 1.87 0.9 [0.3, 1.6] Chchd6 Coiled-coil-helix-coiled-coil-helix domain-containing protein 6 
IPI00315325 1.87 0.9 [0.1, 1.7] Timm22 Mitochondrial import inner membrane translocase subunit Tim22 
IPI00319111 1.87 0.9 [0.3, 1.5] Sdhc Succinate dehydrogenase cytochrome b560 subunit, mitochondrial precursor 
IPI00331318 1.87 0.9 [0.2, 1.5] Ppt1 Palmitoyl-protein thioesterase 
IPI00112139 1.74 0.8 [0.3, 1.2] Ociad2 OCIA domain-containing protein 2 
IPI00114209 1.74 0.8 [0.4, 1.3] Glud1 Glutamate dehydrogenase 1, mitochondrial precursor 
IPI00115454 1.74 0.8 [0.4, 1.2] Sfxn1 Sideroflexin-1 
IPI00116558 1.74 0.8 [0.4, 1.3] Rhog Rho-related GTP-binding protein RhoG precursor 
IPI00123276 1.74 0.8 [0.1, 1.5] Mosc2 MOSC domain-containing protein 2, mitochondrial precursor 
IPI00124221 1.74 0.8 [0.2, 1.3] Atp1b3 Sodium/potassium-transporting ATPase subunit beta-3 
IPI00125460 1.74 0.8 [0.1, 1.5] Atp5j; LOC674583 ATP synthase-coupling factor 6, mitochondrial precursor 
IPI00126115 1.74 0.8 [0.5, 1.1] Sfxn3 Isoform 1 of Sideroflexin-3 
IPI00128296 1.74 0.8 [0.6, 1.1] Ckmt1 Creatine kinase, ubiquitous mitochondrial precursor 
IPI00128346 1.74 0.8 [0.4, 1.1] Cisd1 CDGSH iron sulfur domain-containing protein 1 
IPI00129395 1.74 0.8 [0.1, 1.5] Slc7a5 Large neutral amino acids transporter small subunit 1 
IPI00131771 1.74 0.8 [0.3, 1.3] Cox6c Cytochrome c oxidase polypeptide VIc 
IPI00132002 1.74 0.8 [0.5, 1.1] Mgst3 Microsomal glutathione S-transferase 3 
IPI00133562 1.74 0.8 [0.4, 1.3] Chchd3 Coiled-coil-helix-coiled-coil-helix domain-containing protein 3, 
mitochondrial precursor 
IPI00134131 1.74 0.8 [0.4, 1.3] Scp2 Isoform SCPx of Non-specific lipid-transfer protein 
IPI00153381 1.74 0.8 [0.1, 1.5] 1110020P15Rik Cytochrome b-c1 complex subunit 9 
IPI00222419 1.74 0.8 [0.6, 1.1] ENSMUSG00000058927; Cycs Cytochrome c, somatic 
IPI00224210 1.74 0.8 [0.4, 1.3] Uqcrq Cytochrome b-c1 complex subunit 8 
IPI00230351 1.74 0.8 [0.5, 1.2] Sdha Succinate dehydrogenase [ubiquinone] flavoprotein subunit, 
mitochondrial precursor 
IPI00315135 1.74 0.8 [0.3, 1.3] Tomm22 Mitochondrial import receptor subunit TOM22 homolog 
IPI00315302 1.74 0.8 [0.2, 1.4] Ndufa2 NADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 2 
IPI00315908 1.74 0.8 [0.3, 1.3] 1700020C11Rik Mitochondrial 18 kDa protein 
IPI00323442 1.74 0.8 [0.1, 1.5] Slc4a8 Isoform 1 of Electroneutral sodium bicarbonate exchanger 1 
IPI00344640 1.74 0.8 [0.4, 1.2] Slc25a18 33 kDa protein 
IPI00624653 1.74 0.8 [0.2, 1.4] Usmg5 Up-regulated during skeletal muscle growth protein 5 
IPI00122547 1.62 0.7 [0.4, 1.0] Vdac2 Voltage-dependent anion-selective channel protein 2 
IPI00122548 1.62 0.7 [0.4, 1.0] Vdac3 Voltage-dependent anion channel 3 
IPI00122549 1.62 0.7 [0.6, 0.9] Vdac1 Isoform Pl-VDAC1 of Voltage-dependent anion-selective channel protein 1 
IPI00127558 1.62 0.7 [0.1, 1.3] Acox1 Peroxisomal acyl-coenzyme A oxidase 1 
IPI00227928 1.62 0.7 [0.4, 1.0] Slc6a1 Sodium- and chloride-dependent GABA transporter 1 
IPI00283611 1.62 0.7 [0.4, 1.0] Hk1 Isoform HK1-SA of Hexokinase-1 
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HAB/LAB 
abundance 
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HAB/LAB 
log2 ratio log2 CI Protein Name 
IPI00311682 1.62 0.7 [0.6, 0.9] Atp1a1 Sodium/potassium-transporting ATPase subunit alpha-1 precursor 
IPI00454049 1.62 0.7 [0.2, 1.2] Echs1 Enoyl-coenzyme A hydratase, mitochondrial precursor 
IPI00465999 1.62 0.7 [0.1, 1.3] Shank1 SH3 and multiple ankyrin repeat domains 1 
IPI00117657 1.52 0.6 [0.3, 1.0] Opa1 Isoform 1 of Dynamin-like 120 kDa protein, mitochondrial precursor 
IPI00123540 1.52 0.6 [0.1, 1.0] Tspan7 Tetraspanin-7 
IPI00123744 1.52 0.6 [0.2, 1.0] Cst3 Cystatin-C precursor 
IPI00127713 1.52 0.6 [0.5, 0.8] Atp2b2 Plasma membrane calcium-transporting ATPase 2 
IPI00131472 1.52 0.6 [0.1, 1.2] Gria3 Glutamate receptor 3 precursor 
IPI00223325 1.52 0.6 [0.1, 1.1] Gabbr1 Isoform 1A of Gamma-aminobutyric acid type B receptor subunit 1 precursor 
IPI00322156 1.52 0.6 [0.1, 1.1] Slc38a3 Sodium-coupled neutral amino acid transporter 3 
IPI00380273 1.52 0.6 [0.2, 0.9] Gja1 Gap junction protein 
IPI00459279 1.52 0.6 [0.2, 1.1] Qdpr Dihydropteridine reductase 
IPI00465769 1.52 0.6 [0.4, 0.8] Slc12a5 Isoform 2 of Solute carrier family 12 member 5 
IPI00468685 1.52 0.6 [0.2, 1.0] Gpr37l1 Endothelin B receptor-like protein 2 precursor 
IPI00816921 1.52 0.6 [0.1, 1.1] Map6d1 MAP6 domain-containing protein 1 
IPI00114641 1.41 0.5 [0.2, 0.7] Slc3a2 CD98 heavy chain 
IPI00122094 1.41 0.5 [0.2, 0.8] Dlg4 Isoform 2 of Disks large homolog 4 
IPI00122826 1.41 0.5 [0.1, 0.9] Cend1 Cell cycle exit and neuronal differentiation protein 1 
IPI00124282 1.41 0.5 [0.1, 0.9] Rala Ras-related protein Ral-A precursor 
IPI00125147 1.41 0.5 [0.2, 0.9] Mpp2 Isoform 1 of MAGUK p55 subfamily member 2 
IPI00129268 1.41 0.5 [0.1, 0.9] Gng3 Guanine nucleotide-binding protein G(I)/G(S)/G(O) subunit gamma-3 precursor 
IPI00315794 1.41 0.5 [0.1, 0.9] Cyb5b Cytochrome b5 type B precursor 
IPI00420569 1.41 0.5 [0.3, 0.6] Atp1a2 Sodium/potassium-transporting ATPase subunit alpha-2 precursor 
IPI00420725 1.41 0.5 [0.3, 0.7] Camk2a MKIAA0968 protein 
IPI00114279 1.32 0.4 [0.2, 0.6] Slc1a3 Excitatory amino acid transporter 1 
IPI00119952 1.32 0.4 [0.2, 0.7] Gpm6b Isoform 1 of Neuronal membrane glycoprotein M6-b 
IPI00123390 1.32 0.4 [0.1, 0.8] Acsl6 acyl-coenzyme A synthetase long-chain family member 6 isoform 1 
IPI00123704 1.32 0.4 [0.1, 0.7] Atp1b2 Sodium/potassium-transporting ATPase subunit beta-2 
IPI00134093 1.32 0.4 [0.2, 0.6] Bsn Isoform 1 of Protein bassoon 
IPI00136134 1.32 0.4 [0.1, 0.7] Ndrg2 Isoform 1 of Protein NDRG2 
IPI00136967 1.32 0.4 [0.1, 0.8] Gria2 Isoform 1 of Glutamate receptor 2 precursor 
IPI00162781 1.32 0.4 [0.1, 0.7] Ahcyl1 Putative adenosylhomocysteinase 2 
IPI00230096 1.32 0.4 [0.2, 0.6] Camk2a Isoform Alpha KAP of Calcium/calmodulin-dependent protein kinase type II alpha chain 
IPI00265299 1.32 0.4 [0.1, 0.6] Atp2b3 plasma membrane calcium ATPase 3 
IPI00314749 1.32 0.4 [0.1, 0.6] Slc4a4 Isoform 1 of Electrogenic sodium bicarbonate co-transporter 1 
IPI00329927 1.32 0.4 [0.2, 0.7] Nfasc Neurofascin precursor 
IPI00338983 1.32 0.4 [0.1, 0.7] Cntnap1 Contactin-associated protein 1 precursor 
IPI00396743 1.32 0.4 [0.1, 0.7] P140 Isoform 1 of p130Cas-associated protein 
IPI00463589 1.32 0.4 [0.1, 0.6] Atp2b4 Plasma membrane Ca2+ transporting ATPase 4 splice variant a 
IPI00113112 0.76 -0.4 [-0.7, -0.2] Rab3b Ras-related protein Rab-3B 
IPI00114375 0.76 -0.4 [-0.5, -0.2] Dpysl2 Dihydropyrimidinase-related protein 2 
IPI00115157 0.76 -0.4 [-0.7, -0.1] Snca Isoform 1 of Alpha-synuclein 
IPI00116498 0.76 -0.4 [-0.5, -0.2] Ywhaz 14-3-3 protein zeta/delta 
IPI00117910 0.76 -0.4 [-0.6, -0.1] Prdx2 Peroxiredoxin-2 
IPI00118384 0.76 -0.4 [-0.6, -0.2] Ywhae 14-3-3 protein epsilon 
IPI00119458 0.76 -0.4 [-0.6, -0.2] Aldoc Fructose-bisphosphate aldolase C 
IPI00120415 0.76 -0.4 [-0.7, -0.1] Rtn4 Isoform 3 of Reticulon-4 
IPI00122565 0.76 -0.4 [-0.7, -0.1] Gdi2 Isoform 1 of Rab GDP dissociation inhibitor beta 
IPI00122684 0.76 -0.4 [-0.7, -0.3] Eno2 Enolase 
IPI00124444 0.76 -0.4 [-0.7, -0.1] Pfkp Isoform 1 of 6-phosphofructokinase type C 
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IPI00130589 0.76 -0.4 [-0.7, -0.1] Sod1 Superoxide dismutase 
IPI00135730 0.76 -0.4 [-0.6, -0.2] Arf2 ADP-ribosylation factor 2 
IPI00221613 0.76 -0.4 [-0.7, -0.1] Arf1 ADP-ribosylation factor 1 
IPI00227235 0.76 -0.4 [-0.8, -0.1] Ank2 RIKEN full-length enriched library, clone: A930028N13 product: Similar to Ankyrin-2, full insert sequence (Fragment) 
IPI00227805 0.76 -0.4 [-0.7, -0.1] Pfn2 Isoform 2 of Profilin-2 
IPI00229080 0.76 -0.4 [-0.6, -0.1] Hsp90ab1 Heat shock protein 84b 
IPI00229510 0.76 -0.4 [-0.6, -0.2] Ldhb L-lactate dehydrogenase B chain 
IPI00312527 0.76 -0.4 [-0.6, -0.1] Crmp1 Crmp1 protein 
IPI00319320 0.76 -0.4 [-0.8, -0.1] Nckap1 Isoform 1 of Nck-associated protein 1 
IPI00330804 0.76 -0.4 [-0.6, -0.1] Hsp90aa1 Heat shock protein HSP 90-alpha 
IPI00338604 0.76 -0.4 [-0.7, -0.1] Myh10 Myosin, heavy polypeptide 10, non-muscle 
IPI00343557 0.76 -0.4 [-0.8, -0.1] Mapre3 Microtubule-associated protein RP/EB family member 3 
IPI00407130 0.76 -0.4 [-0.6, -0.2] Pkm2 Isoform M2 of Pyruvate kinase isozymes M1/M2 
IPI00462072 0.76 -0.4 [-0.7, -0.2] EG433182; Eno1; LOC100044223 Alpha-enolase 
IPI00555069 0.76 -0.4 [-0.6, -0.1] Pgk1 Phosphoglycerate kinase 1 
IPI00605677 0.76 -0.4 [-0.6, -0.1] Dmxl2 Dmx-like 2 
IPI00626790 0.76 -0.4 [-0.6, -0.1] Glul Glutamine synthetase 
IPI00108330 0.71 -0.5 [-0.8, -0.1] Cnrip1 Uncharacterized protein C2orf32 homolog 
IPI00109142 0.71 -0.5 [-0.9, -0.1] Esd S-formylglutathione hydrolase 
IPI00114352 0.71 -0.5 [-0.9, -0.1] Bin1 Isoform 1 of Myc box-dependent-interacting protein 1 
IPI00117264 0.71 -0.5 [-0.9, -0.1] Park7 Protein DJ-1 
IPI00122069 0.71 -0.5 [-0.8, -0.1] Prkcc Protein kinase C gamma type 
IPI00122349 0.71 -0.5 [-0.8, -0.1] Dpysl3 Dihydropyrimidinase-related protein 3 
IPI00123613 0.71 -0.5 [-0.8, -0.2] Pacsin1 Protein kinase C and casein kinase substrate in neurons protein 1 
IPI00132575 0.71 -0.5 [-0.9, -0.1] Cotl1 Coactosin-like protein 
IPI00133224 0.71 -0.5 [-0.9, -0.1] Fxyd6 Isoform 1 of FXYD domain-containing ion transport regulator 6 precursor 
IPI00137331 0.71 -0.5 [-0.9, -0.2] Cap1 Adenylyl cyclase-associated protein 1 
IPI00137730 0.71 -0.5 [-0.9, -0.2] Pebp1 Phosphatidylethanolamine-binding protein 1 
IPI00172221 0.71 -0.5 [-0.7, -0.2] Dnm1l Isoform 2 of Dynamin-1-like protein 
IPI00187407 0.71 -0.5 [-1.0, -0.1] Cops8 COP9 signalosome complex subunit 8 
IPI00224740 0.71 -0.5 [-0.8, -0.2] Pfn1 Profilin-1 
IPI00227898 0.71 -0.5 [-0.9, -0.1] Prkcb1 Protein kinase C beta type 
IPI00228583 0.71 -0.5 [-0.9, -0.1] Mtpn Myotrophin 
IPI00228633 0.71 -0.5 [-0.8, -0.3] Gpi1 Glucose-6-phosphate isomerase 
IPI00229534 0.71 -0.5 [-0.9, -0.1] Marcks Myristoylated alanine-rich C-kinase substrate 
IPI00263822 0.71 -0.5 [-1.0, -0.1] Prkacb Isoform 1 of cAMP-dependent protein kinase catalytic subunit beta 
IPI00310240 0.71 -0.5 [-0.9, -0.1] Anxa6 annexin A6 isoform b 
IPI00313151 0.71 -0.5 [-0.8, -0.1] Dpysl4 Isoform 1 of Dihydropyrimidinase-related protein 4 
IPI00314191 0.71 -0.5 [-0.9, -0.1] Cbr1 Carbonyl reductase [NADPH] 1 
IPI00314748 0.71 -0.5 [-0.9, -0.2] Wdr1 WD repeat-containing protein 1 
IPI00322312 0.71 -0.5 [-0.8, -0.1] Arhgdia Rho GDP-dissociation inhibitor 1 
IPI00323179 0.71 -0.5 [-0.8, -0.2] Gdi1 Rab GDP dissociation inhibitor alpha 
IPI00395193 0.71 -0.5 [-0.8, -0.2] Rtn1 Reticulon-1 
IPI00467833 0.71 -0.5 [-0.7, -0.3] Tpi1 Triosephosphate isomerase 
IPI00471372 0.71 -0.5 [-0.9, -0.1] Wasf1 Wiskott-Aldrich syndrome protein family member 1 
IPI00890117 0.71 -0.5 [-0.9, -0.1] Cfl1 Cofilin-1 
IPI00108189 0.66 -0.6 [-1.0, -0.3] Hint1 Histidine triad nucleotide-binding protein 1 
IPI00112776 0.66 -0.6 [-1.0, -0.1] Atp8a1 Probable phospholipid-transporting ATPase IA 
IPI00113214 0.66 -0.6 [-1.0, -0.1] Usp5 Ubiquitin carboxyl-terminal hydrolase 5 
IPI00130920 0.66 -0.6 [-0.8, -0.3] Mtap1b Microtubule-associated protein 1B 
IPI00133713 0.66 -0.6 [-1.2, -0.1] Dtd1 Isoform 1 of D-tyrosyl-tRNA (Tyr) deacylase 1 
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Proteins whose differential expression was validated by Western blot are indicated with a 
bold italic font. 
 
 
 
 
 
Protein ID 
HAB/LAB 
abundance 
ratio 
HAB/LAB 
log2 ratio log2 CI Protein Name 
IPI00154004 0.66 -0.6 [-0.9, -0.3] LOC100046081; Otub1 Ubiquitin thioesterase OTUB1 
IPI00169448 0.66 -0.6 [-1.2, -0.1] Ube2m NEDD8-conjugating enzyme Ubc12 
IPI00221788 0.66 -0.6 [-0.9, -0.3] Hpcal4 Hippocalcin-like protein 4 
IPI00230034 0.66 -0.6 [-1.1, -0.1] Ddt D-dopachrome decarboxylase 
IPI00266899 0.66 -0.6 [-1.0, -0.1] Fkbp1a FK506-binding protein 1A 
IPI00308885 0.66 -0.6 [-0.9, -0.2] Hspd1 Isoform 1 of 60 kDa heat shock protein, mitochondrial precursor 
IPI00313962 0.66 -0.6 [-0.9, -0.4] Uchl1 Ubiquitin carboxyl-terminal hydrolase isozyme L1 
IPI00319994 0.66 -0.6 [-0.8, -0.4] Ldha L-lactate dehydrogenase A chain 
IPI00331066 0.66 -0.6 [-1.0, -0.1] Calb1 Calbindin 
IPI00331299 0.66 -0.6 [-1.0, -0.3] Ncdn Isoform 1 of Neurochondrin 
IPI00331704 0.66 -0.6 [-0.9, -0.2] Eno2 Gamma-enolase 
IPI00387232 0.66 -0.6 [-1.2, -0.1] Nsfl1c Isoform 3 of NSFL1 cofactor p47 
IPI00387312 0.66 -0.6 [-1.1, -0.2] Pfkl phosphofructokinase, liver, B-type 
IPI00469987 0.66 -0.6 [-1.0, -0.2] Gda Guanine deaminase 
IPI00119663 0.62 -0.7 [-1.1, -0.4] Mapk1 Mitogen-activated protein kinase 1 
IPI00121378 0.62 -0.7 [-1.1, -0.3] Alcam CD166 antigen precursor 
IPI00130000 0.62 -0.7 [-1.2, -0.2] Npepps Puromycin-sensitive aminopeptidase 
IPI00133557 0.62 -0.7 [-1.2, -0.2] Tppp3 Tubulin polymerization-promoting protein family member 3 
IPI00120346 0.57 -0.8 [-1.5, -0.2] Rab27b Ras-related protein Rab-27B 
IPI00131548 0.57 -0.8 [-1.5, -0.1] Prosc Proline synthetase co-transcribed bacterial homolog protein 
IPI00222044 0.57 -0.8 [-1.3, -0.2] D12Ertd553e Protein FAM49A 
IPI00228828 0.57 -0.8 [-1.5, -0.1] Guk1 RIKEN full-length enriched library, clone: 1110048P09 product: Guanylate kinase 1, full insert sequence 
IPI00118654 0.54 -0.9 [-1.3, -0.4] Pdxp Pyridoxal phosphate phosphatase 
IPI00134373 0.54 -0.9 [-1.5, -0.3] Ly6h RIKEN full-length enriched library, clone: B230215I21 product: Lymphocyte antigen 6 complex, locus H, full insert sequence 
IPI00283511 0.54 -0.9 [-1.2, -0.5] Pdxk Pyridoxal kinase 
IPI00330477 0.54 -0.9 [-1.7, -0.1] Epn1 Isoform 2 of Epsin-1 
IPI00408626 0.54 -0.9 [-1.5, -0.2] Tpd52 Tumor protein D52 
IPI00318522 0.50 -1 [-1.8, -0.2] Gad2 Glutamate decarboxylase 2 
IPI00466610 0.50 -1 [-1.5, -0.4] Map2k1 Dual specificity mitogen-activated protein kinase kinase 1 
IPI00129319 0.47 -1.1 [-1.6, -0.5] Ppp1r7 Protein phosphatase 1 regulatory subunit 7 
IPI00135231 0.47 -1.1 [-1.9, -0.3] Idh1 RIKEN full-length enriched library, clone: E030024J03 product: Isocitrate dehydrogenase 1 (NADP+), soluble, full insert sequence 
IPI00380799 0.47 -1.1 [-1.4, -0.7] Pde2a RIKEN full-length enriched library, clone: K230012M18 product: Phosphodiesterase 2A, cGMP-stimulated, full insert sequence 
IPI00128973 0.44 -1.2 [-1.6, -0.8] Gap43 Neuromodulin 
IPI00624192 0.44 -1.2 [-1.6, -0.8] Dpysl5 Dihydropyrimidinase-related protein 5 
IPI00129451 0.41 -1.3 [-2.1, -0.5] Cpne6 Copine-6 
IPI00120030 0.27 -1.9 [-2.4, -1.4] Crym Mu-crystallin homolog 
IPI00135604 0.27 -1.9 [-2.7, -1.1] Pcsk1n ProSAAS precursor 
IPI00321734 0.16 -2.6 [-3.0, -2.1] Glo1 Lactoylglutathione lyase 
Appendixes 
_____________________________________________________________________ 
123 
Appendix 5: Differentially expressed proteins (>1.3 fold) in 14N HAB/15N HAB cingulate 
cortex synaptosomes 
 
Protein ID 
15N HAB/14N HAB 
abundance  
ratio 
15N HAB/14N HAB 
log2 ratio log2 CI Protein Name 
IPI00122486 1.41 0.5 [0.3, 0.7] Camkv CaM kinase-like vesicle-associated protein 
IPI00408378 1.32 0.4 [0.5, 0.2] Ywhaq Isoform 1 of 14-3-3 protein theta 
IPI00227392 1.32 0.4 [0.2, 0.6] Ywhah 14-3-3 protein eta 
IPI00230418 1.32 0.4 [0.3, 0.5] Vsnl1 Visinin-like protein 1 
IPI00109061 0.76 -0.4 [-0.6, -0.3] Tubb2b Tubulin beta-2B chain 
IPI00131618 0.76 -0.4 [-0.5, -0.2] Stx1a Syntaxin-1A 
IPI00114279 0.76 -0.4 [-0.5, -0.3] Slc1a3 Excitatory amino acid transporter 1 
IPI00130187 0.76 -0.4 [-0.6, -0.3] Atp6v0a1 Isoform A1-II of Vacuolar proton translocating ATPase 116 kDa subunit a isoform 1 
IPI00230289 0.71 -0.5 [-0.6, -0.4] Slc1a2 Isoform Glt-1A of Excitatory amino acid transporter 2 
IPI00312527 0.71 -0.5 [-0.7, -0.3] Crmp1 Crmp1 protein 
IPI00420569 0.71 -0.5 [-0.6, -0.4] Atp1a2 Sodium/potassium-transporting ATPase 
subunit alpha-2 precursor 
IPI00314749 0.66 -0.6 [-0.7, -0.4] Slc4a4 Isoform 1 of Electrogenic sodium bicarbonate co-transporter 1 
IPI00114641 0.66 -0.6 [-0.7, -0.4] Slc3a2 CD98 heavy chain 
IPI00122094 0.66 -0.6 [-0.8, -0.4] Dlg4 Isoform 2 of Disks large homolog 4 
IPI00136867 0.62 -0.7 [-1.0, -0.5] Slc6a11 Sodium- and chloride-dependent GABA transporter 4 
IPI00222419 0.62 -0.7 [-0.9, -0.6] ENSMUSG00000058927; Cycs Cytochrome c, 
somatic 
IPI00122549 0.57 -0.8 [-0.9, -0.6] Vdac1 Isoform Pl-VDAC1 of Voltage-dependent 
anion-selective channel protein 1 
IPI00663736 0.57 -0.8 [-1.0, -0.6] Syngap1 similar to SynGAP-a 
IPI00109109 0.57 -0.8 [-1.1, -0.6] Sod2 Superoxide dismutase Mn], mitochondrial precursor 
IPI00465999 0.57 -0.8 [-1.1, -0.5] Shank1 SH3 and multiple ankyrin repeat domains 1 
IPI00330754 0.57 -0.8 [-1.1, -0.6] Bdh1 D-beta-hydroxybutyrate dehydrogenase, 
mitochondrial precursor 
IPI00321718 0.54 -0.9 [-1.1, -0.7] Phb2 Prohibitin-2 
IPI00132653 0.54 -0.9 [-1.3, -0.5] Oxct1 Succinyl-coenzyme A: 3-ketoacid-coenzyme A transferase 1, mitochondrial precursor 
IPI00323592 0.54 -0.9 [-1.1, -0.7] Mdh2 Malate dehydrogenase, mitochondrial precursor 
IPI00117312 0.54 -0.9 [-1.1, -0.7] Got2 Aspartate aminotransferase, mitochondrial precursor 
IPI00113141 0.54 -0.9 [-1.1, -0.6] Cs Citrate synthase, mitochondrial precursor 
IPI00137460 0.54 -0.9 [-1.4, -0.4] Armc10 Isoform 2 of Armadillo repeat-containing protein 10 
IPI00116074 0.54 -0.9 [-1.1, -0.7] Aco2 Aconitate hydratase, mitochondrial precursor 
IPI00122548 0.50 -1 [-1.2, -0.7] Vdac3 Voltage-dependent anion channel 3 
IPI00464317 0.50 -1 [-1.3, -0.8] Gls glutaminase isoform 1 
IPI00230241 0.50 -1 [-1.5, -0.5] Atp5e ATP synthase subunit epsilon, mitochondrial 
IPI00154054 0.50 -1 [-1.3, -0.7] Acat1 Acetyl-coenzyme A acetyltransferase, 
mitochondrial precursor 
IPI00323800 0.47 -1.1 [-1.5, -0.7] Nefm Neurofilament medium polypeptide 
IPI00230394 0.47 -1.1 [-1.5, -0.8] Lmnb1 Lamin-B1 
IPI00126635 0.47 -1.1 [-1.5, -0.8] Idh3b Tumor-related protein 
IPI00133903 0.47 -1.1 [-1.7, -0.6] Hspa9 Stress-70 protein, mitochondrial precursor 
IPI00112126 0.47 -1.1 [-1.6, -0.5] 1810027O10Rik UPF0451 protein C17orf61 homolog precursor 
IPI00308885 0.44 -1.2 [-1.5, -0.9] Hspd1 Isoform 1 of 60 kDa heat shock protein, 
mitochondrial precursor 
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Protein ID 
15N HAB/14N HAB 
abundance  
ratio 
15N HAB/14N HAB 
log2 ratio log2 CI Protein Name 
IPI00459725 0.44 -1.2 [-1.5, -0.9] Idh3a Isoform 1 of Isocitrate dehydrogenase NAD] 
subunit alpha, mitochondrial precursor 
IPI00114342 0.41 -1.3 [-1.9, -0.7] Hk2 Hexokinase-2 
IPI00120045 0.41 -1.3 [-1.5, -1.0] EG628438; Hspe1-rs1 CPN10-like protein 
IPI00624192 0.41 -1.3 [-1.6, -1.0] Dpysl5 Dihydropyrimidinase-related protein 5 
IPI00122349 0.41 -1.3 [-1.6, -1.0] Dpysl3 Dihydropyrimidinase-related protein 3 
IPI00134809 0.41 -1.3 [-1.9, -0.7] 
Dlst Isoform 1 of Dihydrolipoyllysine-residue 
succinyltransferase component of 2- oxoglutarate 
dehydrogenase complex, mitochondrial precursor 
IPI00153660 0.41 -1.3 [-1.9, -0.8] 
Dlat Dihydrolipoyllysine-residue acetyltransferase 
component of pyruvate dehydrogenase complex, 
mitochondrial precursor 
IPI00329998 0.38 -1.4 [-1.6, -1.3] - 11 kDa protein 
IPI00274407 0.35 -1.5 [-2.1, -0.9] Tufm Isoform 1 of Elongation factor Tu, 
mitochondrial precursor 
IPI00331564 0.33 -1.6 [-2.1, -1.1] Dld Dihydrolipoyl dehydrogenase 
IPI00227126 0.31 -1.7 [-2.0, -1.5] Tnr Isoform 1 of Tenascin-R precursor 
 
Proteins whose differential expression was validated by Western blot are indicated with a 
bold italic font.
Acknowledgments 
_____________________________________________________________________ 
125 
12 Acknowledgments 
 
First of all, I would like to express my deep gratitude to Prof. Chris Turck for giving me the 
opportunity to work in his group in an innovative field that bridges proteomics technologies 
and behavioral biology. I am really thankful for his helpful guidance and support, for him 
always having his door open for discussions, advice and problem solving, for entrusting me 
with a number of exciting projects and showing interest for my work and for giving me the 
freedom to develop and pursue my own ideas. 
I am very grateful to Prof. Rainer Landgraf not only for taking over my supervision at the LMU 
and being a member of my thesis advisory committee but also for giving me the chance to 
work with the HAB/NAB/LAB animal model, his constructive feedback, insightful suggestions, 
support and motivation throughout my PhD studies.  
My sincere thanks to Prof. George Boyan for his kind willingness to be the second reviewer of 
my thesis.   
I would like to thank my external thesis committee advisor Prof. Manuel Graeber at the Brain 
and Mind Research Institute at the University of Sydney for being an inspiring mentor and 
always being willing to offer advice and help. 
I thank the Director of our Institute, Prof. Florian Holsboer for ensuring financial support for 
our projects. Funding from the Federal Ministry of Education and Research (BMBF) is also 
gratefully acknowledged. 
For her invaluable support with mass spectrometry, her unconfined help concerning all sorts 
of questions, manuscript preparation and troubleshooting as well as her whole-hearted 
encouragement throughout my PhD studies, I am indebted to Dr. Giuseppina Maccarrone.  
I am thankful to all present and past members of the Proteomics and Biomarkers group for 
creating an exceptionally pleasant working environment. A big thanks to Larysa Teplytska for 
being a great help in the lab. Thanks to Yaoyang Zhang for sharing the ups and downs of the 
14N/15N project with me, Stefan Reckow and Philipp Gormanns for help with bioinformatics, 
Maria Lebar and Christiane Rewerts for the excellent organization of our lab, Christian 
Webhofer for the nice team work, Dr. Jeeva Varadarajulu for guidance with cell culture, Dr. 
Acknowledgments 
_____________________________________________________________________ 
126 
Daniel Martins-de-Souza and Dr. Claudia Ditzen for fruitful discussions and Dr. Birgit Bisle for 
help with mass spectrometry. 
Special thanks to all present and past members of the Behavioral Neuroendocrinology group, 
particularly Dr. Lisa Frank, Dr. Melanie Kessler, Dr. Boris Hambsch, Markus Nussbaumer, Dr. 
Ludwig Czibere, Dr. Mirjam Bunck and Alana Knapman for a wonderful collaboration all these 
years and for always being eager to share their knowledge and provide valuable advice. 
Thanks to Prof. Andreas Zimmer, Dr. David Otte and Öznur Yilmaz for welcoming me warmly 
during our collaboration projects in Bonn and providing me with useful insights into the 
G72/G30 animal model. Thanks to Dr. Vladimir Tolstikov and the Metabolomics Core 
personnel of UC Davis for metabolomics measurements. I am also grateful to Dr. Alexandros 
Yassouridis for statistical analysis and for patiently explaining exploratory statistics to me.  
For organizing a great International Max Planck Research School, I would especially like to 
thank Dr. Hans-Joerg Schaeffer and Maxi Reif. 
Thanks to Carola Hetzel, Vesna Cerovac, Albin Varga and the Animal Facility team, the 
Ergotherapy Department and everyone in our Institute that ensures on a daily basis our work-
related well-being.  
 
Finally, a warm thanks to all the people that made these years in Munich an exciting 
experience and so many thanks to my beloved parents, Dimitris and Zoi, for everything!
Curriculum vitae 
_____________________________________________________________________ 
127 
13 Curriculum Vitae 
 
Personal information          
 
Name   Michaela Filiou 
Date of birth  July 9th, 1982 
Nationality  Greek 
 
Education           
 
10/2006 - present  PhD, International Max Planck Research School, 
   Proteomics and Biomarkers, Max Planck Institute of Psychiatry,   
   Munich, Germany 
PhD Thesis  Biomarker discovery for psychiatric disorders: Insights from quantitative 
proteomics studies in animal models  
 
10/2005 - 09/2006  MSc, Human Molecular Genetics, Imperial College, London, UK 
MSc Thesis   DNAJ/HSP40 chaperone family: Expression in Parkinson's disease         Grade A 
 
07/2004 - 08/2004 Internship, Medical Microbiology, Hellenic Pasteur Institute, Athens, Greece  
 
09/2000 - 06/2005 BSc (Hons), Biological Applications and Technologies,  
   University of Ioannina, Ioannina, Greece          Grade ‘Excellent’ 8.71/10 
BSc Thesis Duplications of 15q11-q13 in children with developmental delay      Grade 10/10 
 
Awards-scholarships          
 
2010    ASBMB Postgraduate travel award (Experimental Biology 2010, USA) 
2009 DAAD and ASMS travel scholarships (57th ASMS, USA) 
2008, 2009, 2010 DGPF travel scholarships (Proteomics Summer School, Italy; Proteomic 
Forum, Germany; 4th EUPA Meeting, Portugal) 
2005 - 2006    Georgios Stavros Foundation scholarship for MSc studies 
2005    Valedictorian of the Faculty of Biological Applications and Technologies 
2003, 2004, 2005    Onassis Foundation scholarships (Onassis Foundation Lecture Series)   
2000 - 2002  State Scholarships Foundation scholarship  
(awarded to the top 1% students of each year, based on academic 
excellence)  
 
       
Curriculum vitae 
_____________________________________________________________________ 
128 
Invited talks 
 
Filiou, M.D., Proteomics and metabolomics analysis for biomarker discovery in a trait anxiety 
mouse model, 3rd NGFN Meeting, 25-27 November 2010, Berlin, Germany 
 
Filiou, M.D., 15N isotope effect during metabolic labeling of Escherichia coli proteins, 4th EUPA 
Meeting, 23-27 October 2010, Estoril, Portugal (Young Investigator Award Session) 
 
Filiou, M.D., Biomarker discovery using 15N metabolic labeling and an Orbitrap mass spectrometer, 
1st Greek Orbitrap Users Workshop, 9 October 2010, Heraklion, Greece 
 
Language skills 
 
English   Fluent (Certificate of Proficiency, University of Cambridge) 
German  Fluent (Kleines Deutsches Sprachdiplom, Goethe Institut) 
French  Fluent (Diplôme Approfondi de Langue Française, Institut Français) 
Spanish  Working knowledge (Certificado Inicial, Instituto Cervantes) 
Greek   Mother tongue 
Publications 
_____________________________________________________________________ 
129 
14 Publications 
 
1. Durrenberger, P.F., Filiou, M.D., Moran, L.B., Michael, G.J., Novoselov, S., Cheetham, 
M.E., Clark, P., Pearce, R.K., Graeber, M.B., 2009. DnaJB6 is present in the core of Lewy 
bodies and is highly up-regulated in parkinsonian astrocytes. J Neurosci Res 87, 238-245. 
 
2. Otte, D.M., Bilkei-Gorzó, A., Filiou, M.D., Turck, C.W., Yilmaz, Ö., Holst, M.I., Schilling, 
K., Abou-Jamra, R., Schumacher, J., Benzel, I., Kunz, W.S., Beck, H., Zimmer, A., 2009. 
Behavioral changes in G72/G30 transgenic mice. Eur Neuropsychopharmacol 19, 339-
348. # 
 
3. Frank, E., Kessler, M.S., Filiou, M.D., Zhang, Y., Maccarrone, G., Reckow, S., Bunck, M., 
Heumann, H., Turck, C.W., Landgraf, R., Hambsch, B., 2009. Stable isotope metabolic 
labeling with a novel 15N-enriched bacteria diet for improved proteomic analyses of mouse 
models for psychopathologies. PLoS ONE 4, e7821. # 
 
4.         Zhang, Y., Webhofer, C., Reckow, S., Filiou, M.D., Maccarrone, G., Turck, C.W., 2009. A 
MS data search method for improved 15N-labeled protein identification. Proteomics 9, 
4265-4270. 
 
5. Haegler, K., Mueller, N.S., Maccarrone, G., Hunyadi-Gulyas, E., Webhofer, C., Filiou, 
M.D., Zhang, Y., Turck, C.W., 2009. QuantiSpec – Quantitative mass spectrometry data 
analysis of 15N-metabolically labeled proteins. J Proteomics 71, 601-608. 
 
6. Filiou, M.D., Bisle, B., Reckow, S., Teplytska, L., Maccarrone, G., Turck, C.W., 2010. 
Profiling of mouse synaptosome proteome and phosphoproteome by IEF. Electrophoresis 
31, 1294-1301. # 
 
7. Filiou, M.D., Turck, C.W., Martins-de-Souza, D., 2010. Quantitative proteomics for 
investigating psychiatric disorders. Prot Clin Applications. Dec 6 Epub ahead of print. # 
 
8. Filiou, M.D., Zhang, Y., Teplytska, L., Reckow, S., Gormanns, P., Maccarrone, G., Frank, 
E., Kessler, M.S., Hambsch, B., Nussbaumer, M., Bunck, M., Lebar, M., Yassouridis, A., 
Holsboer, F., Landgraf, R., Turck, C.W., (submitted). Biomarker and pathway discovery in 
a trait anxiety mouse model: Evidence for mitochondrial implication. # 
 
9. Zhang, Y., Filiou, M.D., Reckow, S., Webhofer, C., Gormanns, P., Maccarrone, G., 
Frank, E., Kessler, M.S., Hambsch, B., Landgraf, R., Turck, C.W., (submitted). Proteomic 
and metabolomic analyses of brain and plasma from a trait anxiety mouse model. # 
Publications 
_____________________________________________________________________ 
130 
10. Otte, D.M., Albayram, Ö., Guerrero, C., Kudin, A., Sommersberg, B., Filiou, M.D., Turck, 
C.W., Yilmaz, Ö.,  Bilkei-Gorzó, A., Kunz, W.S.,  Beck, H., Zimmer, A., (submitted). 
Mitochondrial dysfunctions and synaptic deficits in G72/G30 transgenic mice. # 
 
11. Filiou, M.D., Varadarajulu, J., Teplytska, L., Reckow, S., Maccarrone, G., Turck, C.W., (in 
preparation). Altered Escherichia coli protein expression caused by a 15N isotope effect 
during metabolic labeling. # 
 
12. Filiou, M.D., Otte, D.M., Teplytska, L., Yilmaz, Ö., Zimmer, A., Turck, C.W., (in 
preparation). Biomarker discovery in G72/G30 mice by 15N metabolic labeling and 
quantitative proteomics.  
 
13. Filiou, M.D., Conti, D., Michael, G.J., Gentleman, S.M., Dawn, D.C., Graeber, M.B., 
Moran, L.B., (in preparation). Cortical involvement in Parkinson’s disease: Evidence from 
expression profiling.  
 
14. Filiou, M.D.*, Webhofer, C.*, Zhang, Y.*, Bisle, B., Teplytska, L., Frank, E., Kessler, M.S., 
Hambsch, B., Maccarrone, G., Landgraf, R., Turck, C.W., (in preparation). Protein 
correlates of a 15N stable isotope behavioral effect in a mouse model of trait anxiety. 
*equal contribution, alphabetical order #  
 
 
 
# parts of the thesis are included in these publications 
 
 
 
 
Book chapters 
 
1.     Filiou, M.D., Turck, C.W., Psychiatric disorder biomarker discovery using quantitative 
proteomics (submitted).  In: Psychiatric Disorders Methods and Protocols, Humana Press, 
Totowa, NJ, USA. 
 
2.  Filiou, M.D., Turck, C.W., General overview: biomarkers in neuroscience research (in 
preparation). In: International Review of Neurobiology, Academic Press, San Diego, CA, 
USA. 
 
 
Publications 
_____________________________________________________________________ 
131 
Published Conference Abstracts 
(To date, 31 contributions in conference abstracts) 
 
1. Filiou, M.D., Zhang, Y., Teplytska, L., Reckow, S., Frank, E., Kessler, M.S., Maccarrone, 
G., Hambsch, B., Landgraf, R., Turck, C.W., 2010. Biomarker discovery by stable isotope 
labeling and quantitative proteomics. FASEB J 24, 902.3. 
       Experimental Biology 2010, 23-28 May 2010, Anaheim, CA, USA 
 
2. Filiou, M.D., Zhang, Y., Teplytska, L., Frank, E., Kessler, M.S., Reckow, S., Maccarrone, 
G., Hambsch, B., Landgraf, R., Turck, C.W., 2010. Biomarker discovery for psychiatric 
disorders by stable isotope metabolic labeling and quantitative proteomics. Eur Psychiatry 
25, S1, 1464. 
18th European Congress of Psychiatry, 27 February-2 March 2010, Munich, Germany 
 
3. Filiou, M.D., Zhang, Y., Bisle, B., Frank, E., Kessler, M.S., Teplytska, L., Reckow, S., 
Haegler, K., Maccarrone, G., Hambsch, B., Landgraf, R., Turck, C.W., 2009. Stable 
isotope labeling of a mouse model reveals synaptic biomarkers for anxiety disorders. 
Pharmacopsychiatry 42, A37. 
       26th AGNP Symposium, 7-10 October 2009, Munich, Germany  
 
4. Turck, C.W., Landgraf, R., Ditzen, C., Frank, E., Kessler, M., Filiou, M.D., Zhang, Y., 
Bisle, B., Haegler, K., Webhofer, C., Hambsch, B., 2008. The quest for affective disorder 
biomarkers. Int J Neuropsychopharmacol 11, 81.  
       XXVI CINP Congress, 13-17 July 2008, Munich, Germany 
 
5. Kessler, M.S.*, Frank, E.*, Filiou, M.D.*, Zhang, Y.*, Haegler, K., Maccarrone, G., 
Hambsch, B., Landgraf, R., Turck, C.W., 2007. 15N metabolic labeling of high and low 
anxiety-related behavior HAB/LAB mice. Pharmacopsychiatry 40, A126.  
       *equal contribution 
25th AGNP Symposium, 3-6 October 2007, Munich, Germany  
 
6. Durrenberger, P.F., Filiou, M.D., Moran, L.B., Pearce, R.K.B., Graeber, M.B., 2007. The 
DnaJ/HSP40 chaperone family: Involvement in Parkinson’s disease. Neuropathol Appl 
Neurobiol 33, 255-256. 
108th Meeting of the British Neuropathological Society, 10-12 January 2007, London, UK  
 
Declaration/Erklärung 
 
 
Hiermit versichere ich, dass ich die vorliegende Arbeit selbstständig und 
nur mit den angegebenen Quellen und Hilfsmitteln angefertigt habe. Alle 
Ausführungen, die wörtlich oder sinngemäß übernommen wurden, sind als 
solche gekennzeichnet. Auch habe ich nicht anderweitig versucht, eine 
Dissertation einzureichen oder mich der Doktorprüfung zu unterziehen. 
 
München, 23 Juli 2010 
 
 
 
Michaela Filiou 
